>HV781911.1 JP 2010090159-A/11: USE OF LOW DOSES OF OLIGONUCLEOTIDES ANTISENSE TO TGF-BETA, VEGF, INTERLEUKIN-10, C-JUN, C-FOS OR PROSTAGLANDIN E2 GENES IN THE TREATMENT OF TUMORS
CCCGACGAGCCGG
>HV781626.1 JP 2010046099-A/92: METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION
ACGTAGACTGAGG
>HV781624.1 JP 2010046099-A/90: METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION
GAAGTCTGCCGTT
>HV781623.1 JP 2010046099-A/89: METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION
GAAGTCTGCCGTT
>HV781590.1 JP 2010046099-A/56: METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION
AACACGAAACGTG
>HV781559.1 JP 2010046099-A/25: METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION
TAGAGGAGAAAGG
>HV856578.1 JP 2010507386-A/37: Oligoribonucleotides and uses thereof
CCCCTTTTGGGGG
>HV856574.1 JP 2010507386-A/33: Oligoribonucleotides and uses thereof
GGGGTTTTGGGGG
>HV856564.1 JP 2010507386-A/23: Oligoribonucleotides and uses thereof
GTTGTGTGGGGGG
>HV812953.1 JP 2011015686-A/47: Mutations in NOD2 are Associated with Fibrostenosing Disease in Patients with Crohn's Disease
TGCTCCGGCGCCA
>HV812952.1 JP 2011015686-A/46: Mutations in NOD2 are Associated with Fibrostenosing Disease in Patients with Crohn's Disease
CATGGCTGGATCC
>HV812951.1 JP 2011015686-A/45: Mutations in NOD2 are Associated with Fibrostenosing Disease in Patients with Crohn's Disease
CATGGCTGGACCC
>HV818014.1 JP 2011036259-A/16: Methods for Identifying Functionally Related Genes and Drug Targets
TTTTGTTTTCCTT
>HV818006.1 JP 2011036259-A/8: Methods for Identifying Functionally Related Genes and Drug Targets
ATTTTATCTGTTA
>HV817877.1 JP 2011101659-A/40: REPRODUCTIVE ABLATION CONSTRUCTS
TCTCTGCGGCCGC
>HV785248.1 JP 2010046092-A/71: Evolving New Molecular Function
TCCCTGATCGACC
>HV785245.1 JP 2010046092-A/68: Evolving New Molecular Function
AAGGTGGTATACC
>HV785243.1 JP 2010046092-A/66: Evolving New Molecular Function
TCCCGAGTCGACC
>HV785242.1 JP 2010046092-A/65: Evolving New Molecular Function
TCCCGAGTCGACC
>HV816847.1 JP 2011078429-A/28: RECOMBINANT ALPHAVIRUS VECTORS
TAACGGCCGCCAC
>HV821546.1 JP 2011137838-A/16: Methods for isolating and characterizing endogenous mRNA-protein (mRNP) complexes
TTTTGTTTTCCTT
>HV821538.1 JP 2011137838-A/8: Methods for isolating and characterizing endogenous mRNA-protein (mRNP) complexes
ATTTTATCTGTTA
>HV784813.1 JP 2010001310-A/98: Methods and Products for Stimulating the Immune System Using Immunotherapeutic Oligonucleotides and Cytokines
TGTCGTTGTCGTT
>HV784681.1 JP 2010099090-A/37: TARGET DETECTION SYSTEM HAVING A CONFORMATIONALLY SENSITIVE PROBE COMPRISING A NUCLEIC ACID BASED SIGNAL TRANSDUCER
ATCCCATTACTCC
>HV784466.1 JP 2010075209-A/181: PROTEASE SCREENING METHODS AND PROTEASES IDENTIFIED THEREBY
ATGGAACCCTGAA
>GZ594034.1 Sequence 18 from patent US 8309794
GTACTCTGCAGGA
>GZ594033.1 Sequence 17 from patent US 8309794
TCCTGCAGAGTAC
>GZ591517.1 Sequence 21 from patent US 8309356
TCAAGTACAGTAT
>GZ591516.1 Sequence 20 from patent US 8309356
AGTTCATGTCATA
>GZ591505.1 Sequence 9 from patent US 8309356
AGTTCATGTCATA
>GZ591504.1 Sequence 8 from patent US 8309356
TATGACATGAACT
>GZ591503.1 Sequence 7 from patent US 8309356
NGNNCNNGNCNNN
>GZ591502.1 Sequence 6 from patent US 8309356
NNNGNCNNGNNCN
>GZ514941.1 Sequence 17 from patent US 8278284
GATCCAAGCTTGC
>GZ514940.1 Sequence 16 from patent US 8278284
GGCCGCAAGCTTG
>GZ513548.1 Sequence 9 from patent US 8278049
SSSSSSSSSSSSS
>GZ513514.1 Sequence 133 from patent US 8278043
RTTGGCTTTTTTA
>GZ590475.1 Sequence 6 from patent US 8306757
GTCGTACGGCTAA
>GZ589398.1 Sequence 357 from patent US 8304396
TCGTCGTTTTGAC
>GZ589384.1 Sequence 343 from patent US 8304396
ACGTTTTGTCGTT
>GZ589373.1 Sequence 332 from patent US 8304396
TCGCGNCGCGCGN
>GZ588487.1 Sequence 40 from patent US 8304214
CGGCGGGTGTGGA
>GZ588465.1 Sequence 18 from patent US 8304214
GCCGTGGTGGTGA
>GZ549127.1 Sequence 75 from patent US 8298819
AGCTTGGGCCCTT
>GZ548137.1 Sequence 35 from patent US 8298794
CCCACGCAGGGCG
>GZ548136.1 Sequence 34 from patent US 8298794
CCCACGTAGGGCG
>GZ544745.1 Sequence 3 from patent US 8298760
CGTGGTACCCCTT
>GZ544743.1 Sequence 1 from patent US 8298760
CGTGGTGACCCTT
>GZ544592.1 Sequence 488 from patent US 8298547
CGGCGCCGTGCCG
>GZ543857.1 Sequence 30 from patent US 8296075
AACCCACATCAAA
>GZ543855.1 Sequence 28 from patent US 8296075
AACCCACATCAAA
>GZ543853.1 Sequence 26 from patent US 8296075
ATTTTTTCCCCCT
>GZ543851.1 Sequence 24 from patent US 8296075
ATTTTTTCCCCCT
>GZ543534.1 Sequence 91 from patent US 8293979
AGCTTGCGGCCGC
>GZ543533.1 Sequence 90 from patent US 8293979
AATTCGCGGCCGC
>GZ534384.1 Sequence 80 from patent US 8293503
GGCCNNNNNGGCC
>GZ534381.1 Sequence 77 from patent US 8293503
GGCCNNNNNGGCC
>GZ534366.1 Sequence 20 from patent US 8293503
GGCCNNNNNGGCC
>GZ534351.1 Sequence 5 from patent US 8293503
GCAGCNNNNNNNN
>GZ533414.1 Sequence 183 from patent US 8293480
CACATCGATACTG
>GZ529540.1 Sequence 6 from patent US 8293082
GTCGTACGGCTAA
>GZ528822.1 Sequence 154 from patent US 8283334
GCAGACCCCGCTG
>GZ528797.1 Sequence 123 from patent US 8283334
ACAGGCCCCTGAG
>GZ528409.1 Sequence 357 from patent US 8283328
TCGTCGTTTTGAC
>GZ528395.1 Sequence 343 from patent US 8283328
ACGTTTTGTCGTT
>GZ528384.1 Sequence 332 from patent US 8283328
TCGCGNCGCGCGN
>GZ527988.1 Sequence 52 from patent US 8283170
GGGGCGGGTACAG
>GZ524130.1 Sequence 6 from patent US 8282916
GTCCTAAATAGTC
>GZ524093.1 Sequence 7 from patent US 8280640
GCCTATGACTCGA
>HV780427.1 JP 2012514021-A/130: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
GCATTGGTATTCA
>HV780426.1 JP 2012514021-A/129: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
GCATTGGTATTCA
>HV780425.1 JP 2012514021-A/128: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
GCATTGGTATTCA
>HV780424.1 JP 2012514021-A/127: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
GCATTGGTATTCA
>HV780423.1 JP 2012514021-A/126: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
GCATTGGTATTCA
>HV780422.1 JP 2012514021-A/125: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
GCATTGGTATTCA
>HV780421.1 JP 2012514021-A/124: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
GCATTGGTATTCA
>HV780420.1 JP 2012514021-A/123: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
GCATTGGTATTCA
>HV780404.1 JP 2012514021-A/107: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
CATTGGTATTCAG
>HV780403.1 JP 2012514021-A/106: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
GCATTGGTATTCA
>HV780402.1 JP 2012514021-A/105: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
AGCATTGGTATTC
>HV780401.1 JP 2012514021-A/104: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
CAGCATTGGTATT
>HV780336.1 JP 2012514021-A/39: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
CAGATCCTTGCAC
>HV780329.1 JP 2012514021-A/32: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
CGTTGGAGTAAGC
>HV780323.1 JP 2012514021-A/26: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
GCATTGGTATTCA
>HV780310.1 JP 2012514021-A/13: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
CAGATCCTTGCAC
>HV780303.1 JP 2012514021-A/6: USE OF LNA APOB ANTISENSE OLIGOMERS FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES
CGTTGGAGTAAGC
>HV778258.1 WO 2012091101-A/30: A bioluminescent probe system for multiply recognizing ligands
AGAATGTAGGTCA
>GZ511032.1 Sequence 1 from patent US 8271206
GCTTGTCTAGTCA
>GZ511030.1 Sequence 6 from patent US 8269261
GTCGTACGGCTAA
>GZ510814.1 Sequence 58 from patent US 8269065
CAGCGCGACTCTT
>GZ510456.1 Sequence 337 from patent US 8268986
TTCCGCGTACGNN
>GZ510452.1 Sequence 331 from patent US 8268986
TTCCGCGTACGNN
>GZ510419.1 Sequence 296 from patent US 8268986
TTCCGCGTACGNN
>GZ510418.1 Sequence 294 from patent US 8268986
TTCCGCGTACGNN
>GZ510210.1 Sequence 84 from patent US 8268986
TTCCGCGTACGNN
>GZ508952.1 Sequence 234 from patent US 8268793
TAGCCTGTCACTT
>GZ508950.1 Sequence 232 from patent US 8268793
TAGCCTGTCACTT
>GZ508849.1 Sequence 131 from patent US 8268793
TCTGATGACTCTG
>GZ508848.1 Sequence 130 from patent US 8268793
CTCTGATGACTCT
>GZ508847.1 Sequence 129 from patent US 8268793
CCTCTGATGACTC
>GZ508846.1 Sequence 128 from patent US 8268793
CCCTCTGATGACT
>GZ508834.1 Sequence 116 from patent US 8268793
TGTGTATTTCCCA
>GZ508833.1 Sequence 115 from patent US 8268793
GTGTGTATTTCCC
>GZ508832.1 Sequence 114 from patent US 8268793
TGTGTGTATTTCC
>GZ508831.1 Sequence 113 from patent US 8268793
GTGTGTGTATTTC
>GZ508819.1 Sequence 101 from patent US 8268793
CAATTTGTACTCC
>GZ508818.1 Sequence 100 from patent US 8268793
GCAATTTGTACTC
>GZ508817.1 Sequence 99 from patent US 8268793
GGCAATTTGTACT
>GZ508816.1 Sequence 98 from patent US 8268793
TGGCAATTTGTAC
>GZ508803.1 Sequence 85 from patent US 8268793
ACACTTTGCCCTC
>GZ508802.1 Sequence 84 from patent US 8268793
CACACTTTGCCCT
>GZ508801.1 Sequence 83 from patent US 8268793
ACACACTTTGCCC
>GZ508800.1 Sequence 82 from patent US 8268793
CACACACTTTGCC
>GZ508786.1 Sequence 68 from patent US 8268793
TAATTTCCTTCAG
>GZ508785.1 Sequence 67 from patent US 8268793
CTAATTTCCTTCA
>GZ508784.1 Sequence 66 from patent US 8268793
ACTAATTTCCTTC
>GZ508783.1 Sequence 65 from patent US 8268793
CACTAATTTCCTT
>GZ508761.1 Sequence 43 from patent US 8268793
CACCATAGCTCCA
>GZ508760.1 Sequence 42 from patent US 8268793
ACACCATAGCTCC
>GZ508759.1 Sequence 41 from patent US 8268793
CACACCATAGCTC
>GZ508758.1 Sequence 40 from patent US 8268793
TCACACCATAGCT
>GZ508746.1 Sequence 28 from patent US 8268793
GCTCCAGACATCA
>GZ508745.1 Sequence 27 from patent US 8268793
AGCTCCAGACATC
>GZ508744.1 Sequence 26 from patent US 8268793
TAGCTCCAGACAT
>GZ508743.1 Sequence 25 from patent US 8268793
ATAGCTCCAGACA
>GZ508728.1 Sequence 10 from patent US 8268793
CCAGACATCACTC
>GZ508727.1 Sequence 9 from patent US 8268793
TCCAGACATCACT
>GZ508726.1 Sequence 8 from patent US 8268793
CTCCAGACATCAC
>GZ508725.1 Sequence 7 from patent US 8268793
GCTCCAGACATCA
>GZ507556.1 Sequence 7 from patent US 8268565
CGTGGTACCCCTT
>GZ507554.1 Sequence 5 from patent US 8268565
CGTGGTGACCCTT
>HV764813.1 JP 2012105662-A/15: HUMAN TOLL HOMOLOGUES
GGCCGCTTACCGC
>HV764548.1 JP 2012110338-A/16: NOVEL P-SELECTIN LIGAND PROTEIN
CTGCGGCCGCAGT
>HV774328.1 JP 2012511927-A/217: METHODS, COMPOSITIONS, AND KITS FOR DETECTING ALLELIC VARIANTS
TGAGGCGCTGCCC
>HV774321.1 JP 2012511927-A/210: METHODS, COMPOSITIONS, AND KITS FOR DETECTING ALLELIC VARIANTS
CGCCACCAGCTCC
>HV774320.1 JP 2012511927-A/209: METHODS, COMPOSITIONS, AND KITS FOR DETECTING ALLELIC VARIANTS
CGCCACCAGCTCC
>HV774317.1 JP 2012511927-A/206: METHODS, COMPOSITIONS, AND KITS FOR DETECTING ALLELIC VARIANTS
CGCCACCAGCTCC
>HV774302.1 JP 2012511927-A/191: METHODS, COMPOSITIONS, AND KITS FOR DETECTING ALLELIC VARIANTS
TGAGGCACTGCCC
>HV774295.1 JP 2012511927-A/184: METHODS, COMPOSITIONS, AND KITS FOR DETECTING ALLELIC VARIANTS
CGCCAGCAGCTCC
>HV774294.1 JP 2012511927-A/183: METHODS, COMPOSITIONS, AND KITS FOR DETECTING ALLELIC VARIANTS
CGCCATCAGCTCC
>HV761221.1 JP 2012105644-A/11: PROBE FOR DETECTING POYMORPHISM
CACCTTCTAGTTC
>HV766684.1 WO 2012077800-A/3: Novel Nucleoside Analogue and Use thereof
GAAAGANGAGGAA
>HV766683.1 WO 2012077800-A/2: Novel Nucleoside Analogue and Use thereof
AAGGAGNAGAAAG
>HV766682.1 WO 2012077800-A/1: Novel Nucleoside Analogue and Use thereof
CTTTCTNCTCCTT
>HV766498.1 WO 2012077737-A/8: Anti-PSK polyclonal antibody, and immunological analyzing method for PSK and immunological analyzing kit for PSK using the same
TGGGGCCAAGGCA
>HV755959.1 JP 2012508016-A/1396: COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF
GGCCNNNNNGGCC
>HV757199.1 JP 2012508244-A/234: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
TAGCCTGTCACTT
>HV757197.1 JP 2012508244-A/232: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
TAGCCTGTCACTT
>HV758733.1 JP 2012509678-A/6: Promoters for recombinant viral expression
TTCAGTCCTATGG
>HV757096.1 JP 2012508244-A/131: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
TCTGATGACTCTG
>HV757095.1 JP 2012508244-A/130: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
CTCTGATGACTCT
>HV757094.1 JP 2012508244-A/129: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
CCTCTGATGACTC
>HV757093.1 JP 2012508244-A/128: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
CCCTCTGATGACT
>HV757081.1 JP 2012508244-A/116: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
TGTGTATTTCCCA
>HV757080.1 JP 2012508244-A/115: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
GTGTGTATTTCCC
>HV757079.1 JP 2012508244-A/114: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
TGTGTGTATTTCC
>HV757078.1 JP 2012508244-A/113: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
GTGTGTGTATTTC
>HV757066.1 JP 2012508244-A/101: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
CAATTTGTACTCC
>HV757065.1 JP 2012508244-A/100: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
GCAATTTGTACTC
>HV757064.1 JP 2012508244-A/99: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
GGCAATTTGTACT
>HV757063.1 JP 2012508244-A/98: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
TGGCAATTTGTAC
>HV757050.1 JP 2012508244-A/85: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
ACACTTTGCCCTC
>HV757049.1 JP 2012508244-A/84: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
CACACTTTGCCCT
>HV757048.1 JP 2012508244-A/83: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
ACACACTTTGCCC
>HV757047.1 JP 2012508244-A/82: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
CACACACTTTGCC
>HV757033.1 JP 2012508244-A/68: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
TAATTTCCTTCAG
>HV757032.1 JP 2012508244-A/67: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
CTAATTTCCTTCA
>HV757031.1 JP 2012508244-A/66: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
ACTAATTTCCTTC
>HV757030.1 JP 2012508244-A/65: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
CACTAATTTCCTT
>HV757008.1 JP 2012508244-A/43: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
CACCATAGCTCCA
>HV757007.1 JP 2012508244-A/42: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
ACACCATAGCTCC
>HV757006.1 JP 2012508244-A/41: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
CACACCATAGCTC
>HV757005.1 JP 2012508244-A/40: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
TCACACCATAGCT
>HV756993.1 JP 2012508244-A/28: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
GCTCCAGACATCA
>HV756992.1 JP 2012508244-A/27: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
AGCTCCAGACATC
>HV756991.1 JP 2012508244-A/26: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
TAGCTCCAGACAT
>HV756990.1 JP 2012508244-A/25: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
ATAGCTCCAGACA
>HV756975.1 JP 2012508244-A/10: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
CCAGACATCACTC
>HV756974.1 JP 2012508244-A/9: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
TCCAGACATCACT
>HV756973.1 JP 2012508244-A/8: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
CTCCAGACATCAC
>HV756972.1 JP 2012508244-A/7: ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY
GCTCCAGACATCA
>HV751425.1 JP 2012508563-A/1: BETAG1-IgG Intron for Enhanced Anti-IGF1R Expression
GCCGCCACCATGG
>HV759711.1 JP 2012508779-A/76: Dosage of oligonucleotides suitable for the treatment of tumors
GGATTTCTTTGGC
>HV759689.1 JP 2012508779-A/54: Dosage of oligonucleotides suitable for the treatment of tumors
CGGCAGTGCCCCG
>HV759686.1 JP 2012508779-A/51: Dosage of oligonucleotides suitable for the treatment of tumors
CCCGACGAGCCGG
>GZ506635.1 Sequence 115 from patent US 8273949
YGRCAGGATATAT
>GZ506625.1 Sequence 105 from patent US 8273949
YGRCAGGATATAT
>GZ506477.1 Sequence 1315 from patent US 8273944
ACAGCAGCAAACC
>GZ506476.1 Sequence 1314 from patent US 8273944
CACAGCAACAAAC
>GZ506469.1 Sequence 1307 from patent US 8273944
CAGCGCAGGGCTA
>GZ506468.1 Sequence 1306 from patent US 8273944
CAGCGCAGAGCTA
>GZ503073.1 Sequence 337 from patent US 8273866
TTCCGCGTACGTT
>GZ503069.1 Sequence 331 from patent US 8273866
TTCCGCGTACGNN
>GZ503036.1 Sequence 296 from patent US 8273866
TTCCGCGTACGTT
>GZ503035.1 Sequence 294 from patent US 8273866
TTCCGCGTACGTT
>GZ502827.1 Sequence 84 from patent US 8273866
TTCCGCGTACGNN
>GZ497270.1 Sequence 7 from patent US 8265878
CGTGGTACCCCTT
>GZ497268.1 Sequence 5 from patent US 8265878
CGTGGTGACCCTT
>GZ497262.1 Sequence 6 from patent US 8264014
GTCGTACGGCTAA
>GZ497247.1 Sequence 36 from patent US 8263826
WMWACTDTTAKWH
>GZ497238.1 Sequence 27 from patent US 8263826
WMWACTDTTDNNH
>GZ497203.1 Sequence 27 from patent US 8263824
DTAAACATGTAGG
>GZ494913.1 Sequence 9 from patent US 8263336
GTCGTACGGCTAA
>GZ494902.1 Sequence 12 from patent US 8263335
GGTTGGATCCGAT
>GZ494891.1 Sequence 1 from patent US 8263335
ATCGGATCCATTT
>GZ493999.1 Sequence 6 from patent US 8262900
GTCGTACGGCTAA
>GZ486568.1 Sequence 401 from patent US 8257969
CCAAAGTTGGGGT
>GZ486565.1 Sequence 398 from patent US 8257969
TGGGGTTTTTCCC
>GZ486564.1 Sequence 397 from patent US 8257969
GAATGGGAAAAAC
>GZ486559.1 Sequence 392 from patent US 8257969
TCCTGGGAATGGG
>GZ486548.1 Sequence 381 from patent US 8257969
GGGTCAGGGATCA
>GZ486540.1 Sequence 373 from patent US 8257969
ATTAACGGTGGTG
>GZ486526.1 Sequence 359 from patent US 8257969
CTGATGTCATCCT
>GZ486518.1 Sequence 351 from patent US 8257969
GCTGTTAATTAAA
>GZ486515.1 Sequence 348 from patent US 8257969
ATTTAATTAACAG
>GZ486512.1 Sequence 345 from patent US 8257969
TGTTAATTAAATG
>GZ486508.1 Sequence 341 from patent US 8257969
ACATTTAATTAAC
>GZ486499.1 Sequence 332 from patent US 8257969
AGGCTCCATGCTC
>GZ486497.1 Sequence 330 from patent US 8257969
GAATGGGAAGGTC
>GZ486494.1 Sequence 327 from patent US 8257969
AGGAATGAATGGG
>GZ486492.1 Sequence 325 from patent US 8257969
ATGGAGGAATGAA
>GZ486489.1 Sequence 322 from patent US 8257969
AGGAAGGAATGGA
>GZ486488.1 Sequence 321 from patent US 8257969
CAGGAAGGAATGG
>GZ486482.1 Sequence 315 from patent US 8257969
AGCACAGAATGGG
>GZ486479.1 Sequence 312 from patent US 8257969
TAGGGATAAGTGT
>GZ486469.1 Sequence 302 from patent US 8257969
TGAAAGATGAGTT
>GZ486465.1 Sequence 298 from patent US 8257969
GGAGGAGGGGCAC
>GZ486462.1 Sequence 295 from patent US 8257969
TCCCCAAGGCCAG
>GZ486458.1 Sequence 290 from patent US 8257969
CACTCACCTGGGA
>GZ486454.1 Sequence 286 from patent US 8257969
AATAATTAATGAG
>GZ486452.1 Sequence 284 from patent US 8257969
CTCATTAATTATT
>GZ486451.1 Sequence 283 from patent US 8257969
AAATAATTAATGA
>GZ486448.1 Sequence 280 from patent US 8257969
AGAAATAATTAAT
>GZ486437.1 Sequence 269 from patent US 8257969
TGTGCAGAATGAA
>GZ486433.1 Sequence 264 from patent US 8257969
TGGCTGGGGGAAG
>GZ486425.1 Sequence 256 from patent US 8257969
GGCCCAAGGTTAG
>GZ486423.1 Sequence 254 from patent US 8257969
AGGGGGCTGCCCC
>GZ486422.1 Sequence 253 from patent US 8257969
GGGGCTGCCCCCG
>GZ486418.1 Sequence 248 from patent US 8257969
TGGAATTTGCGCC
>GZ486394.1 Sequence 224 from patent US 8257969
TCTGGGGGGGTCA
>GZ486373.1 Sequence 203 from patent US 8257969
TCAGCATCTGGGA
>GZ486371.1 Sequence 201 from patent US 8257969
ATCTGGGAGATTG
>GZ486362.1 Sequence 192 from patent US 8257969
GGGGATTAATATG
>GZ486360.1 Sequence 189 from patent US 8257969
GGGCCTAATTGGC
>GZ486355.1 Sequence 184 from patent US 8257969
GGGCCAAGGTGAC
>GZ486351.1 Sequence 180 from patent US 8257969
ATTAACGCTGGTC
>GZ486349.1 Sequence 178 from patent US 8257969
ATGAGGTCAAGGT
>GZ486345.1 Sequence 174 from patent US 8257969
GGCATTGAATGGA
>GZ486335.1 Sequence 164 from patent US 8257969
CTCTTAAGCCTCA
>GZ486328.1 Sequence 157 from patent US 8257969
GGGGGGGGGGTCT
>GZ486320.1 Sequence 149 from patent US 8257969
TGAAGGGGGGGGG
>GZ486317.1 Sequence 146 from patent US 8257969
AAACCATCTGATC
>GZ486315.1 Sequence 144 from patent US 8257969
GACAGATCAGATG
>GZ486307.1 Sequence 136 from patent US 8257969
CCCAACAGGCGTC
>GZ486304.1 Sequence 133 from patent US 8257969
GCACTGTTTCCTC
>GZ486294.1 Sequence 123 from patent US 8257969
GCCATATGCAAAT
>GZ486292.1 Sequence 121 from patent US 8257969
GCCTTGAACTGAA
>GZ486281.1 Sequence 110 from patent US 8257969
ACATTTATTAATG
>GZ486272.1 Sequence 101 from patent US 8257969
GTGTCTAATTGCT
>GZ484067.1 Sequence 90 from patent US 8252977
AGTCGCAAAGTCC
>GZ475229.1 Sequence 15 from patent US 8252533
GAGCCAAGATAAC
>GZ475228.1 Sequence 14 from patent US 8252533
GAGCCAGGTAAAC
>GZ465289.1 Sequence 337 from patent US 8242257
TTCCGCGTACGTT
>GZ465285.1 Sequence 331 from patent US 8242257
TTCCGCGTACGNN
>GZ465252.1 Sequence 296 from patent US 8242257
TTCCGCGTACGTT
>GZ465251.1 Sequence 294 from patent US 8242257
TTCCGCGTACGTT
>GZ465043.1 Sequence 84 from patent US 8242257
TTCCGCGTACGTT
>GZ464653.1 Sequence 1241 from patent US 8242254
TGCAGCTGATTGT
>GZ464614.1 Sequence 1202 from patent US 8242254
TGCAGCTGATTGT
>GZ464028.1 Sequence 616 from patent US 8242254
TGGTGCTAGCATT
>GZ464024.1 Sequence 612 from patent US 8242254
TGGTGCTAGCATT
>GZ462681.1 Sequence 115 from patent US 8241896
AGAAAGCTGGGTN
>GZ462287.1 Sequence 170 from patent US 8241879
AAWNRTAAAYARG
>GZ462264.1 Sequence 147 from patent US 8241879
TTCTTKTYYTTTT
>GZ462236.1 Sequence 119 from patent US 8241879
GRTGYAYGGRTGY
>GZ462173.1 Sequence 56 from patent US 8241879
RMACCCANNCAYY
>GZ462169.1 Sequence 52 from patent US 8241879
GAANNTTCNNGAA
>GZ459293.1 Sequence 337 from patent US 8236944
TTCCGCGTACGTT
>GZ459289.1 Sequence 331 from patent US 8236944
TTCCGCGTACGNN
>GZ459256.1 Sequence 296 from patent US 8236944
TTCCGCGTACGTT
>GZ459255.1 Sequence 294 from patent US 8236944
TTCCGCGTACGTT
>GZ459047.1 Sequence 84 from patent US 8236944
TTCCGCGTACGTT
>GZ453821.1 Sequence 25 from patent US 8236493
AGTACTTTCTTTT
>GZ453820.1 Sequence 24 from patent US 8236493
AGTACTGTCTTTT
>GZ453819.1 Sequence 23 from patent US 8236493
AGTACTCTCTTTT
>GZ453818.1 Sequence 22 from patent US 8236493
AGTACTATCTTTT
>GZ453817.1 Sequence 21 from patent US 8236493
GTACTGTCTTTTT
>GZ453816.1 Sequence 20 from patent US 8236493
GTACTGGCTTTTT
>GZ453815.1 Sequence 19 from patent US 8236493
GTACTGCCTTTTT
>GZ453814.1 Sequence 18 from patent US 8236493
GTACTGACTTTTT
>GZ453813.1 Sequence 17 from patent US 8236493
TACTGTTTTTTTT
>GZ453812.1 Sequence 16 from patent US 8236493
TACTGTGTTTTTT
>GZ453811.1 Sequence 15 from patent US 8236493
TACTGTCTTTTTT
>GZ453810.1 Sequence 14 from patent US 8236493
TACTGTATTTTTT
>GZ453807.1 Sequence 11 from patent US 8236493
CCAACCAAAMNMM
>GZ453806.1 Sequence 10 from patent US 8236493
CCAACCAAACCCC
>GZ452904.1 Sequence 51 from patent US 8232584
TGTGGGTGTGGTG
>GZ452902.1 Sequence 49 from patent US 8232584
TTACACGGGGGGG
>GZ452898.1 Sequence 42 from patent US 8232584
TTACCGGGGGGGG
>GZ452894.1 Sequence 34 from patent US 8232584
TTACAGGGGGGGG
>GZ450962.1 Sequence 337 from patent US 8232383
TTCCGCGTACGTT
>GZ450958.1 Sequence 331 from patent US 8232383
TTCCGCGTACGNN
>GZ450925.1 Sequence 296 from patent US 8232383
TTCCGCGTACGTT
>GZ450924.1 Sequence 294 from patent US 8232383
TTCCGCGTACGTT
>GZ450716.1 Sequence 84 from patent US 8232383
TTCCGCGTACGTT
>GZ450264.1 Sequence 78 from patent US 8232259
GGGGTCGACAGGG
>GZ450260.1 Sequence 74 from patent US 8232259
GGCGTCGACGGGG
>GZ450203.1 Sequence 17 from patent US 8232259
CTCGAGCGTTCTC
>GZ450081.1 Sequence 18 from patent US 8232252
CTGCGGCCGCAGT
>GZ449817.1 Sequence 44 from patent US 8232081
AGAAAGGAGGTGA
>GZ449584.1 Sequence 324 from patent US 8232058
CCAAAACAGAAAC
>GZ448800.1 Sequence 183 from patent US 8231877
CACATCGATACTG
>GZ448338.1 Sequence 3 from patent US 8227192
GCTAATACGCCGC
>GZ448336.1 Sequence 1 from patent US 8227192
AGACGTGCATAGT
>HV743642.1 JP 2012507307-A/6: Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells
GGGTCGCAGCTGG
>HV743351.1 JP 2012507308-A/1: Methods and compounds for the treatment of multiple sclerosis
GGGTCGCAGCTGG
>HV742650.1 JP 2012506709-A/113: Sequencing of nucleic acid molecules by mass spectrometry
GCGTGGTGTGATC
>HV742610.1 JP 2012506709-A/73: Sequencing of nucleic acid molecules by mass spectrometry
GCACGTCCCTCAC
>HV742560.1 JP 2012506709-A/23: Sequencing of nucleic acid molecules by mass spectrometry
GCACGTCCCTCAC
>HV704834.1 JP 2012504962-A/55: TELOMERASE INHIBITORS AND METHODS OF USE THEREOF
ACGGTAGCATCTT
>HV704806.1 JP 2012504962-A/27: TELOMERASE INHIBITORS AND METHODS OF USE THEREOF
GTCAGCGAGAAAA
>HV702794.1 JP 2012080886-A/40: Mutant AOX1 promoters
ATCATCCAAAAAG
>HV702788.1 JP 2012080886-A/34: Mutant AOX1 promoters
GAGCTCCAATCAA
>HV702787.1 JP 2012080886-A/33: Mutant AOX1 promoters
CAAGCCCAATAAC
>HV701532.1 JP 2012083193-A/28: METHOD FOR DETECTING GLYCOSYLATION OF HISTONE PROTEINS, AND ANTIBODIES USED IN THE METHOD
NGNNCANNGNNCN
>HV704694.1 JP 2012504959-A/17: Engineered Cells Expressing Multiple Immunomodulators and Uses Thereof
AGGTCANAGGTCA
>GZ444574.1 Sequence 21 from patent US 8207142
ACAGTCGNGTACC
>GZ444573.1 Sequence 20 from patent US 8207142
TGTCAGNGCATGG
>GZ443316.1 Sequence 12 from patent US 8206952
GGTTGGATCCGAT
>GZ443305.1 Sequence 1 from patent US 8206952
ATCGGATCCATTT
>GZ441637.1 Sequence 24 from patent US 8206921
GCGGAGGCTAACT
>GZ441636.1 Sequence 23 from patent US 8206921
GCGGAGGCTAACT
>GZ440982.1 Sequence 71 from patent US 8206914
TCCCTGATCGACC
>GZ440979.1 Sequence 68 from patent US 8206914
AAGGTGGTATACC
>GZ440977.1 Sequence 66 from patent US 8206914
TCCCGAGTCGACC
>GZ440976.1 Sequence 65 from patent US 8206914
TCCCGAGTCGACC
>GZ440441.1 Sequence 194 from patent US 8206904
CACTCGAACGTCG
>GZ440413.1 Sequence 166 from patent US 8206904
CACTGCTTCGTGG
>GZ440377.1 Sequence 130 from patent US 8206904
CACTCGAACGTCG
>GZ440376.1 Sequence 129 from patent US 8206904
CACTGCTTCGTGG
>GZ440307.1 Sequence 60 from patent US 8206904
CGGCGTGGCGAGC
>GZ440300.1 Sequence 53 from patent US 8206904
AACTATACAACCG
>GZ440268.1 Sequence 21 from patent US 8206904
CACTGCTTCGTGG
>GZ440064.1 Sequence 4 from patent US 8206899
GGGGGGGGGGGGG
>GZ440063.1 Sequence 3 from patent US 8206899
GGGGGGGGGGGGG
>GZ439390.1 Sequence 7 from patent US 8214154
CGTGGTACCCCTT
>GZ439388.1 Sequence 5 from patent US 8214154
CGTGGTGACCCTT
>GZ435402.1 Sequence 394 from patent US 8211428
ATGGAACCCTGAA
>GZ342786.1 Sequence 66 from patent US 8197821
GGCCTTCGTCCGG
>GZ342784.1 Sequence 64 from patent US 8197821
TTCGTGGCCCCTG
>GZ379453.1 Sequence 32 from patent US 8224578
AAGAAGGAANATG
>GZ379449.1 Sequence 28 from patent US 8224578
TAASGAGGTNDTG
>GZ378533.1 Sequence 60 from patent US 8222481
TGGGAGGCAATTC
>GZ378426.1 Sequence 126 from patent US 8222398
TCGGAAANGTTCG
>GZ378416.1 Sequence 116 from patent US 8222398
TNGTGAACGTTCG
>GZ378414.1 Sequence 114 from patent US 8222398
TCGTTAACGTTCG
>GZ378408.1 Sequence 108 from patent US 8222398
TCGGAACCGTTCG
>GZ378407.1 Sequence 107 from patent US 8222398
TCGGTACCGTTCG
>GZ378406.1 Sequence 106 from patent US 8222398
TCGGTATCGGTCG
>GZ378405.1 Sequence 105 from patent US 8222398
TCGTGAACGTTCG
>GZ378401.1 Sequence 101 from patent US 8222398
TCGTTAACGTTCG
>GZ378399.1 Sequence 99 from patent US 8222398
TNGTGAACGTTCG
>GZ378397.1 Sequence 97 from patent US 8222398
TCGTGAACGTTCG
>GZ375807.1 Sequence 21 from patent US 8222373
GACCATACTTCAC
>GZ374435.1 Sequence 6 from patent US 8222005
GTTGGATCCTGGG
>GZ373517.1 Sequence 77 from patent US 8221971
GTGGCCTAGGCAC
>GZ373076.1 Sequence 5355 from patent US 8216786
TGCTGGCCGTCCA
>GZ372203.1 Sequence 4482 from patent US 8216786
CATCCCGCGCCAC
>GZ372202.1 Sequence 4481 from patent US 8216786
CATCCCGCGCCAT
>GZ372032.1 Sequence 4311 from patent US 8216786
TGCGGCTCCACCA
>GZ366725.1 Sequence 153 from patent US 8217160
NNATCNCTNGCNG
>GZ366162.1 Sequence 2 from patent US 8217016
GCCGCCACCATGG
>GZ364995.1 Sequence 27 from patent US 8216580
GCTGCATAAGTGC
>GZ364213.1 Sequence 64 from patent US 8097715
GCTGGCCGAGGAG
>GZ364212.1 Sequence 63 from patent US 8097715
AGGGCTCCAGGCG
>GZ364211.1 Sequence 62 from patent US 8097715
CTCCTCGGCCAGC
>GZ364210.1 Sequence 61 from patent US 8097715
CGCCTGGAGCCCT
>GZ364172.1 Sequence 21 from patent US 8097715
CTGGGCGAGGCAG
>GZ364170.1 Sequence 19 from patent US 8097715
CTGCCTCGCCCAG
>GZ363766.1 Sequence 36 from patent US 8097597
GGATTTCTTTGGC
>GZ363744.1 Sequence 14 from patent US 8097597
CGGCAGTGCCCCG
>GZ363741.1 Sequence 11 from patent US 8097597
CCCGACGAGCCGG
>GZ362578.1 Sequence 1241 from patent US 8097416
TGCAGCTGATTGT
>GZ362539.1 Sequence 1202 from patent US 8097416
TGCAGCTGATTGT
>GZ361953.1 Sequence 616 from patent US 8097416
TGGTGCTAGCATT
>GZ361949.1 Sequence 612 from patent US 8097416
TGGTGCTAGCATT
>GZ361256.1 Sequence 10 from patent US 8097412
TGACCCTCCTTCC
>GZ358435.1 Sequence 666 from patent US 8093037
TTCTTKTYYTTTT
>GZ358408.1 Sequence 639 from patent US 8093037
GRTGYAYGGRTGY
>GZ358342.1 Sequence 573 from patent US 8093037
AAWNRTAAAYARG
>GZ358307.1 Sequence 538 from patent US 8093037
RMACCCANNCAYY
>GZ358303.1 Sequence 534 from patent US 8093037
GAANNTTCNNGAA
>GZ357804.1 Sequence 76 from patent US 8093036
GGGCCGGATCCGC
>GZ357488.1 Sequence 25 from patent US 8093021
GCGCGCCTCTAGA
>GZ356026.1 Sequence 21 from patent US 8202981
GTGCTGACAGCCA
>GZ355749.1 Sequence 337 from patent US 8202979
TTCCGCGTACGTT
>GZ355745.1 Sequence 331 from patent US 8202979
TTCCGCGTACGTT
>GZ355712.1 Sequence 296 from patent US 8202979
TTCCGCGTACGTT
>GZ355711.1 Sequence 294 from patent US 8202979
TTCCGCGTACGTT
>GZ355503.1 Sequence 84 from patent US 8202979
TTCCGCGTACGTT
>GZ355413.1 Sequence 21 from patent US 8202978
GAGAGACTAACGC
>GZ355057.1 Sequence 58 from patent US 8202850
CTATCTGACGTTC
>GZ355053.1 Sequence 54 from patent US 8202850
CCTACTAGCGTTC
>GZ355050.1 Sequence 51 from patent US 8202850
TAGCGTTCTCATC
>GZ355024.1 Sequence 25 from patent US 8202850
NNTCTGACNTTCT
>GZ355020.1 Sequence 21 from patent US 8202850
NNTCTGTCNTTCT
>GZ355002.1 Sequence 3 from patent US 8202850
TGACGTTCTCTGT
>GZ354813.1 Sequence 9 from patent US 8202823
TCAGCNNNNNNNN
>GZ354805.1 Sequence 1 from patent US 8202823
GGCCNNNNNGGCC
>GZ354344.1 Sequence 84 from patent US 8202688
TGTCGTTGTCGTT
>AB415555.1 Bombyx mori non-coding RNA, ovarian small RNA-29365, complete sequence
TCGTTGTTCCGGG
>HV696418.1 JP 2012502991-A/413: RNA INTERFERENCE IN SKIN INDICATIONS
CAGCCGTGAATTC
>HV696417.1 JP 2012502991-A/412: RNA INTERFERENCE IN SKIN INDICATIONS
CAGACGAGGACAT
>HV700513.1 JP 2012504413-A/15: Papio cynocephalus Toll-like Receptor 3
CATCCAACAGAAT
>HV699911.1 JP 2012504657-A/81: TREATMENT OF APOLIPOPROTEIN-A1 RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO APOLIPOPROTEIN-A1
AAACTGAGCTCCA
>HV693398.1 WO 2012029870-A/11: Oligonucleotide and therapeutic agent for dyslipidemia containing the same as an active ingredient
CTGCTGCCCACGT
>HV693394.1 WO 2012029870-A/7: Oligonucleotide and therapeutic agent for dyslipidemia containing the same as an active ingredient
GCCTGCCTCTACT
>HV693392.1 WO 2012029870-A/5: Oligonucleotide and therapeutic agent for dyslipidemia containing the same as an active ingredient
GGTCAGCGGCCGG
>HV693390.1 WO 2012029870-A/3: Oligonucleotide and therapeutic agent for dyslipidemia containing the same as an active ingredient
GCACCCTCATAGG
>HV699833.1 JP 2012504657-A/3: TREATMENT OF APOLIPOPROTEIN-A1 RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO APOLIPOPROTEIN-A1
TGGAGCTCAGTTT
>HV693042.1 WO 2012029434-A/4: Oligonucleotide and use thereof
GATTGCNGATACC
>HV693039.1 WO 2012029434-A/1: Oligonucleotide and use thereof
GGTATCNGCAATC
>HV698150.1 JP 2012504416-A/45: IMPROVED ANTIBODY LIBRARIES
CCACGCTGCTGAG
>HV698149.1 JP 2012504416-A/44: IMPROVED ANTIBODY LIBRARIES
GAAGGTGTGCACG
>HV698050.1 JP 2012504390-A/76: Methods for using positively and negatively selectable genes in a filamentous fungal cell
DTAAACATGTAGG
>HV697941.1 JP 2012503983-A/15: Compatible Display Vector Systems
GCCGCCACCATGG
>HV697939.1 JP 2012503983-A/13: Compatible Display Vector Systems
GGCCNNNNNGGCC
>HV697932.1 JP 2012503983-A/6: Compatible Display Vector Systems
GGCCTCAGGGGCC
>HV697931.1 JP 2012503983-A/5: Compatible Display Vector Systems
GGCCCAGGCGGCC
>HV697926.1 JP 2012503982-A/15: Phage Display Vector
GCCGCCACCATGG
>HV697924.1 JP 2012503982-A/13: Phage Display Vector
GGCCNNNNNGGCC
>HV697917.1 JP 2012503982-A/6: Phage Display Vector
GGCCTCAGGGGCC
>HV697916.1 JP 2012503982-A/5: Phage Display Vector
GGCCCAGGCGGCC
>HV697864.1 JP 2012503490-A/11: Single Chain Antibody Library Design
GCCGCCACCATGG
>HV697862.1 JP 2012503490-A/9: Single Chain Antibody Library Design
GGCCNNNNNGGCC
>HV697647.1 JP 2012502657-A/821: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACCTGCCAGCAAC
>HV697646.1 JP 2012502657-A/820: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GACTCGAACGACT
>HV697645.1 JP 2012502657-A/819: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCAGCAATTAATA
>HV697644.1 JP 2012502657-A/818: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTCCAGCAATTAA
>HV697643.1 JP 2012502657-A/817: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTGAGTCTGGAAA
>HV697642.1 JP 2012502657-A/816: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AATGTGTATCTAT
>HV697641.1 JP 2012502657-A/815: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTCAGCCGTGAAT
>HV697640.1 JP 2012502657-A/814: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GATGTGATTGATA
>HV697639.1 JP 2012502657-A/813: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GACCAGAGTGCTG
>HV697638.1 JP 2012502657-A/812: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGTTTATGGACT
>HV697637.1 JP 2012502657-A/811: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGGTCACTGATT
>HV697636.1 JP 2012502657-A/810: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCAACGAAAGCCA
>HV697635.1 JP 2012502657-A/809: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACCATGAGAATTG
>HV697634.1 JP 2012502657-A/808: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGTCAATTGCTTA
>HV697633.1 JP 2012502657-A/807: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AATTCCACAGCCA
>HV697632.1 JP 2012502657-A/806: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGAGCATTCCGAT
>HV697631.1 JP 2012502657-A/805: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAGTGCTGAAACC
>HV697630.1 JP 2012502657-A/804: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAACAGGCTGATT
>HV697629.1 JP 2012502657-A/803: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACTACCATGAGAA
>HV697628.1 JP 2012502657-A/802: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTCAGCCGTGAA
>HV697627.1 JP 2012502657-A/801: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATAGTCAGGAACT
>HV697626.1 JP 2012502657-A/800: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGCCAATGATGA
>HV697625.1 JP 2012502657-A/799: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TAGTGTGGTTTAT
>HV697624.1 JP 2012502657-A/798: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACGACTCTGATGA
>HV697623.1 JP 2012502657-A/797: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCAATTAATAAA
>HV697622.1 JP 2012502657-A/796: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTCAATTGCTTAT
>HV697621.1 JP 2012502657-A/795: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AACTATCACTGTA
>HV697620.1 JP 2012502657-A/794: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TCATTCTATAGAA
>HV697619.1 JP 2012502657-A/793: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATAACTAATGTGT
>HV697618.1 JP 2012502657-A/792: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTCCGATGTGATT
>HV697617.1 JP 2012502657-A/791: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TATAAGCGGAAAG
>HV697616.1 JP 2012502657-A/790: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTCAGCTGGATG
>HV697615.1 JP 2012502657-A/789: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTTGAATGGTGC
>HV697614.1 JP 2012502657-A/788: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CACCTCACACATG
>HV697613.1 JP 2012502657-A/787: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCCAGCAACCGAA
>HV697612.1 JP 2012502657-A/786: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TCATGAATAGAAA
>HV697611.1 JP 2012502657-A/785: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGAAATAACTAAT
>HV697610.1 JP 2012502657-A/784: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGTTGAATGTGTA
>HV697609.1 JP 2012502657-A/783: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATTGGTTGAATGT
>HV697608.1 JP 2012502657-A/782: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAGCCATGAATTT
>HV697607.1 JP 2012502657-A/781: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCAGAGTGCTGAA
>HV697606.1 JP 2012502657-A/780: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGAAACGAGTCA
>HV697605.1 JP 2012502657-A/779: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGTGCATACAAG
>HV697604.1 JP 2012502657-A/778: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTAGATAGTGCAT
>HV697603.1 JP 2012502657-A/777: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCAATGAGCATT
>HV697602.1 JP 2012502657-A/776: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGTTTCGCAGAC
>HV697601.1 JP 2012502657-A/775: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTCCAACGAAAG
>HV697600.1 JP 2012502657-A/774: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTTTGTGGCTTC
>HV697599.1 JP 2012502657-A/773: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTCTGGAAATAA
>HV697598.1 JP 2012502657-A/772: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAGCCGTGAATTC
>HV697597.1 JP 2012502657-A/771: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAGACGAGGACAT
>HV697596.1 JP 2012502657-A/770: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TAGACACATATGA
>HV697595.1 JP 2012502657-A/769: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTCTGATGAGTCT
>HV697594.1 JP 2012502657-A/768: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGCATTTAGTCAA
>HV697593.1 JP 2012502657-A/767: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TAGTCAGGAACTT
>HV697592.1 JP 2012502657-A/766: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCATTCCGATGT
>HV697591.1 JP 2012502657-A/765: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCAGTCCAGATT
>HV697590.1 JP 2012502657-A/764: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATATGATGGCCGA
>HV697589.1 JP 2012502657-A/763: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAATGGTGCATAC
>HV697588.1 JP 2012502657-A/762: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCGACCAAGGAAA
>HV697587.1 JP 2012502657-A/761: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGTTCATTCTATA
>HV697586.1 JP 2012502657-A/760: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TACCAGTTAAACA
>HV697585.1 JP 2012502657-A/759: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATATAAGCGGAAA
>HV697584.1 JP 2012502657-A/758: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAGTCCAGATTAT
>HV697583.1 JP 2012502657-A/757: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTATGAAACGAGT
>HV697582.1 JP 2012502657-A/756: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGTTGAATGTGT
>HV697581.1 JP 2012502657-A/755: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCAGTCCAGATTA
>HV697580.1 JP 2012502657-A/754: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACATGGAAAGCGA
>HV697579.1 JP 2012502657-A/753: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTGTCCAGCAATT
>HV697578.1 JP 2012502657-A/752: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTCTATAGAAGAA
>HV697577.1 JP 2012502657-A/751: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGTGTATCTATT
>HV697576.1 JP 2012502657-A/750: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGATAGTGCATCT
>HV697575.1 JP 2012502657-A/749: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGATTGATAGTCA
>HV697574.1 JP 2012502657-A/748: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCGAGGAGTTGAA
>HV697573.1 JP 2012502657-A/747: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGATGAGAGCAA
>HV697572.1 JP 2012502657-A/746: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGTCCAACGAAA
>HV697571.1 JP 2012502657-A/745: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTCTCATGAATAG
>HV697570.1 JP 2012502657-A/744: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATTTCTCATGAAT
>HV697569.1 JP 2012502657-A/743: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCGCCTTCTGATT
>HV697568.1 JP 2012502657-A/742: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAAATTTCGTATT
>HV697567.1 JP 2012502657-A/741: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACATGGATGATAT
>HV697566.1 JP 2012502657-A/740: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAAGCCATGACCA
>HV697565.1 JP 2012502657-A/739: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATTTCGTATTTCT
>HV697564.1 JP 2012502657-A/738: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAATTTCGTATTT
>HV697563.1 JP 2012502657-A/737: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCGGAAAGCCAAT
>HV697562.1 JP 2012502657-A/736: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGCCATGACCAC
>HV697561.1 JP 2012502657-A/735: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCCATGACCACAT
>HV697560.1 JP 2012502657-A/734: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACCACATGGATGA
>HV697559.1 JP 2012502657-A/733: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCGGAAAGCCAA
>HV697558.1 JP 2012502657-A/732: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGCGGAAAGCCA
>HV697557.1 JP 2012502657-A/731: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTCTCACCATTC
>HV697556.1 JP 2012502657-A/730: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TCACAGCCATGAA
>HV697555.1 JP 2012502657-A/729: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GACTGAGGTCAAA
>HV697554.1 JP 2012502657-A/728: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAGTCTCACCATT
>HV697553.1 JP 2012502657-A/727: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGACTGAGGTCA
>HV697552.1 JP 2012502657-A/726: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTCTGATGAATCT
>HV697551.1 JP 2012502657-A/725: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTCAGCTGGATGA
>HV697550.1 JP 2012502657-A/724: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTCTGAGGTCAAT
>HV697549.1 JP 2012502657-A/723: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGAGGTCAATTAA
>HV697548.1 JP 2012502657-A/722: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TCTGAGGTCAATT
>HV697547.1 JP 2012502657-A/721: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAGGTCAATTAAA
>HV697546.1 JP 2012502657-A/720: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGAGGTCAATTA
>HV697545.1 JP 2012502657-A/719: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTCATGAATTAGA
>HV697439.1 JP 2012502657-A/613: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AATGAAGAAAGTA
>HV697435.1 JP 2012502657-A/609: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AATGAAGAAAGTA
>HV697434.1 JP 2012502657-A/608: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TACTTTCTTCATT
>HV697427.1 JP 2012502657-A/601: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697426.1 JP 2012502657-A/600: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TAGACTTCCACAG
>HV697424.1 JP 2012502657-A/598: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697420.1 JP 2012502657-A/594: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACAAATACGATTT
>HV697419.1 JP 2012502657-A/593: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACAAATACGATTT
>HV697416.1 JP 2012502657-A/590: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGCTACAAAAACA
>HV697415.1 JP 2012502657-A/589: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCATTTAGTCAAA
>HV697414.1 JP 2012502657-A/588: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAAGCTGACCTGG
>HV697413.1 JP 2012502657-A/587: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TATCAAGTTTGAG
>HV697412.1 JP 2012502657-A/586: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCGCAAGATCGGC
>HV697411.1 JP 2012502657-A/585: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGACACGTTTGGC
>HV697410.1 JP 2012502657-A/584: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTAAATTCTGTGG
>HV697409.1 JP 2012502657-A/583: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCTAAATTCTGTG
>HV697408.1 JP 2012502657-A/582: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGACTTCGGC
>HV697407.1 JP 2012502657-A/581: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCTTGCGAAGCTG
>HV697406.1 JP 2012502657-A/580: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGCGAAGCTGACC
>HV697405.1 JP 2012502657-A/579: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TACGGAGACATGG
>HV697404.1 JP 2012502657-A/578: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCTGTTCCAAGAC
>HV697403.1 JP 2012502657-A/577: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTACCAGTGCACG
>HV697402.1 JP 2012502657-A/576: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAATGACAACGCC
>HV697401.1 JP 2012502657-A/575: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTGCGAAGCTGAC
>HV697400.1 JP 2012502657-A/574: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CGAAGCTGACCTG
>HV697399.1 JP 2012502657-A/573: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGTTCCAAGACCT
>HV697398.1 JP 2012502657-A/572: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCTATCAAGTTTG
>HV697397.1 JP 2012502657-A/571: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCGACTGGAAGAC
>HV697396.1 JP 2012502657-A/570: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTTGCGAAGCTGA
>HV697395.1 JP 2012502657-A/569: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGCCTTGCGAAGC
>HV697394.1 JP 2012502657-A/568: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CGAGGTCATGAAG
>HV697393.1 JP 2012502657-A/567: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGACACGTTTGG
>HV697392.1 JP 2012502657-A/566: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAGCTAAATTCTG
>HV697391.1 JP 2012502657-A/565: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGTCAGGCCTTGC
>HV697390.1 JP 2012502657-A/564: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCTAGAGAAGCAG
>HV697389.1 JP 2012502657-A/563: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGAGTATGTACC
>HV697388.1 JP 2012502657-A/562: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCCAGAACTGCAG
>HV697387.1 JP 2012502657-A/561: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TCAAGTTTGAGCT
>HV697386.1 JP 2012502657-A/560: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGTCAGGCCTTG
>HV697385.1 JP 2012502657-A/559: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGACTTCGGCTCC
>HV697384.1 JP 2012502657-A/558: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTGACTTCGGCTC
>HV697383.1 JP 2012502657-A/557: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGAAGATGTACGG
>HV697382.1 JP 2012502657-A/556: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCGAAGCTGACCT
>HV697381.1 JP 2012502657-A/555: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TCAGGCCTTGCGA
>HV697380.1 JP 2012502657-A/554: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACGGAGACATGGC
>HV697379.1 JP 2012502657-A/553: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GACACGTTTGGCC
>HV697378.1 JP 2012502657-A/552: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGCGAGGTCATGA
>HV697377.1 JP 2012502657-A/551: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AATGACAACGCCT
>HV697376.1 JP 2012502657-A/550: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGATGTACGGAG
>HV697375.1 JP 2012502657-A/549: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGAAGACACGTT
>HV697374.1 JP 2012502657-A/548: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TAAATTCTGTGGA
>HV697373.1 JP 2012502657-A/547: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAGGTCATGAAGA
>HV697372.1 JP 2012502657-A/546: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGACAACGCCTC
>HV697371.1 JP 2012502657-A/545: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CGGAGACATGGCA
>HV697370.1 JP 2012502657-A/544: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TCTGTGGAGTATG
>HV697369.1 JP 2012502657-A/543: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CGAGCTAAATTCT
>HV697368.1 JP 2012502657-A/542: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAGGCCTTGCGAA
>HV697367.1 JP 2012502657-A/541: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACCGCAAGATCGG
>HV697366.1 JP 2012502657-A/540: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TACCGACTGGAAG
>HV697365.1 JP 2012502657-A/539: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGGCCTTGCGAAG
>HV697364.1 JP 2012502657-A/538: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAAGACACGTTTG
>HV697363.1 JP 2012502657-A/537: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGGTCAGGCCTT
>HV697362.1 JP 2012502657-A/536: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGTCATGAAGAAG
>HV697361.1 JP 2012502657-A/535: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGCTGACCTGGA
>HV697360.1 JP 2012502657-A/534: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATTTGAAGTGTAA
>HV697359.1 JP 2012502657-A/533: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTTGTTCCTTAA
>HV697358.1 JP 2012502657-A/532: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCAGAAAGGTTA
>HV697357.1 JP 2012502657-A/531: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACATACCGAGCTA
>HV697356.1 JP 2012502657-A/530: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTGTTGAGAGTGT
>HV697355.1 JP 2012502657-A/529: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATACCGAGCTAAA
>HV697354.1 JP 2012502657-A/528: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGGCCTTTATTA
>HV697353.1 JP 2012502657-A/527: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GACTGGACAGCTT
>HV697352.1 JP 2012502657-A/526: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TATACGAGTAATA
>HV697351.1 JP 2012502657-A/525: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTATCTAAGTTAA
>HV697350.1 JP 2012502657-A/524: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTCTGCTCAGATA
>HV697349.1 JP 2012502657-A/523: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCTGATCAGTTT
>HV697348.1 JP 2012502657-A/522: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGGTAGAATGTAA
>HV697347.1 JP 2012502657-A/521: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCTAAATTCTGT
>HV697346.1 JP 2012502657-A/520: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTATCAAGTTTGA
>HV697345.1 JP 2012502657-A/519: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGAAGACACGTTT
>HV697344.1 JP 2012502657-A/518: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTACCAGTGCAC
>HV697343.1 JP 2012502657-A/517: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAATGACATCTTT
>HV697342.1 JP 2012502657-A/516: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTTCAGTAGCACA
>HV697341.1 JP 2012502657-A/515: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAATTCTGTGGAG
>HV697340.1 JP 2012502657-A/514: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAGTATGT
>HV697339.1 JP 2012502657-A/513: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAAGTTTGAGCTT
>HV697338.1 JP 2012502657-A/512: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCCTATCAAGTT
>HV697337.1 JP 2012502657-A/511: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGTACGGAGACAT
>HV697336.1 JP 2012502657-A/510: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AATTCTGTGGAGT
>HV697335.1 JP 2012502657-A/509: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCCTATCAAGTTT
>HV697334.1 JP 2012502657-A/508: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCTGCGAGGAGTG
>HV697333.1 JP 2012502657-A/507: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCCTTGCGAAGCT
>HV697332.1 JP 2012502657-A/506: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGTACGGAGACA
>HV697331.1 JP 2012502657-A/505: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACCGACTGGAAGA
>HV697330.1 JP 2012502657-A/504: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGAGTGGAGCGCC
>HV697329.1 JP 2012502657-A/503: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CATTACAACTGTC
>HV697328.1 JP 2012502657-A/502: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATTACAACTGTCC
>HV697327.1 JP 2012502657-A/501: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGCCATTACAAC
>HV697326.1 JP 2012502657-A/500: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCATTACAACTGT
>HV697325.1 JP 2012502657-A/499: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCTGGTCCAGACC
>HV697324.1 JP 2012502657-A/498: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAGAGTGGAGCGC
>HV697323.1 JP 2012502657-A/497: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGACCTGTGCCTG
>HV697322.1 JP 2012502657-A/496: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AACTGCCTGGTCC
>HV697321.1 JP 2012502657-A/495: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACTGGAAGACACG
>HV697320.1 JP 2012502657-A/494: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGCCATTACAACT
>HV697319.1 JP 2012502657-A/493: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTTTGAGCTTTCT
>HV697318.1 JP 2012502657-A/492: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGAGCGCCTGTT
>HV697317.1 JP 2012502657-A/491: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTGGAGCGCCTG
>HV697316.1 JP 2012502657-A/490: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAGCTTTCTGGCT
>HV697315.1 JP 2012502657-A/489: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCCATTACAACTG
>HV697314.1 JP 2012502657-A/488: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGAGCGCCTGTTC
>HV697313.1 JP 2012502657-A/487: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CGACTGGAAGACA
>HV697312.1 JP 2012502657-A/486: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAGTGGAGCGCCT
>HV697311.1 JP 2012502657-A/485: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACAGGAAGATGTA
>HV697310.1 JP 2012502657-A/484: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697307.1 JP 2012502657-A/481: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACTGAATACCAAT
>HV697306.1 JP 2012502657-A/480: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACTGAATACCAAT
>HV697304.1 JP 2012502657-A/478: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTCCCTCAAACA
>HV697302.1 JP 2012502657-A/476: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGAGAAACAACAT
>HV697299.1 JP 2012502657-A/473: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GACTCATCTGCTA
>HV697298.1 JP 2012502657-A/472: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GACTCATCTGCTA
>HV697296.1 JP 2012502657-A/470: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATCTGGAGAAACA
>HV697295.1 JP 2012502657-A/469: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGTAGGATGTCTA
>HV697292.1 JP 2012502657-A/466: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGCTACAAAAACA
>HV697291.1 JP 2012502657-A/465: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697290.1 JP 2012502657-A/464: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACTGAATACCAAT
>HV697289.1 JP 2012502657-A/463: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACTGAATACCAAT
>HV697288.1 JP 2012502657-A/462: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACCTGCCAGCAAC
>HV697287.1 JP 2012502657-A/461: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GACTCGAACGACT
>HV697286.1 JP 2012502657-A/460: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCAGCAATTAATA
>HV697285.1 JP 2012502657-A/459: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTCCAGCAATTAA
>HV697284.1 JP 2012502657-A/458: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTGAGTCTGGAAA
>HV697283.1 JP 2012502657-A/457: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AATGTGTATCTAT
>HV697282.1 JP 2012502657-A/456: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTCAGCCGTGAAT
>HV697281.1 JP 2012502657-A/455: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GATGTGATTGATA
>HV697280.1 JP 2012502657-A/454: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GACCAGAGTGCTG
>HV697279.1 JP 2012502657-A/453: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGTTTATGGACT
>HV697278.1 JP 2012502657-A/452: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGGTCACTGATT
>HV697277.1 JP 2012502657-A/451: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCAACGAAAGCCA
>HV697276.1 JP 2012502657-A/450: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACCATGAGAATTG
>HV697275.1 JP 2012502657-A/449: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGTCAATTGCTTA
>HV697274.1 JP 2012502657-A/448: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AATTCCACAGCCA
>HV697273.1 JP 2012502657-A/447: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGAGCATTCCGAT
>HV697272.1 JP 2012502657-A/446: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAGTGCTGAAACC
>HV697271.1 JP 2012502657-A/445: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAACAGGCTGATT
>HV697270.1 JP 2012502657-A/444: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACTACCATGAGAA
>HV697269.1 JP 2012502657-A/443: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTCAGCCGTGAA
>HV697268.1 JP 2012502657-A/442: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATAGTCAGGAACT
>HV697267.1 JP 2012502657-A/441: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGCCAATGATGA
>HV697266.1 JP 2012502657-A/440: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TAGTGTGGTTTAT
>HV697265.1 JP 2012502657-A/439: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACGACTCTGATGA
>HV697264.1 JP 2012502657-A/438: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCAATTAATAAA
>HV697263.1 JP 2012502657-A/437: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTCAATTGCTTAT
>HV697262.1 JP 2012502657-A/436: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AACTATCACTGTA
>HV697261.1 JP 2012502657-A/435: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TCATTCTATAGAA
>HV697260.1 JP 2012502657-A/434: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATAACTAATGTGT
>HV697259.1 JP 2012502657-A/433: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTCCGATGTGATT
>HV697258.1 JP 2012502657-A/432: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TATAAGCGGAAAG
>HV697257.1 JP 2012502657-A/431: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTCAGCTGGATG
>HV697256.1 JP 2012502657-A/430: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTTGAATGGTGC
>HV697255.1 JP 2012502657-A/429: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CACCTCACACATG
>HV697254.1 JP 2012502657-A/428: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCCAGCAACCGAA
>HV697253.1 JP 2012502657-A/427: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TCATGAATAGAAA
>HV697252.1 JP 2012502657-A/426: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGAAATAACTAAT
>HV697251.1 JP 2012502657-A/425: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGTTGAATGTGTA
>HV697250.1 JP 2012502657-A/424: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATTGGTTGAATGT
>HV697249.1 JP 2012502657-A/423: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAGCCATGAATTT
>HV697248.1 JP 2012502657-A/422: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCAGAGTGCTGAA
>HV697247.1 JP 2012502657-A/421: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGAAACGAGTCA
>HV697246.1 JP 2012502657-A/420: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGTGCATACAAG
>HV697245.1 JP 2012502657-A/419: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTAGATAGTGCAT
>HV697244.1 JP 2012502657-A/418: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCAATGAGCATT
>HV697243.1 JP 2012502657-A/417: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGTTTCGCAGAC
>HV697242.1 JP 2012502657-A/416: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTCCAACGAAAG
>HV697241.1 JP 2012502657-A/415: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTTTGTGGCTTC
>HV697240.1 JP 2012502657-A/414: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTCTGGAAATAA
>HV697239.1 JP 2012502657-A/413: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAGCCGTGAATTC
>HV697238.1 JP 2012502657-A/412: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAGACGAGGACAT
>HV697237.1 JP 2012502657-A/411: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TAGACACATATGA
>HV697236.1 JP 2012502657-A/410: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTCTGATGAGTCT
>HV697235.1 JP 2012502657-A/409: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGCATTTAGTCAA
>HV697234.1 JP 2012502657-A/408: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TAGTCAGGAACTT
>HV697233.1 JP 2012502657-A/407: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCATTCCGATGT
>HV697232.1 JP 2012502657-A/406: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCATTTAGTCAAA
>HV697231.1 JP 2012502657-A/405: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCAGTCCAGATT
>HV697230.1 JP 2012502657-A/404: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATATGATGGCCGA
>HV697229.1 JP 2012502657-A/403: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAATGGTGCATAC
>HV697228.1 JP 2012502657-A/402: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCGACCAAGGAAA
>HV697227.1 JP 2012502657-A/401: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGTTCATTCTATA
>HV697226.1 JP 2012502657-A/400: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TACCAGTTAAACA
>HV697225.1 JP 2012502657-A/399: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATATAAGCGGAAA
>HV697224.1 JP 2012502657-A/398: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAGTCCAGATTAT
>HV697223.1 JP 2012502657-A/397: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTATGAAACGAGT
>HV697222.1 JP 2012502657-A/396: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGTTGAATGTGT
>HV697221.1 JP 2012502657-A/395: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCAGTCCAGATTA
>HV697220.1 JP 2012502657-A/394: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACATGGAAAGCGA
>HV697219.1 JP 2012502657-A/393: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTGTCCAGCAATT
>HV697216.1 JP 2012502657-A/390: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGATAGTGCATCT
>HV697215.1 JP 2012502657-A/389: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGATTGATAGTCA
>HV697214.1 JP 2012502657-A/388: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCGAGGAGTTGAA
>HV697213.1 JP 2012502657-A/387: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGATGAGAGCAA
>HV697212.1 JP 2012502657-A/386: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGTCCAACGAAA
>HV697211.1 JP 2012502657-A/385: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTCTCATGAATAG
>HV697210.1 JP 2012502657-A/384: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATTTCTCATGAAT
>HV697209.1 JP 2012502657-A/383: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCGCCTTCTGATT
>HV697208.1 JP 2012502657-A/382: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAAATTTCGTATT
>HV697207.1 JP 2012502657-A/381: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACATGGATGATAT
>HV697206.1 JP 2012502657-A/380: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAAGCCATGACCA
>HV697205.1 JP 2012502657-A/379: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATTTCGTATTTCT
>HV697204.1 JP 2012502657-A/378: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAATTTCGTATTT
>HV697203.1 JP 2012502657-A/377: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCGGAAAGCCAAT
>HV697202.1 JP 2012502657-A/376: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGCCATGACCAC
>HV697201.1 JP 2012502657-A/375: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCCATGACCACAT
>HV697200.1 JP 2012502657-A/374: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACCACATGGATGA
>HV697199.1 JP 2012502657-A/373: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCGGAAAGCCAA
>HV697198.1 JP 2012502657-A/372: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGCGGAAAGCCA
>HV697197.1 JP 2012502657-A/371: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTCTCACCATTC
>HV697196.1 JP 2012502657-A/370: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TCACAGCCATGAA
>HV697195.1 JP 2012502657-A/369: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GACTGAGGTCAAA
>HV697194.1 JP 2012502657-A/368: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAGTCTCACCATT
>HV697193.1 JP 2012502657-A/367: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGACTGAGGTCA
>HV697192.1 JP 2012502657-A/366: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTCTGATGAATCT
>HV697191.1 JP 2012502657-A/365: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTCAGCTGGATGA
>HV697190.1 JP 2012502657-A/364: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTCTGAGGTCAAT
>HV697189.1 JP 2012502657-A/363: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGAGGTCAATTAA
>HV697188.1 JP 2012502657-A/362: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TCTGAGGTCAATT
>HV697187.1 JP 2012502657-A/361: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAGGTCAATTAAA
>HV697186.1 JP 2012502657-A/360: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGAGGTCAATTA
>HV697185.1 JP 2012502657-A/359: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTCATGAATTAGA
>HV697184.1 JP 2012502657-A/358: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAAGCTGACCTGG
>HV697183.1 JP 2012502657-A/357: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TATCAAGTTTGAG
>HV697182.1 JP 2012502657-A/356: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCGCAAGATCGGC
>HV697181.1 JP 2012502657-A/355: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGACACGTTTGGC
>HV697180.1 JP 2012502657-A/354: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTAAATTCTGTGG
>HV697179.1 JP 2012502657-A/353: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCTAAATTCTGTG
>HV697178.1 JP 2012502657-A/352: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGACTTCGGC
>HV697177.1 JP 2012502657-A/351: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCTTGCGAAGCTG
>HV697176.1 JP 2012502657-A/350: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGCGAAGCTGACC
>HV697175.1 JP 2012502657-A/349: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TACGGAGACATGG
>HV697174.1 JP 2012502657-A/348: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCTGTTCCAAGAC
>HV697173.1 JP 2012502657-A/347: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTACCAGTGCACG
>HV697172.1 JP 2012502657-A/346: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAATGACAACGCC
>HV697171.1 JP 2012502657-A/345: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTGCGAAGCTGAC
>HV697170.1 JP 2012502657-A/344: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CGAAGCTGACCTG
>HV697169.1 JP 2012502657-A/343: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGTTCCAAGACCT
>HV697168.1 JP 2012502657-A/342: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCTATCAAGTTTG
>HV697167.1 JP 2012502657-A/341: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCGACTGGAAGAC
>HV697166.1 JP 2012502657-A/340: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTTGCGAAGCTGA
>HV697165.1 JP 2012502657-A/339: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGCCTTGCGAAGC
>HV697164.1 JP 2012502657-A/338: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CGAGGTCATGAAG
>HV697163.1 JP 2012502657-A/337: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGACACGTTTGG
>HV697162.1 JP 2012502657-A/336: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAGCTAAATTCTG
>HV697161.1 JP 2012502657-A/335: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGTCAGGCCTTGC
>HV697160.1 JP 2012502657-A/334: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCTAGAGAAGCAG
>HV697159.1 JP 2012502657-A/333: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGAGTATGTACC
>HV697158.1 JP 2012502657-A/332: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCCAGAACTGCAG
>HV697157.1 JP 2012502657-A/331: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TCAAGTTTGAGCT
>HV697156.1 JP 2012502657-A/330: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGTCAGGCCTTG
>HV697155.1 JP 2012502657-A/329: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGACTTCGGCTCC
>HV697154.1 JP 2012502657-A/328: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTGACTTCGGCTC
>HV697153.1 JP 2012502657-A/327: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGAAGATGTACGG
>HV697152.1 JP 2012502657-A/326: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCGAAGCTGACCT
>HV697151.1 JP 2012502657-A/325: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TCAGGCCTTGCGA
>HV697150.1 JP 2012502657-A/324: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACGGAGACATGGC
>HV697149.1 JP 2012502657-A/323: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GACACGTTTGGCC
>HV697148.1 JP 2012502657-A/322: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGCGAGGTCATGA
>HV697147.1 JP 2012502657-A/321: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AATGACAACGCCT
>HV697146.1 JP 2012502657-A/320: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGATGTACGGAG
>HV697145.1 JP 2012502657-A/319: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGAAGACACGTT
>HV697144.1 JP 2012502657-A/318: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TAAATTCTGTGGA
>HV697143.1 JP 2012502657-A/317: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAGGTCATGAAGA
>HV697142.1 JP 2012502657-A/316: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGACAACGCCTC
>HV697141.1 JP 2012502657-A/315: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CGGAGACATGGCA
>HV697140.1 JP 2012502657-A/314: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TCTGTGGAGTATG
>HV697139.1 JP 2012502657-A/313: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CGAGCTAAATTCT
>HV697138.1 JP 2012502657-A/312: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAGGCCTTGCGAA
>HV697137.1 JP 2012502657-A/311: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACCGCAAGATCGG
>HV697136.1 JP 2012502657-A/310: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TACCGACTGGAAG
>HV697135.1 JP 2012502657-A/309: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGGCCTTGCGAAG
>HV697134.1 JP 2012502657-A/308: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAAGACACGTTTG
>HV697133.1 JP 2012502657-A/307: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGGTCAGGCCTT
>HV697132.1 JP 2012502657-A/306: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGTCATGAAGAAG
>HV697131.1 JP 2012502657-A/305: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAGCTGACCTGGA
>HV697130.1 JP 2012502657-A/304: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATTTGAAGTGTAA
>HV697129.1 JP 2012502657-A/303: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTTGTTCCTTAA
>HV697128.1 JP 2012502657-A/302: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCAGAAAGGTTA
>HV697127.1 JP 2012502657-A/301: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACATACCGAGCTA
>HV697126.1 JP 2012502657-A/300: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTGTTGAGAGTGT
>HV697125.1 JP 2012502657-A/299: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATACCGAGCTAAA
>HV697124.1 JP 2012502657-A/298: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGGCCTTTATTA
>HV697123.1 JP 2012502657-A/297: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GACTGGACAGCTT
>HV697122.1 JP 2012502657-A/296: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TATACGAGTAATA
>HV697121.1 JP 2012502657-A/295: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTATCTAAGTTAA
>HV697120.1 JP 2012502657-A/294: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTCTGCTCAGATA
>HV697119.1 JP 2012502657-A/293: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCTGATCAGTTT
>HV697118.1 JP 2012502657-A/292: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGGTAGAATGTAA
>HV697117.1 JP 2012502657-A/291: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCTAAATTCTGT
>HV697116.1 JP 2012502657-A/290: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTATCAAGTTTGA
>HV697115.1 JP 2012502657-A/289: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGAAGACACGTTT
>HV697114.1 JP 2012502657-A/288: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTACCAGTGCAC
>HV697113.1 JP 2012502657-A/287: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAATGACATCTTT
>HV697112.1 JP 2012502657-A/286: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTTCAGTAGCACA
>HV697111.1 JP 2012502657-A/285: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AAATTCTGTGGAG
>HV697110.1 JP 2012502657-A/284: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAGTATGT
>HV697109.1 JP 2012502657-A/283: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAAGTTTGAGCTT
>HV697108.1 JP 2012502657-A/282: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGCCTATCAAGTT
>HV697107.1 JP 2012502657-A/281: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGTACGGAGACAT
>HV697106.1 JP 2012502657-A/280: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AATTCTGTGGAGT
>HV697105.1 JP 2012502657-A/279: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCCTATCAAGTTT
>HV697104.1 JP 2012502657-A/278: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCTGCGAGGAGTG
>HV697103.1 JP 2012502657-A/277: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCCTTGCGAAGCT
>HV697102.1 JP 2012502657-A/276: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGTACGGAGACA
>HV697101.1 JP 2012502657-A/275: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACCGACTGGAAGA
>HV697100.1 JP 2012502657-A/274: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGAGTGGAGCGCC
>HV697099.1 JP 2012502657-A/273: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CATTACAACTGTC
>HV697098.1 JP 2012502657-A/272: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATTACAACTGTCC
>HV697097.1 JP 2012502657-A/271: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGCCATTACAAC
>HV697096.1 JP 2012502657-A/270: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCATTACAACTGT
>HV697095.1 JP 2012502657-A/269: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CCTGGTCCAGACC
>HV697094.1 JP 2012502657-A/268: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CAGAGTGGAGCGC
>HV697093.1 JP 2012502657-A/267: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGACCTGTGCCTG
>HV697092.1 JP 2012502657-A/266: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AACTGCCTGGTCC
>HV697091.1 JP 2012502657-A/265: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACTGGAAGACACG
>HV697090.1 JP 2012502657-A/264: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGCCATTACAACT
>HV697089.1 JP 2012502657-A/263: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GTTTGAGCTTTCT
>HV697088.1 JP 2012502657-A/262: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGGAGCGCCTGTT
>HV697087.1 JP 2012502657-A/261: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTGGAGCGCCTG
>HV697086.1 JP 2012502657-A/260: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAGCTTTCTGGCT
>HV697085.1 JP 2012502657-A/259: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GCCATTACAACTG
>HV697084.1 JP 2012502657-A/258: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGAGCGCCTGTTC
>HV697083.1 JP 2012502657-A/257: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CGACTGGAAGACA
>HV697082.1 JP 2012502657-A/256: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAGTGGAGCGCCT
>HV697081.1 JP 2012502657-A/255: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACAGGAAGATGTA
>HV697079.1 JP 2012502657-A/253: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACAAATACGATTT
>HV697078.1 JP 2012502657-A/252: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACAAATACGATTT
>HV697077.1 JP 2012502657-A/251: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATTTCGAGCAGAA
>HV697076.1 JP 2012502657-A/250: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGACTTGGGCAAT
>HV697075.1 JP 2012502657-A/249: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGTGACTGCTGA
>HV697074.1 JP 2012502657-A/248: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAAAGTACAAAGA
>HV697073.1 JP 2012502657-A/247: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGAAAGTACAAAG
>HV697072.1 JP 2012502657-A/246: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGGTGGAAATGAA
>HV697071.1 JP 2012502657-A/245: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AATGAAGAAAGTA
>HV697069.1 JP 2012502657-A/243: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACTGAATACCAAT
>HV697064.1 JP 2012502657-A/238: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGCTACAAAAACA
>HV697063.1 JP 2012502657-A/237: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGTCCCTCAAACA
>HV697062.1 JP 2012502657-A/236: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GGAGAAACAACAT
>HV697061.1 JP 2012502657-A/235: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GACTCATCTGCTA
>HV697060.1 JP 2012502657-A/234: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TCAGAACAAGAAA
>HV697059.1 JP 2012502657-A/233: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATCTGGAGAAACA
>HV697058.1 JP 2012502657-A/232: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATTTCGAGCAGAA
>HV697057.1 JP 2012502657-A/231: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGACTTGGGCAAT
>HV697056.1 JP 2012502657-A/230: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGTGACTGCTGA
>HV697055.1 JP 2012502657-A/229: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
GAAAGTACAAAGA
>HV697054.1 JP 2012502657-A/228: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGAAAGTACAAAG
>HV697053.1 JP 2012502657-A/227: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AGGTGGAAATGAA
>HV697052.1 JP 2012502657-A/226: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
AATGAAGAAAGTA
>HV697051.1 JP 2012502657-A/225: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697050.1 JP 2012502657-A/224: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACAAATACGATTT
>HV697049.1 JP 2012502657-A/223: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACAAATACGATTT
>HV697048.1 JP 2012502657-A/222: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATTTGGCTACAAA
>HV697045.1 JP 2012502657-A/219: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697044.1 JP 2012502657-A/218: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697043.1 JP 2012502657-A/217: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697042.1 JP 2012502657-A/216: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697041.1 JP 2012502657-A/215: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697040.1 JP 2012502657-A/214: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697039.1 JP 2012502657-A/213: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697038.1 JP 2012502657-A/212: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697037.1 JP 2012502657-A/211: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697036.1 JP 2012502657-A/210: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697035.1 JP 2012502657-A/209: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697034.1 JP 2012502657-A/208: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697033.1 JP 2012502657-A/207: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697032.1 JP 2012502657-A/206: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ACTGAATACCAAT
>HV697031.1 JP 2012502657-A/205: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697030.1 JP 2012502657-A/204: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697029.1 JP 2012502657-A/203: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TGTAGGATGTCTA
>HV697026.1 JP 2012502657-A/200: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697021.1 JP 2012502657-A/195: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697020.1 JP 2012502657-A/194: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697019.1 JP 2012502657-A/193: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697018.1 JP 2012502657-A/192: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697017.1 JP 2012502657-A/191: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697016.1 JP 2012502657-A/190: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697013.1 JP 2012502657-A/187: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697012.1 JP 2012502657-A/186: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697011.1 JP 2012502657-A/185: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697010.1 JP 2012502657-A/184: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697009.1 JP 2012502657-A/183: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697008.1 JP 2012502657-A/182: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697007.1 JP 2012502657-A/181: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697006.1 JP 2012502657-A/180: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697005.1 JP 2012502657-A/179: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV697004.1 JP 2012502657-A/178: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
CTGTGGAAGTCTA
>HV696826.1 JP 2012502991-A/821: RNA INTERFERENCE IN SKIN INDICATIONS
ACCTGCCAGCAAC
>HV696825.1 JP 2012502991-A/820: RNA INTERFERENCE IN SKIN INDICATIONS
GACTCGAACGACT
>HV696824.1 JP 2012502991-A/819: RNA INTERFERENCE IN SKIN INDICATIONS
CCAGCAATTAATA
>HV696823.1 JP 2012502991-A/818: RNA INTERFERENCE IN SKIN INDICATIONS
GTCCAGCAATTAA
>HV696822.1 JP 2012502991-A/817: RNA INTERFERENCE IN SKIN INDICATIONS
TTGAGTCTGGAAA
>HV696821.1 JP 2012502991-A/816: RNA INTERFERENCE IN SKIN INDICATIONS
AATGTGTATCTAT
>HV696820.1 JP 2012502991-A/815: RNA INTERFERENCE IN SKIN INDICATIONS
GTCAGCCGTGAAT
>HV696819.1 JP 2012502991-A/814: RNA INTERFERENCE IN SKIN INDICATIONS
GATGTGATTGATA
>HV696818.1 JP 2012502991-A/813: RNA INTERFERENCE IN SKIN INDICATIONS
GACCAGAGTGCTG
>HV696817.1 JP 2012502991-A/812: RNA INTERFERENCE IN SKIN INDICATIONS
TGGTTTATGGACT
>HV696816.1 JP 2012502991-A/811: RNA INTERFERENCE IN SKIN INDICATIONS
CTGGTCACTGATT
>HV696815.1 JP 2012502991-A/810: RNA INTERFERENCE IN SKIN INDICATIONS
CCAACGAAAGCCA
>HV696814.1 JP 2012502991-A/809: RNA INTERFERENCE IN SKIN INDICATIONS
ACCATGAGAATTG
>HV696813.1 JP 2012502991-A/808: RNA INTERFERENCE IN SKIN INDICATIONS
TGTCAATTGCTTA
>HV696812.1 JP 2012502991-A/807: RNA INTERFERENCE IN SKIN INDICATIONS
AATTCCACAGCCA
>HV696811.1 JP 2012502991-A/806: RNA INTERFERENCE IN SKIN INDICATIONS
TGAGCATTCCGAT
>HV696810.1 JP 2012502991-A/805: RNA INTERFERENCE IN SKIN INDICATIONS
GAGTGCTGAAACC
>HV696809.1 JP 2012502991-A/804: RNA INTERFERENCE IN SKIN INDICATIONS
AAACAGGCTGATT
>HV696808.1 JP 2012502991-A/803: RNA INTERFERENCE IN SKIN INDICATIONS
ACTACCATGAGAA
>HV696807.1 JP 2012502991-A/802: RNA INTERFERENCE IN SKIN INDICATIONS
AGTCAGCCGTGAA
>HV696806.1 JP 2012502991-A/801: RNA INTERFERENCE IN SKIN INDICATIONS
ATAGTCAGGAACT
>HV696805.1 JP 2012502991-A/800: RNA INTERFERENCE IN SKIN INDICATIONS
AAGCCAATGATGA
>HV696804.1 JP 2012502991-A/799: RNA INTERFERENCE IN SKIN INDICATIONS
TAGTGTGGTTTAT
>HV696803.1 JP 2012502991-A/798: RNA INTERFERENCE IN SKIN INDICATIONS
ACGACTCTGATGA
>HV696802.1 JP 2012502991-A/797: RNA INTERFERENCE IN SKIN INDICATIONS
AGCAATTAATAAA
>HV696801.1 JP 2012502991-A/796: RNA INTERFERENCE IN SKIN INDICATIONS
GTCAATTGCTTAT
>HV696800.1 JP 2012502991-A/795: RNA INTERFERENCE IN SKIN INDICATIONS
AACTATCACTGTA
>HV696799.1 JP 2012502991-A/794: RNA INTERFERENCE IN SKIN INDICATIONS
TCATTCTATAGAA
>HV696798.1 JP 2012502991-A/793: RNA INTERFERENCE IN SKIN INDICATIONS
ATAACTAATGTGT
>HV696797.1 JP 2012502991-A/792: RNA INTERFERENCE IN SKIN INDICATIONS
TTCCGATGTGATT
>HV696796.1 JP 2012502991-A/791: RNA INTERFERENCE IN SKIN INDICATIONS
TATAAGCGGAAAG
>HV696795.1 JP 2012502991-A/790: RNA INTERFERENCE IN SKIN INDICATIONS
AGTCAGCTGGATG
>HV696794.1 JP 2012502991-A/789: RNA INTERFERENCE IN SKIN INDICATIONS
AGTTGAATGGTGC
>HV696793.1 JP 2012502991-A/788: RNA INTERFERENCE IN SKIN INDICATIONS
CACCTCACACATG
>HV696792.1 JP 2012502991-A/787: RNA INTERFERENCE IN SKIN INDICATIONS
GCCAGCAACCGAA
>HV696791.1 JP 2012502991-A/786: RNA INTERFERENCE IN SKIN INDICATIONS
TCATGAATAGAAA
>HV696790.1 JP 2012502991-A/785: RNA INTERFERENCE IN SKIN INDICATIONS
GGAAATAACTAAT
>HV696789.1 JP 2012502991-A/784: RNA INTERFERENCE IN SKIN INDICATIONS
GGTTGAATGTGTA
>HV696788.1 JP 2012502991-A/783: RNA INTERFERENCE IN SKIN INDICATIONS
ATTGGTTGAATGT
>HV696787.1 JP 2012502991-A/782: RNA INTERFERENCE IN SKIN INDICATIONS
CAGCCATGAATTT
>HV696786.1 JP 2012502991-A/781: RNA INTERFERENCE IN SKIN INDICATIONS
CCAGAGTGCTGAA
>HV696785.1 JP 2012502991-A/780: RNA INTERFERENCE IN SKIN INDICATIONS
ATGAAACGAGTCA
>HV696784.1 JP 2012502991-A/779: RNA INTERFERENCE IN SKIN INDICATIONS
TGGTGCATACAAG
>HV696783.1 JP 2012502991-A/778: RNA INTERFERENCE IN SKIN INDICATIONS
TTAGATAGTGCAT
>HV696782.1 JP 2012502991-A/777: RNA INTERFERENCE IN SKIN INDICATIONS
AGCAATGAGCATT
>HV696781.1 JP 2012502991-A/776: RNA INTERFERENCE IN SKIN INDICATIONS
AAGTTTCGCAGAC
>HV696780.1 JP 2012502991-A/775: RNA INTERFERENCE IN SKIN INDICATIONS
AGTCCAACGAAAG
>HV696779.1 JP 2012502991-A/774: RNA INTERFERENCE IN SKIN INDICATIONS
AGTTTGTGGCTTC
>HV696778.1 JP 2012502991-A/773: RNA INTERFERENCE IN SKIN INDICATIONS
AGTCTGGAAATAA
>HV696777.1 JP 2012502991-A/772: RNA INTERFERENCE IN SKIN INDICATIONS
CAGCCGTGAATTC
>HV696776.1 JP 2012502991-A/771: RNA INTERFERENCE IN SKIN INDICATIONS
CAGACGAGGACAT
>HV696775.1 JP 2012502991-A/770: RNA INTERFERENCE IN SKIN INDICATIONS
TAGACACATATGA
>HV696774.1 JP 2012502991-A/769: RNA INTERFERENCE IN SKIN INDICATIONS
GTCTGATGAGTCT
>HV696773.1 JP 2012502991-A/768: RNA INTERFERENCE IN SKIN INDICATIONS
TGCATTTAGTCAA
>HV696772.1 JP 2012502991-A/767: RNA INTERFERENCE IN SKIN INDICATIONS
TAGTCAGGAACTT
>HV696771.1 JP 2012502991-A/766: RNA INTERFERENCE IN SKIN INDICATIONS
AGCATTCCGATGT
>HV696770.1 JP 2012502991-A/765: RNA INTERFERENCE IN SKIN INDICATIONS
AGCAGTCCAGATT
>HV696769.1 JP 2012502991-A/764: RNA INTERFERENCE IN SKIN INDICATIONS
ATATGATGGCCGA
>HV696768.1 JP 2012502991-A/763: RNA INTERFERENCE IN SKIN INDICATIONS
GAATGGTGCATAC
>HV696767.1 JP 2012502991-A/762: RNA INTERFERENCE IN SKIN INDICATIONS
CCGACCAAGGAAA
>HV696766.1 JP 2012502991-A/761: RNA INTERFERENCE IN SKIN INDICATIONS
TGTTCATTCTATA
>HV696765.1 JP 2012502991-A/760: RNA INTERFERENCE IN SKIN INDICATIONS
TACCAGTTAAACA
>HV696764.1 JP 2012502991-A/759: RNA INTERFERENCE IN SKIN INDICATIONS
ATATAAGCGGAAA
>HV696763.1 JP 2012502991-A/758: RNA INTERFERENCE IN SKIN INDICATIONS
CAGTCCAGATTAT
>HV696762.1 JP 2012502991-A/757: RNA INTERFERENCE IN SKIN INDICATIONS
TTATGAAACGAGT
>HV696761.1 JP 2012502991-A/756: RNA INTERFERENCE IN SKIN INDICATIONS
TGGTTGAATGTGT
>HV696760.1 JP 2012502991-A/755: RNA INTERFERENCE IN SKIN INDICATIONS
GCAGTCCAGATTA
>HV696759.1 JP 2012502991-A/754: RNA INTERFERENCE IN SKIN INDICATIONS
ACATGGAAAGCGA
>HV696758.1 JP 2012502991-A/753: RNA INTERFERENCE IN SKIN INDICATIONS
TTGTCCAGCAATT
>HV696757.1 JP 2012502991-A/752: RNA INTERFERENCE IN SKIN INDICATIONS
TTCTATAGAAGAA
>HV696756.1 JP 2012502991-A/751: RNA INTERFERENCE IN SKIN INDICATIONS
ATGTGTATCTATT
>HV696755.1 JP 2012502991-A/750: RNA INTERFERENCE IN SKIN INDICATIONS
AGATAGTGCATCT
>HV696754.1 JP 2012502991-A/749: RNA INTERFERENCE IN SKIN INDICATIONS
TGATTGATAGTCA
>HV696753.1 JP 2012502991-A/748: RNA INTERFERENCE IN SKIN INDICATIONS
GCGAGGAGTTGAA
>HV696752.1 JP 2012502991-A/747: RNA INTERFERENCE IN SKIN INDICATIONS
ATGATGAGAGCAA
>HV696751.1 JP 2012502991-A/746: RNA INTERFERENCE IN SKIN INDICATIONS
AAGTCCAACGAAA
>HV696750.1 JP 2012502991-A/745: RNA INTERFERENCE IN SKIN INDICATIONS
CTCTCATGAATAG
>HV696749.1 JP 2012502991-A/744: RNA INTERFERENCE IN SKIN INDICATIONS
ATTTCTCATGAAT
>HV696748.1 JP 2012502991-A/743: RNA INTERFERENCE IN SKIN INDICATIONS
GCGCCTTCTGATT
>HV696747.1 JP 2012502991-A/742: RNA INTERFERENCE IN SKIN INDICATIONS
GAAATTTCGTATT
>HV696746.1 JP 2012502991-A/741: RNA INTERFERENCE IN SKIN INDICATIONS
ACATGGATGATAT
>HV696745.1 JP 2012502991-A/740: RNA INTERFERENCE IN SKIN INDICATIONS
AAAGCCATGACCA
>HV696744.1 JP 2012502991-A/739: RNA INTERFERENCE IN SKIN INDICATIONS
ATTTCGTATTTCT
>HV696743.1 JP 2012502991-A/738: RNA INTERFERENCE IN SKIN INDICATIONS
AAATTTCGTATTT
>HV696742.1 JP 2012502991-A/737: RNA INTERFERENCE IN SKIN INDICATIONS
GCGGAAAGCCAAT
>HV696741.1 JP 2012502991-A/736: RNA INTERFERENCE IN SKIN INDICATIONS
AAGCCATGACCAC
>HV696740.1 JP 2012502991-A/735: RNA INTERFERENCE IN SKIN INDICATIONS
GCCATGACCACAT
>HV696739.1 JP 2012502991-A/734: RNA INTERFERENCE IN SKIN INDICATIONS
ACCACATGGATGA
>HV696738.1 JP 2012502991-A/733: RNA INTERFERENCE IN SKIN INDICATIONS
AGCGGAAAGCCAA
>HV696737.1 JP 2012502991-A/732: RNA INTERFERENCE IN SKIN INDICATIONS
AAGCGGAAAGCCA
>HV696736.1 JP 2012502991-A/731: RNA INTERFERENCE IN SKIN INDICATIONS
AGTCTCACCATTC
>HV696735.1 JP 2012502991-A/730: RNA INTERFERENCE IN SKIN INDICATIONS
TCACAGCCATGAA
>HV696734.1 JP 2012502991-A/729: RNA INTERFERENCE IN SKIN INDICATIONS
GACTGAGGTCAAA
>HV696733.1 JP 2012502991-A/728: RNA INTERFERENCE IN SKIN INDICATIONS
GAGTCTCACCATT
>HV696732.1 JP 2012502991-A/727: RNA INTERFERENCE IN SKIN INDICATIONS
TGGACTGAGGTCA
>HV696731.1 JP 2012502991-A/726: RNA INTERFERENCE IN SKIN INDICATIONS
TTCTGATGAATCT
>HV696730.1 JP 2012502991-A/725: RNA INTERFERENCE IN SKIN INDICATIONS
GTCAGCTGGATGA
>HV696729.1 JP 2012502991-A/724: RNA INTERFERENCE IN SKIN INDICATIONS
TTCTGAGGTCAAT
>HV696728.1 JP 2012502991-A/723: RNA INTERFERENCE IN SKIN INDICATIONS
TGAGGTCAATTAA
>HV696727.1 JP 2012502991-A/722: RNA INTERFERENCE IN SKIN INDICATIONS
TCTGAGGTCAATT
>HV696726.1 JP 2012502991-A/721: RNA INTERFERENCE IN SKIN INDICATIONS
GAGGTCAATTAAA
>HV696725.1 JP 2012502991-A/720: RNA INTERFERENCE IN SKIN INDICATIONS
CTGAGGTCAATTA
>HV696724.1 JP 2012502991-A/719: RNA INTERFERENCE IN SKIN INDICATIONS
CTCATGAATTAGA
>HV697218.1 JP 2012502657-A/392: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
TTCTATAGAAGAA
>HV697217.1 JP 2012502657-A/391: REDUCED SIZE SELF-DELIVERING RNAi COMPOUNDS
ATGTGTATCTATT
>HV689533.1 JP 2012060901-A/4: Oligonucleotide and use thereof
GATTGCTGATACC
>HV696614.1 JP 2012502991-A/609: RNA INTERFERENCE IN SKIN INDICATIONS
AATGAAGAAAGTA
>HV696613.1 JP 2012502991-A/608: RNA INTERFERENCE IN SKIN INDICATIONS
TACTTTCTTCATT
>HV696606.1 JP 2012502991-A/601: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696605.1 JP 2012502991-A/600: RNA INTERFERENCE IN SKIN INDICATIONS
TAGACTTCCACAG
>HV696603.1 JP 2012502991-A/598: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696599.1 JP 2012502991-A/594: RNA INTERFERENCE IN SKIN INDICATIONS
ACAAATACGATTT
>HV696598.1 JP 2012502991-A/593: RNA INTERFERENCE IN SKIN INDICATIONS
ACAAATACGATTT
>HV696595.1 JP 2012502991-A/590: RNA INTERFERENCE IN SKIN INDICATIONS
GGCTACAAAAACA
>HV696594.1 JP 2012502991-A/589: RNA INTERFERENCE IN SKIN INDICATIONS
GCATTTAGTCAAA
>HV696593.1 JP 2012502991-A/588: RNA INTERFERENCE IN SKIN INDICATIONS
GAAGCTGACCTGG
>HV696592.1 JP 2012502991-A/587: RNA INTERFERENCE IN SKIN INDICATIONS
TATCAAGTTTGAG
>HV696591.1 JP 2012502991-A/586: RNA INTERFERENCE IN SKIN INDICATIONS
CCGCAAGATCGGC
>HV696590.1 JP 2012502991-A/585: RNA INTERFERENCE IN SKIN INDICATIONS
AGACACGTTTGGC
>HV696589.1 JP 2012502991-A/584: RNA INTERFERENCE IN SKIN INDICATIONS
CTAAATTCTGTGG
>HV696588.1 JP 2012502991-A/583: RNA INTERFERENCE IN SKIN INDICATIONS
GCTAAATTCTGTG
>HV696587.1 JP 2012502991-A/582: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGACTTCGGC
>HV696586.1 JP 2012502991-A/581: RNA INTERFERENCE IN SKIN INDICATIONS
CCTTGCGAAGCTG
>HV696585.1 JP 2012502991-A/580: RNA INTERFERENCE IN SKIN INDICATIONS
TGCGAAGCTGACC
>HV696584.1 JP 2012502991-A/579: RNA INTERFERENCE IN SKIN INDICATIONS
TACGGAGACATGG
>HV696583.1 JP 2012502991-A/578: RNA INTERFERENCE IN SKIN INDICATIONS
CCTGTTCCAAGAC
>HV696582.1 JP 2012502991-A/577: RNA INTERFERENCE IN SKIN INDICATIONS
GTACCAGTGCACG
>HV696581.1 JP 2012502991-A/576: RNA INTERFERENCE IN SKIN INDICATIONS
CAATGACAACGCC
>HV696580.1 JP 2012502991-A/575: RNA INTERFERENCE IN SKIN INDICATIONS
TTGCGAAGCTGAC
>HV696579.1 JP 2012502991-A/574: RNA INTERFERENCE IN SKIN INDICATIONS
CGAAGCTGACCTG
>HV696578.1 JP 2012502991-A/573: RNA INTERFERENCE IN SKIN INDICATIONS
TGTTCCAAGACCT
>HV696577.1 JP 2012502991-A/572: RNA INTERFERENCE IN SKIN INDICATIONS
CCTATCAAGTTTG
>HV696576.1 JP 2012502991-A/571: RNA INTERFERENCE IN SKIN INDICATIONS
CCGACTGGAAGAC
>HV696575.1 JP 2012502991-A/570: RNA INTERFERENCE IN SKIN INDICATIONS
CTTGCGAAGCTGA
>HV696574.1 JP 2012502991-A/569: RNA INTERFERENCE IN SKIN INDICATIONS
GGCCTTGCGAAGC
>HV696573.1 JP 2012502991-A/568: RNA INTERFERENCE IN SKIN INDICATIONS
CGAGGTCATGAAG
>HV696572.1 JP 2012502991-A/567: RNA INTERFERENCE IN SKIN INDICATIONS
AAGACACGTTTGG
>HV696571.1 JP 2012502991-A/566: RNA INTERFERENCE IN SKIN INDICATIONS
GAGCTAAATTCTG
>HV696570.1 JP 2012502991-A/565: RNA INTERFERENCE IN SKIN INDICATIONS
GGTCAGGCCTTGC
>HV696569.1 JP 2012502991-A/564: RNA INTERFERENCE IN SKIN INDICATIONS
GCTAGAGAAGCAG
>HV696568.1 JP 2012502991-A/563: RNA INTERFERENCE IN SKIN INDICATIONS
TGGAGTATGTACC
>HV696567.1 JP 2012502991-A/562: RNA INTERFERENCE IN SKIN INDICATIONS
GCCAGAACTGCAG
>HV696566.1 JP 2012502991-A/561: RNA INTERFERENCE IN SKIN INDICATIONS
TCAAGTTTGAGCT
>HV696565.1 JP 2012502991-A/560: RNA INTERFERENCE IN SKIN INDICATIONS
TGGTCAGGCCTTG
>HV696564.1 JP 2012502991-A/559: RNA INTERFERENCE IN SKIN INDICATIONS
TGACTTCGGCTCC
>HV696563.1 JP 2012502991-A/558: RNA INTERFERENCE IN SKIN INDICATIONS
GTGACTTCGGCTC
>HV696562.1 JP 2012502991-A/557: RNA INTERFERENCE IN SKIN INDICATIONS
GGAAGATGTACGG
>HV696561.1 JP 2012502991-A/556: RNA INTERFERENCE IN SKIN INDICATIONS
GCGAAGCTGACCT
>HV696560.1 JP 2012502991-A/555: RNA INTERFERENCE IN SKIN INDICATIONS
TCAGGCCTTGCGA
>HV696559.1 JP 2012502991-A/554: RNA INTERFERENCE IN SKIN INDICATIONS
ACGGAGACATGGC
>HV696558.1 JP 2012502991-A/553: RNA INTERFERENCE IN SKIN INDICATIONS
GACACGTTTGGCC
>HV696557.1 JP 2012502991-A/552: RNA INTERFERENCE IN SKIN INDICATIONS
GGCGAGGTCATGA
>HV696556.1 JP 2012502991-A/551: RNA INTERFERENCE IN SKIN INDICATIONS
AATGACAACGCCT
>HV696555.1 JP 2012502991-A/550: RNA INTERFERENCE IN SKIN INDICATIONS
AAGATGTACGGAG
>HV696554.1 JP 2012502991-A/549: RNA INTERFERENCE IN SKIN INDICATIONS
TGGAAGACACGTT
>HV696553.1 JP 2012502991-A/548: RNA INTERFERENCE IN SKIN INDICATIONS
TAAATTCTGTGGA
>HV696552.1 JP 2012502991-A/547: RNA INTERFERENCE IN SKIN INDICATIONS
GAGGTCATGAAGA
>HV696551.1 JP 2012502991-A/546: RNA INTERFERENCE IN SKIN INDICATIONS
ATGACAACGCCTC
>HV696550.1 JP 2012502991-A/545: RNA INTERFERENCE IN SKIN INDICATIONS
CGGAGACATGGCA
>HV696549.1 JP 2012502991-A/544: RNA INTERFERENCE IN SKIN INDICATIONS
TCTGTGGAGTATG
>HV696548.1 JP 2012502991-A/543: RNA INTERFERENCE IN SKIN INDICATIONS
CGAGCTAAATTCT
>HV696547.1 JP 2012502991-A/542: RNA INTERFERENCE IN SKIN INDICATIONS
CAGGCCTTGCGAA
>HV696546.1 JP 2012502991-A/541: RNA INTERFERENCE IN SKIN INDICATIONS
ACCGCAAGATCGG
>HV696545.1 JP 2012502991-A/540: RNA INTERFERENCE IN SKIN INDICATIONS
TACCGACTGGAAG
>HV696544.1 JP 2012502991-A/539: RNA INTERFERENCE IN SKIN INDICATIONS
AGGCCTTGCGAAG
>HV696543.1 JP 2012502991-A/538: RNA INTERFERENCE IN SKIN INDICATIONS
GAAGACACGTTTG
>HV696542.1 JP 2012502991-A/537: RNA INTERFERENCE IN SKIN INDICATIONS
ATGGTCAGGCCTT
>HV696541.1 JP 2012502991-A/536: RNA INTERFERENCE IN SKIN INDICATIONS
GGTCATGAAGAAG
>HV696540.1 JP 2012502991-A/535: RNA INTERFERENCE IN SKIN INDICATIONS
AAGCTGACCTGGA
>HV696539.1 JP 2012502991-A/534: RNA INTERFERENCE IN SKIN INDICATIONS
ATTTGAAGTGTAA
>HV696538.1 JP 2012502991-A/533: RNA INTERFERENCE IN SKIN INDICATIONS
AGTTGTTCCTTAA
>HV696537.1 JP 2012502991-A/532: RNA INTERFERENCE IN SKIN INDICATIONS
AGCAGAAAGGTTA
>HV696536.1 JP 2012502991-A/531: RNA INTERFERENCE IN SKIN INDICATIONS
ACATACCGAGCTA
>HV696535.1 JP 2012502991-A/530: RNA INTERFERENCE IN SKIN INDICATIONS
TTGTTGAGAGTGT
>HV696534.1 JP 2012502991-A/529: RNA INTERFERENCE IN SKIN INDICATIONS
ATACCGAGCTAAA
>HV696533.1 JP 2012502991-A/528: RNA INTERFERENCE IN SKIN INDICATIONS
ATGGCCTTTATTA
>HV696532.1 JP 2012502991-A/527: RNA INTERFERENCE IN SKIN INDICATIONS
GACTGGACAGCTT
>HV696531.1 JP 2012502991-A/526: RNA INTERFERENCE IN SKIN INDICATIONS
TATACGAGTAATA
>HV696530.1 JP 2012502991-A/525: RNA INTERFERENCE IN SKIN INDICATIONS
TTATCTAAGTTAA
>HV696529.1 JP 2012502991-A/524: RNA INTERFERENCE IN SKIN INDICATIONS
TTCTGCTCAGATA
>HV696528.1 JP 2012502991-A/523: RNA INTERFERENCE IN SKIN INDICATIONS
AGCTGATCAGTTT
>HV696527.1 JP 2012502991-A/522: RNA INTERFERENCE IN SKIN INDICATIONS
AGGTAGAATGTAA
>HV696526.1 JP 2012502991-A/521: RNA INTERFERENCE IN SKIN INDICATIONS
AGCTAAATTCTGT
>HV696525.1 JP 2012502991-A/520: RNA INTERFERENCE IN SKIN INDICATIONS
CTATCAAGTTTGA
>HV696524.1 JP 2012502991-A/519: RNA INTERFERENCE IN SKIN INDICATIONS
GGAAGACACGTTT
>HV696523.1 JP 2012502991-A/518: RNA INTERFERENCE IN SKIN INDICATIONS
AGTACCAGTGCAC
>HV696522.1 JP 2012502991-A/517: RNA INTERFERENCE IN SKIN INDICATIONS
CAATGACATCTTT
>HV696521.1 JP 2012502991-A/516: RNA INTERFERENCE IN SKIN INDICATIONS
TTTCAGTAGCACA
>HV696520.1 JP 2012502991-A/515: RNA INTERFERENCE IN SKIN INDICATIONS
AAATTCTGTGGAG
>HV696519.1 JP 2012502991-A/514: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAGTATGT
>HV696518.1 JP 2012502991-A/513: RNA INTERFERENCE IN SKIN INDICATIONS
CAAGTTTGAGCTT
>HV696517.1 JP 2012502991-A/512: RNA INTERFERENCE IN SKIN INDICATIONS
AGCCTATCAAGTT
>HV696516.1 JP 2012502991-A/511: RNA INTERFERENCE IN SKIN INDICATIONS
TGTACGGAGACAT
>HV696515.1 JP 2012502991-A/510: RNA INTERFERENCE IN SKIN INDICATIONS
AATTCTGTGGAGT
>HV696514.1 JP 2012502991-A/509: RNA INTERFERENCE IN SKIN INDICATIONS
GCCTATCAAGTTT
>HV696513.1 JP 2012502991-A/508: RNA INTERFERENCE IN SKIN INDICATIONS
GCTGCGAGGAGTG
>HV696512.1 JP 2012502991-A/507: RNA INTERFERENCE IN SKIN INDICATIONS
GCCTTGCGAAGCT
>HV696511.1 JP 2012502991-A/506: RNA INTERFERENCE IN SKIN INDICATIONS
ATGTACGGAGACA
>HV696510.1 JP 2012502991-A/505: RNA INTERFERENCE IN SKIN INDICATIONS
ACCGACTGGAAGA
>HV696509.1 JP 2012502991-A/504: RNA INTERFERENCE IN SKIN INDICATIONS
AGAGTGGAGCGCC
>HV696508.1 JP 2012502991-A/503: RNA INTERFERENCE IN SKIN INDICATIONS
CATTACAACTGTC
>HV696507.1 JP 2012502991-A/502: RNA INTERFERENCE IN SKIN INDICATIONS
ATTACAACTGTCC
>HV696506.1 JP 2012502991-A/501: RNA INTERFERENCE IN SKIN INDICATIONS
CTGCCATTACAAC
>HV696505.1 JP 2012502991-A/500: RNA INTERFERENCE IN SKIN INDICATIONS
CCATTACAACTGT
>HV696504.1 JP 2012502991-A/499: RNA INTERFERENCE IN SKIN INDICATIONS
CCTGGTCCAGACC
>HV696503.1 JP 2012502991-A/498: RNA INTERFERENCE IN SKIN INDICATIONS
CAGAGTGGAGCGC
>HV696502.1 JP 2012502991-A/497: RNA INTERFERENCE IN SKIN INDICATIONS
AGACCTGTGCCTG
>HV696501.1 JP 2012502991-A/496: RNA INTERFERENCE IN SKIN INDICATIONS
AACTGCCTGGTCC
>HV696500.1 JP 2012502991-A/495: RNA INTERFERENCE IN SKIN INDICATIONS
ACTGGAAGACACG
>HV696499.1 JP 2012502991-A/494: RNA INTERFERENCE IN SKIN INDICATIONS
TGCCATTACAACT
>HV696498.1 JP 2012502991-A/493: RNA INTERFERENCE IN SKIN INDICATIONS
GTTTGAGCTTTCT
>HV696497.1 JP 2012502991-A/492: RNA INTERFERENCE IN SKIN INDICATIONS
TGGAGCGCCTGTT
>HV696496.1 JP 2012502991-A/491: RNA INTERFERENCE IN SKIN INDICATIONS
AGTGGAGCGCCTG
>HV696495.1 JP 2012502991-A/490: RNA INTERFERENCE IN SKIN INDICATIONS
GAGCTTTCTGGCT
>HV696494.1 JP 2012502991-A/489: RNA INTERFERENCE IN SKIN INDICATIONS
GCCATTACAACTG
>HV696493.1 JP 2012502991-A/488: RNA INTERFERENCE IN SKIN INDICATIONS
GGAGCGCCTGTTC
>HV696492.1 JP 2012502991-A/487: RNA INTERFERENCE IN SKIN INDICATIONS
CGACTGGAAGACA
>HV696491.1 JP 2012502991-A/486: RNA INTERFERENCE IN SKIN INDICATIONS
GAGTGGAGCGCCT
>HV696490.1 JP 2012502991-A/485: RNA INTERFERENCE IN SKIN INDICATIONS
ACAGGAAGATGTA
>HV696489.1 JP 2012502991-A/484: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696486.1 JP 2012502991-A/481: RNA INTERFERENCE IN SKIN INDICATIONS
ACTGAATACCAAT
>HV696485.1 JP 2012502991-A/480: RNA INTERFERENCE IN SKIN INDICATIONS
ACTGAATACCAAT
>HV696483.1 JP 2012502991-A/478: RNA INTERFERENCE IN SKIN INDICATIONS
AGTCCCTCAAACA
>HV696481.1 JP 2012502991-A/476: RNA INTERFERENCE IN SKIN INDICATIONS
GGAGAAACAACAT
>HV696478.1 JP 2012502991-A/473: RNA INTERFERENCE IN SKIN INDICATIONS
GACTCATCTGCTA
>HV696477.1 JP 2012502991-A/472: RNA INTERFERENCE IN SKIN INDICATIONS
GACTCATCTGCTA
>HV696475.1 JP 2012502991-A/470: RNA INTERFERENCE IN SKIN INDICATIONS
ATCTGGAGAAACA
>HV696474.1 JP 2012502991-A/469: RNA INTERFERENCE IN SKIN INDICATIONS
TGTAGGATGTCTA
>HV696471.1 JP 2012502991-A/466: RNA INTERFERENCE IN SKIN INDICATIONS
GGCTACAAAAACA
>HV696470.1 JP 2012502991-A/465: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696469.1 JP 2012502991-A/464: RNA INTERFERENCE IN SKIN INDICATIONS
ACTGAATACCAAT
>HV696468.1 JP 2012502991-A/463: RNA INTERFERENCE IN SKIN INDICATIONS
ACTGAATACCAAT
>HV696467.1 JP 2012502991-A/462: RNA INTERFERENCE IN SKIN INDICATIONS
ACCTGCCAGCAAC
>HV696466.1 JP 2012502991-A/461: RNA INTERFERENCE IN SKIN INDICATIONS
GACTCGAACGACT
>HV696465.1 JP 2012502991-A/460: RNA INTERFERENCE IN SKIN INDICATIONS
CCAGCAATTAATA
>HV696464.1 JP 2012502991-A/459: RNA INTERFERENCE IN SKIN INDICATIONS
GTCCAGCAATTAA
>HV696463.1 JP 2012502991-A/458: RNA INTERFERENCE IN SKIN INDICATIONS
TTGAGTCTGGAAA
>HV696462.1 JP 2012502991-A/457: RNA INTERFERENCE IN SKIN INDICATIONS
AATGTGTATCTAT
>HV696461.1 JP 2012502991-A/456: RNA INTERFERENCE IN SKIN INDICATIONS
GTCAGCCGTGAAT
>HV696460.1 JP 2012502991-A/455: RNA INTERFERENCE IN SKIN INDICATIONS
GATGTGATTGATA
>HV696459.1 JP 2012502991-A/454: RNA INTERFERENCE IN SKIN INDICATIONS
GACCAGAGTGCTG
>HV696458.1 JP 2012502991-A/453: RNA INTERFERENCE IN SKIN INDICATIONS
TGGTTTATGGACT
>HV696457.1 JP 2012502991-A/452: RNA INTERFERENCE IN SKIN INDICATIONS
CTGGTCACTGATT
>HV696456.1 JP 2012502991-A/451: RNA INTERFERENCE IN SKIN INDICATIONS
CCAACGAAAGCCA
>HV696455.1 JP 2012502991-A/450: RNA INTERFERENCE IN SKIN INDICATIONS
ACCATGAGAATTG
>HV696454.1 JP 2012502991-A/449: RNA INTERFERENCE IN SKIN INDICATIONS
TGTCAATTGCTTA
>HV696453.1 JP 2012502991-A/448: RNA INTERFERENCE IN SKIN INDICATIONS
AATTCCACAGCCA
>HV696452.1 JP 2012502991-A/447: RNA INTERFERENCE IN SKIN INDICATIONS
TGAGCATTCCGAT
>HV696451.1 JP 2012502991-A/446: RNA INTERFERENCE IN SKIN INDICATIONS
GAGTGCTGAAACC
>HV696450.1 JP 2012502991-A/445: RNA INTERFERENCE IN SKIN INDICATIONS
AAACAGGCTGATT
>HV696449.1 JP 2012502991-A/444: RNA INTERFERENCE IN SKIN INDICATIONS
ACTACCATGAGAA
>HV696448.1 JP 2012502991-A/443: RNA INTERFERENCE IN SKIN INDICATIONS
AGTCAGCCGTGAA
>HV696447.1 JP 2012502991-A/442: RNA INTERFERENCE IN SKIN INDICATIONS
ATAGTCAGGAACT
>HV696446.1 JP 2012502991-A/441: RNA INTERFERENCE IN SKIN INDICATIONS
AAGCCAATGATGA
>HV696445.1 JP 2012502991-A/440: RNA INTERFERENCE IN SKIN INDICATIONS
TAGTGTGGTTTAT
>HV696444.1 JP 2012502991-A/439: RNA INTERFERENCE IN SKIN INDICATIONS
ACGACTCTGATGA
>HV696443.1 JP 2012502991-A/438: RNA INTERFERENCE IN SKIN INDICATIONS
AGCAATTAATAAA
>HV696442.1 JP 2012502991-A/437: RNA INTERFERENCE IN SKIN INDICATIONS
GTCAATTGCTTAT
>HV696441.1 JP 2012502991-A/436: RNA INTERFERENCE IN SKIN INDICATIONS
AACTATCACTGTA
>HV696440.1 JP 2012502991-A/435: RNA INTERFERENCE IN SKIN INDICATIONS
TCATTCTATAGAA
>HV696439.1 JP 2012502991-A/434: RNA INTERFERENCE IN SKIN INDICATIONS
ATAACTAATGTGT
>HV696438.1 JP 2012502991-A/433: RNA INTERFERENCE IN SKIN INDICATIONS
TTCCGATGTGATT
>HV696437.1 JP 2012502991-A/432: RNA INTERFERENCE IN SKIN INDICATIONS
TATAAGCGGAAAG
>HV696436.1 JP 2012502991-A/431: RNA INTERFERENCE IN SKIN INDICATIONS
AGTCAGCTGGATG
>HV696435.1 JP 2012502991-A/430: RNA INTERFERENCE IN SKIN INDICATIONS
AGTTGAATGGTGC
>HV696434.1 JP 2012502991-A/429: RNA INTERFERENCE IN SKIN INDICATIONS
CACCTCACACATG
>HV696433.1 JP 2012502991-A/428: RNA INTERFERENCE IN SKIN INDICATIONS
GCCAGCAACCGAA
>HV696432.1 JP 2012502991-A/427: RNA INTERFERENCE IN SKIN INDICATIONS
TCATGAATAGAAA
>HV696431.1 JP 2012502991-A/426: RNA INTERFERENCE IN SKIN INDICATIONS
GGAAATAACTAAT
>HV696430.1 JP 2012502991-A/425: RNA INTERFERENCE IN SKIN INDICATIONS
GGTTGAATGTGTA
>HV696429.1 JP 2012502991-A/424: RNA INTERFERENCE IN SKIN INDICATIONS
ATTGGTTGAATGT
>HV696428.1 JP 2012502991-A/423: RNA INTERFERENCE IN SKIN INDICATIONS
CAGCCATGAATTT
>HV696427.1 JP 2012502991-A/422: RNA INTERFERENCE IN SKIN INDICATIONS
CCAGAGTGCTGAA
>HV696426.1 JP 2012502991-A/421: RNA INTERFERENCE IN SKIN INDICATIONS
ATGAAACGAGTCA
>HV696425.1 JP 2012502991-A/420: RNA INTERFERENCE IN SKIN INDICATIONS
TGGTGCATACAAG
>HV696424.1 JP 2012502991-A/419: RNA INTERFERENCE IN SKIN INDICATIONS
TTAGATAGTGCAT
>HV696423.1 JP 2012502991-A/418: RNA INTERFERENCE IN SKIN INDICATIONS
AGCAATGAGCATT
>HV696422.1 JP 2012502991-A/417: RNA INTERFERENCE IN SKIN INDICATIONS
AAGTTTCGCAGAC
>HV696421.1 JP 2012502991-A/416: RNA INTERFERENCE IN SKIN INDICATIONS
AGTCCAACGAAAG
>HV696420.1 JP 2012502991-A/415: RNA INTERFERENCE IN SKIN INDICATIONS
AGTTTGTGGCTTC
>HV696618.1 JP 2012502991-A/613: RNA INTERFERENCE IN SKIN INDICATIONS
AATGAAGAAAGTA
>HV696419.1 JP 2012502991-A/414: RNA INTERFERENCE IN SKIN INDICATIONS
AGTCTGGAAATAA
>HV696416.1 JP 2012502991-A/411: RNA INTERFERENCE IN SKIN INDICATIONS
TAGACACATATGA
>HV696415.1 JP 2012502991-A/410: RNA INTERFERENCE IN SKIN INDICATIONS
GTCTGATGAGTCT
>HV696414.1 JP 2012502991-A/409: RNA INTERFERENCE IN SKIN INDICATIONS
TGCATTTAGTCAA
>HV696413.1 JP 2012502991-A/408: RNA INTERFERENCE IN SKIN INDICATIONS
TAGTCAGGAACTT
>HV696412.1 JP 2012502991-A/407: RNA INTERFERENCE IN SKIN INDICATIONS
AGCATTCCGATGT
>HV696411.1 JP 2012502991-A/406: RNA INTERFERENCE IN SKIN INDICATIONS
GCATTTAGTCAAA
>HV696410.1 JP 2012502991-A/405: RNA INTERFERENCE IN SKIN INDICATIONS
AGCAGTCCAGATT
>HV696409.1 JP 2012502991-A/404: RNA INTERFERENCE IN SKIN INDICATIONS
ATATGATGGCCGA
>HV696408.1 JP 2012502991-A/403: RNA INTERFERENCE IN SKIN INDICATIONS
GAATGGTGCATAC
>HV696407.1 JP 2012502991-A/402: RNA INTERFERENCE IN SKIN INDICATIONS
CCGACCAAGGAAA
>HV696406.1 JP 2012502991-A/401: RNA INTERFERENCE IN SKIN INDICATIONS
TGTTCATTCTATA
>HV696405.1 JP 2012502991-A/400: RNA INTERFERENCE IN SKIN INDICATIONS
TACCAGTTAAACA
>HV696404.1 JP 2012502991-A/399: RNA INTERFERENCE IN SKIN INDICATIONS
ATATAAGCGGAAA
>HV696403.1 JP 2012502991-A/398: RNA INTERFERENCE IN SKIN INDICATIONS
CAGTCCAGATTAT
>HV696402.1 JP 2012502991-A/397: RNA INTERFERENCE IN SKIN INDICATIONS
TTATGAAACGAGT
>HV696401.1 JP 2012502991-A/396: RNA INTERFERENCE IN SKIN INDICATIONS
TGGTTGAATGTGT
>HV696400.1 JP 2012502991-A/395: RNA INTERFERENCE IN SKIN INDICATIONS
GCAGTCCAGATTA
>HV696399.1 JP 2012502991-A/394: RNA INTERFERENCE IN SKIN INDICATIONS
ACATGGAAAGCGA
>HV696398.1 JP 2012502991-A/393: RNA INTERFERENCE IN SKIN INDICATIONS
TTGTCCAGCAATT
>HV696397.1 JP 2012502991-A/392: RNA INTERFERENCE IN SKIN INDICATIONS
TTCTATAGAAGAA
>HV696396.1 JP 2012502991-A/391: RNA INTERFERENCE IN SKIN INDICATIONS
ATGTGTATCTATT
>HV696395.1 JP 2012502991-A/390: RNA INTERFERENCE IN SKIN INDICATIONS
AGATAGTGCATCT
>HV696394.1 JP 2012502991-A/389: RNA INTERFERENCE IN SKIN INDICATIONS
TGATTGATAGTCA
>HV696393.1 JP 2012502991-A/388: RNA INTERFERENCE IN SKIN INDICATIONS
GCGAGGAGTTGAA
>HV696392.1 JP 2012502991-A/387: RNA INTERFERENCE IN SKIN INDICATIONS
ATGATGAGAGCAA
>HV696391.1 JP 2012502991-A/386: RNA INTERFERENCE IN SKIN INDICATIONS
AAGTCCAACGAAA
>HV696390.1 JP 2012502991-A/385: RNA INTERFERENCE IN SKIN INDICATIONS
CTCTCATGAATAG
>HV696389.1 JP 2012502991-A/384: RNA INTERFERENCE IN SKIN INDICATIONS
ATTTCTCATGAAT
>HV696388.1 JP 2012502991-A/383: RNA INTERFERENCE IN SKIN INDICATIONS
GCGCCTTCTGATT
>HV696387.1 JP 2012502991-A/382: RNA INTERFERENCE IN SKIN INDICATIONS
GAAATTTCGTATT
>HV696386.1 JP 2012502991-A/381: RNA INTERFERENCE IN SKIN INDICATIONS
ACATGGATGATAT
>HV696385.1 JP 2012502991-A/380: RNA INTERFERENCE IN SKIN INDICATIONS
AAAGCCATGACCA
>HV696384.1 JP 2012502991-A/379: RNA INTERFERENCE IN SKIN INDICATIONS
ATTTCGTATTTCT
>HV696383.1 JP 2012502991-A/378: RNA INTERFERENCE IN SKIN INDICATIONS
AAATTTCGTATTT
>HV696382.1 JP 2012502991-A/377: RNA INTERFERENCE IN SKIN INDICATIONS
GCGGAAAGCCAAT
>HV696381.1 JP 2012502991-A/376: RNA INTERFERENCE IN SKIN INDICATIONS
AAGCCATGACCAC
>HV696380.1 JP 2012502991-A/375: RNA INTERFERENCE IN SKIN INDICATIONS
GCCATGACCACAT
>HV696379.1 JP 2012502991-A/374: RNA INTERFERENCE IN SKIN INDICATIONS
ACCACATGGATGA
>HV696378.1 JP 2012502991-A/373: RNA INTERFERENCE IN SKIN INDICATIONS
AGCGGAAAGCCAA
>HV696377.1 JP 2012502991-A/372: RNA INTERFERENCE IN SKIN INDICATIONS
AAGCGGAAAGCCA
>HV696376.1 JP 2012502991-A/371: RNA INTERFERENCE IN SKIN INDICATIONS
AGTCTCACCATTC
>HV696375.1 JP 2012502991-A/370: RNA INTERFERENCE IN SKIN INDICATIONS
TCACAGCCATGAA
>HV696374.1 JP 2012502991-A/369: RNA INTERFERENCE IN SKIN INDICATIONS
GACTGAGGTCAAA
>HV696373.1 JP 2012502991-A/368: RNA INTERFERENCE IN SKIN INDICATIONS
GAGTCTCACCATT
>HV696372.1 JP 2012502991-A/367: RNA INTERFERENCE IN SKIN INDICATIONS
TGGACTGAGGTCA
>HV696371.1 JP 2012502991-A/366: RNA INTERFERENCE IN SKIN INDICATIONS
TTCTGATGAATCT
>HV696370.1 JP 2012502991-A/365: RNA INTERFERENCE IN SKIN INDICATIONS
GTCAGCTGGATGA
>HV696369.1 JP 2012502991-A/364: RNA INTERFERENCE IN SKIN INDICATIONS
TTCTGAGGTCAAT
>HV696368.1 JP 2012502991-A/363: RNA INTERFERENCE IN SKIN INDICATIONS
TGAGGTCAATTAA
>HV696367.1 JP 2012502991-A/362: RNA INTERFERENCE IN SKIN INDICATIONS
TCTGAGGTCAATT
>HV696366.1 JP 2012502991-A/361: RNA INTERFERENCE IN SKIN INDICATIONS
GAGGTCAATTAAA
>HV696365.1 JP 2012502991-A/360: RNA INTERFERENCE IN SKIN INDICATIONS
CTGAGGTCAATTA
>HV696364.1 JP 2012502991-A/359: RNA INTERFERENCE IN SKIN INDICATIONS
CTCATGAATTAGA
>HV696363.1 JP 2012502991-A/358: RNA INTERFERENCE IN SKIN INDICATIONS
GAAGCTGACCTGG
>HV696362.1 JP 2012502991-A/357: RNA INTERFERENCE IN SKIN INDICATIONS
TATCAAGTTTGAG
>HV696361.1 JP 2012502991-A/356: RNA INTERFERENCE IN SKIN INDICATIONS
CCGCAAGATCGGC
>HV696360.1 JP 2012502991-A/355: RNA INTERFERENCE IN SKIN INDICATIONS
AGACACGTTTGGC
>HV696359.1 JP 2012502991-A/354: RNA INTERFERENCE IN SKIN INDICATIONS
CTAAATTCTGTGG
>HV696358.1 JP 2012502991-A/353: RNA INTERFERENCE IN SKIN INDICATIONS
GCTAAATTCTGTG
>HV696357.1 JP 2012502991-A/352: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGACTTCGGC
>HV696356.1 JP 2012502991-A/351: RNA INTERFERENCE IN SKIN INDICATIONS
CCTTGCGAAGCTG
>HV696355.1 JP 2012502991-A/350: RNA INTERFERENCE IN SKIN INDICATIONS
TGCGAAGCTGACC
>HV696354.1 JP 2012502991-A/349: RNA INTERFERENCE IN SKIN INDICATIONS
TACGGAGACATGG
>HV696353.1 JP 2012502991-A/348: RNA INTERFERENCE IN SKIN INDICATIONS
CCTGTTCCAAGAC
>HV696352.1 JP 2012502991-A/347: RNA INTERFERENCE IN SKIN INDICATIONS
GTACCAGTGCACG
>HV696351.1 JP 2012502991-A/346: RNA INTERFERENCE IN SKIN INDICATIONS
CAATGACAACGCC
>HV696350.1 JP 2012502991-A/345: RNA INTERFERENCE IN SKIN INDICATIONS
TTGCGAAGCTGAC
>HV696349.1 JP 2012502991-A/344: RNA INTERFERENCE IN SKIN INDICATIONS
CGAAGCTGACCTG
>HV696348.1 JP 2012502991-A/343: RNA INTERFERENCE IN SKIN INDICATIONS
TGTTCCAAGACCT
>HV696347.1 JP 2012502991-A/342: RNA INTERFERENCE IN SKIN INDICATIONS
CCTATCAAGTTTG
>HV696346.1 JP 2012502991-A/341: RNA INTERFERENCE IN SKIN INDICATIONS
CCGACTGGAAGAC
>HV696345.1 JP 2012502991-A/340: RNA INTERFERENCE IN SKIN INDICATIONS
CTTGCGAAGCTGA
>HV696344.1 JP 2012502991-A/339: RNA INTERFERENCE IN SKIN INDICATIONS
GGCCTTGCGAAGC
>HV696343.1 JP 2012502991-A/338: RNA INTERFERENCE IN SKIN INDICATIONS
CGAGGTCATGAAG
>HV696342.1 JP 2012502991-A/337: RNA INTERFERENCE IN SKIN INDICATIONS
AAGACACGTTTGG
>HV696341.1 JP 2012502991-A/336: RNA INTERFERENCE IN SKIN INDICATIONS
GAGCTAAATTCTG
>HV696340.1 JP 2012502991-A/335: RNA INTERFERENCE IN SKIN INDICATIONS
GGTCAGGCCTTGC
>HV696339.1 JP 2012502991-A/334: RNA INTERFERENCE IN SKIN INDICATIONS
GCTAGAGAAGCAG
>HV696338.1 JP 2012502991-A/333: RNA INTERFERENCE IN SKIN INDICATIONS
TGGAGTATGTACC
>HV696337.1 JP 2012502991-A/332: RNA INTERFERENCE IN SKIN INDICATIONS
GCCAGAACTGCAG
>HV696336.1 JP 2012502991-A/331: RNA INTERFERENCE IN SKIN INDICATIONS
TCAAGTTTGAGCT
>HV696335.1 JP 2012502991-A/330: RNA INTERFERENCE IN SKIN INDICATIONS
TGGTCAGGCCTTG
>HV696334.1 JP 2012502991-A/329: RNA INTERFERENCE IN SKIN INDICATIONS
TGACTTCGGCTCC
>HV696333.1 JP 2012502991-A/328: RNA INTERFERENCE IN SKIN INDICATIONS
GTGACTTCGGCTC
>HV696332.1 JP 2012502991-A/327: RNA INTERFERENCE IN SKIN INDICATIONS
GGAAGATGTACGG
>HV696331.1 JP 2012502991-A/326: RNA INTERFERENCE IN SKIN INDICATIONS
GCGAAGCTGACCT
>HV696330.1 JP 2012502991-A/325: RNA INTERFERENCE IN SKIN INDICATIONS
TCAGGCCTTGCGA
>HV696329.1 JP 2012502991-A/324: RNA INTERFERENCE IN SKIN INDICATIONS
ACGGAGACATGGC
>HV696328.1 JP 2012502991-A/323: RNA INTERFERENCE IN SKIN INDICATIONS
GACACGTTTGGCC
>HV696327.1 JP 2012502991-A/322: RNA INTERFERENCE IN SKIN INDICATIONS
GGCGAGGTCATGA
>HV696326.1 JP 2012502991-A/321: RNA INTERFERENCE IN SKIN INDICATIONS
AATGACAACGCCT
>HV696325.1 JP 2012502991-A/320: RNA INTERFERENCE IN SKIN INDICATIONS
AAGATGTACGGAG
>HV696324.1 JP 2012502991-A/319: RNA INTERFERENCE IN SKIN INDICATIONS
TGGAAGACACGTT
>HV696323.1 JP 2012502991-A/318: RNA INTERFERENCE IN SKIN INDICATIONS
TAAATTCTGTGGA
>HV696322.1 JP 2012502991-A/317: RNA INTERFERENCE IN SKIN INDICATIONS
GAGGTCATGAAGA
>HV696321.1 JP 2012502991-A/316: RNA INTERFERENCE IN SKIN INDICATIONS
ATGACAACGCCTC
>HV696320.1 JP 2012502991-A/315: RNA INTERFERENCE IN SKIN INDICATIONS
CGGAGACATGGCA
>HV696319.1 JP 2012502991-A/314: RNA INTERFERENCE IN SKIN INDICATIONS
TCTGTGGAGTATG
>HV696318.1 JP 2012502991-A/313: RNA INTERFERENCE IN SKIN INDICATIONS
CGAGCTAAATTCT
>HV696317.1 JP 2012502991-A/312: RNA INTERFERENCE IN SKIN INDICATIONS
CAGGCCTTGCGAA
>HV696316.1 JP 2012502991-A/311: RNA INTERFERENCE IN SKIN INDICATIONS
ACCGCAAGATCGG
>HV696315.1 JP 2012502991-A/310: RNA INTERFERENCE IN SKIN INDICATIONS
TACCGACTGGAAG
>HV696314.1 JP 2012502991-A/309: RNA INTERFERENCE IN SKIN INDICATIONS
AGGCCTTGCGAAG
>HV696313.1 JP 2012502991-A/308: RNA INTERFERENCE IN SKIN INDICATIONS
GAAGACACGTTTG
>HV696312.1 JP 2012502991-A/307: RNA INTERFERENCE IN SKIN INDICATIONS
ATGGTCAGGCCTT
>HV696311.1 JP 2012502991-A/306: RNA INTERFERENCE IN SKIN INDICATIONS
GGTCATGAAGAAG
>HV696310.1 JP 2012502991-A/305: RNA INTERFERENCE IN SKIN INDICATIONS
AAGCTGACCTGGA
>HV696309.1 JP 2012502991-A/304: RNA INTERFERENCE IN SKIN INDICATIONS
ATTTGAAGTGTAA
>HV696308.1 JP 2012502991-A/303: RNA INTERFERENCE IN SKIN INDICATIONS
AGTTGTTCCTTAA
>HV696307.1 JP 2012502991-A/302: RNA INTERFERENCE IN SKIN INDICATIONS
AGCAGAAAGGTTA
>HV696306.1 JP 2012502991-A/301: RNA INTERFERENCE IN SKIN INDICATIONS
ACATACCGAGCTA
>HV696305.1 JP 2012502991-A/300: RNA INTERFERENCE IN SKIN INDICATIONS
TTGTTGAGAGTGT
>HV696304.1 JP 2012502991-A/299: RNA INTERFERENCE IN SKIN INDICATIONS
ATACCGAGCTAAA
>HV696303.1 JP 2012502991-A/298: RNA INTERFERENCE IN SKIN INDICATIONS
ATGGCCTTTATTA
>HV696302.1 JP 2012502991-A/297: RNA INTERFERENCE IN SKIN INDICATIONS
GACTGGACAGCTT
>HV696301.1 JP 2012502991-A/296: RNA INTERFERENCE IN SKIN INDICATIONS
TATACGAGTAATA
>HV696300.1 JP 2012502991-A/295: RNA INTERFERENCE IN SKIN INDICATIONS
TTATCTAAGTTAA
>HV696299.1 JP 2012502991-A/294: RNA INTERFERENCE IN SKIN INDICATIONS
TTCTGCTCAGATA
>HV696298.1 JP 2012502991-A/293: RNA INTERFERENCE IN SKIN INDICATIONS
AGCTGATCAGTTT
>HV696297.1 JP 2012502991-A/292: RNA INTERFERENCE IN SKIN INDICATIONS
AGGTAGAATGTAA
>HV696296.1 JP 2012502991-A/291: RNA INTERFERENCE IN SKIN INDICATIONS
AGCTAAATTCTGT
>HV696295.1 JP 2012502991-A/290: RNA INTERFERENCE IN SKIN INDICATIONS
CTATCAAGTTTGA
>HV696294.1 JP 2012502991-A/289: RNA INTERFERENCE IN SKIN INDICATIONS
GGAAGACACGTTT
>HV696293.1 JP 2012502991-A/288: RNA INTERFERENCE IN SKIN INDICATIONS
AGTACCAGTGCAC
>HV696292.1 JP 2012502991-A/287: RNA INTERFERENCE IN SKIN INDICATIONS
CAATGACATCTTT
>HV696291.1 JP 2012502991-A/286: RNA INTERFERENCE IN SKIN INDICATIONS
TTTCAGTAGCACA
>HV696290.1 JP 2012502991-A/285: RNA INTERFERENCE IN SKIN INDICATIONS
AAATTCTGTGGAG
>HV696289.1 JP 2012502991-A/284: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAGTATGT
>HV696288.1 JP 2012502991-A/283: RNA INTERFERENCE IN SKIN INDICATIONS
CAAGTTTGAGCTT
>HV696287.1 JP 2012502991-A/282: RNA INTERFERENCE IN SKIN INDICATIONS
AGCCTATCAAGTT
>HV696286.1 JP 2012502991-A/281: RNA INTERFERENCE IN SKIN INDICATIONS
TGTACGGAGACAT
>HV696285.1 JP 2012502991-A/280: RNA INTERFERENCE IN SKIN INDICATIONS
AATTCTGTGGAGT
>HV696284.1 JP 2012502991-A/279: RNA INTERFERENCE IN SKIN INDICATIONS
GCCTATCAAGTTT
>HV696283.1 JP 2012502991-A/278: RNA INTERFERENCE IN SKIN INDICATIONS
GCTGCGAGGAGTG
>HV696282.1 JP 2012502991-A/277: RNA INTERFERENCE IN SKIN INDICATIONS
GCCTTGCGAAGCT
>HV696281.1 JP 2012502991-A/276: RNA INTERFERENCE IN SKIN INDICATIONS
ATGTACGGAGACA
>HV696280.1 JP 2012502991-A/275: RNA INTERFERENCE IN SKIN INDICATIONS
ACCGACTGGAAGA
>HV696279.1 JP 2012502991-A/274: RNA INTERFERENCE IN SKIN INDICATIONS
AGAGTGGAGCGCC
>HV696278.1 JP 2012502991-A/273: RNA INTERFERENCE IN SKIN INDICATIONS
CATTACAACTGTC
>HV696277.1 JP 2012502991-A/272: RNA INTERFERENCE IN SKIN INDICATIONS
ATTACAACTGTCC
>HV696276.1 JP 2012502991-A/271: RNA INTERFERENCE IN SKIN INDICATIONS
CTGCCATTACAAC
>HV696275.1 JP 2012502991-A/270: RNA INTERFERENCE IN SKIN INDICATIONS
CCATTACAACTGT
>HV696274.1 JP 2012502991-A/269: RNA INTERFERENCE IN SKIN INDICATIONS
CCTGGTCCAGACC
>HV696273.1 JP 2012502991-A/268: RNA INTERFERENCE IN SKIN INDICATIONS
CAGAGTGGAGCGC
>HV696272.1 JP 2012502991-A/267: RNA INTERFERENCE IN SKIN INDICATIONS
AGACCTGTGCCTG
>HV696271.1 JP 2012502991-A/266: RNA INTERFERENCE IN SKIN INDICATIONS
AACTGCCTGGTCC
>HV696270.1 JP 2012502991-A/265: RNA INTERFERENCE IN SKIN INDICATIONS
ACTGGAAGACACG
>HV696269.1 JP 2012502991-A/264: RNA INTERFERENCE IN SKIN INDICATIONS
TGCCATTACAACT
>HV696268.1 JP 2012502991-A/263: RNA INTERFERENCE IN SKIN INDICATIONS
GTTTGAGCTTTCT
>HV696267.1 JP 2012502991-A/262: RNA INTERFERENCE IN SKIN INDICATIONS
TGGAGCGCCTGTT
>HV696266.1 JP 2012502991-A/261: RNA INTERFERENCE IN SKIN INDICATIONS
AGTGGAGCGCCTG
>HV696265.1 JP 2012502991-A/260: RNA INTERFERENCE IN SKIN INDICATIONS
GAGCTTTCTGGCT
>HV696264.1 JP 2012502991-A/259: RNA INTERFERENCE IN SKIN INDICATIONS
GCCATTACAACTG
>HV696263.1 JP 2012502991-A/258: RNA INTERFERENCE IN SKIN INDICATIONS
GGAGCGCCTGTTC
>HV696262.1 JP 2012502991-A/257: RNA INTERFERENCE IN SKIN INDICATIONS
CGACTGGAAGACA
>HV696261.1 JP 2012502991-A/256: RNA INTERFERENCE IN SKIN INDICATIONS
GAGTGGAGCGCCT
>HV696260.1 JP 2012502991-A/255: RNA INTERFERENCE IN SKIN INDICATIONS
ACAGGAAGATGTA
>HV696258.1 JP 2012502991-A/253: RNA INTERFERENCE IN SKIN INDICATIONS
ACAAATACGATTT
>HV696257.1 JP 2012502991-A/252: RNA INTERFERENCE IN SKIN INDICATIONS
ACAAATACGATTT
>HV696256.1 JP 2012502991-A/251: RNA INTERFERENCE IN SKIN INDICATIONS
ATTTCGAGCAGAA
>HV696255.1 JP 2012502991-A/250: RNA INTERFERENCE IN SKIN INDICATIONS
AGACTTGGGCAAT
>HV696254.1 JP 2012502991-A/249: RNA INTERFERENCE IN SKIN INDICATIONS
ATGTGACTGCTGA
>HV696253.1 JP 2012502991-A/248: RNA INTERFERENCE IN SKIN INDICATIONS
GAAAGTACAAAGA
>HV696252.1 JP 2012502991-A/247: RNA INTERFERENCE IN SKIN INDICATIONS
AGAAAGTACAAAG
>HV696251.1 JP 2012502991-A/246: RNA INTERFERENCE IN SKIN INDICATIONS
AGGTGGAAATGAA
>HV696250.1 JP 2012502991-A/245: RNA INTERFERENCE IN SKIN INDICATIONS
AATGAAGAAAGTA
>HV696248.1 JP 2012502991-A/243: RNA INTERFERENCE IN SKIN INDICATIONS
ACTGAATACCAAT
>HV696243.1 JP 2012502991-A/238: RNA INTERFERENCE IN SKIN INDICATIONS
GGCTACAAAAACA
>HV696242.1 JP 2012502991-A/237: RNA INTERFERENCE IN SKIN INDICATIONS
AGTCCCTCAAACA
>HV696241.1 JP 2012502991-A/236: RNA INTERFERENCE IN SKIN INDICATIONS
GGAGAAACAACAT
>HV696240.1 JP 2012502991-A/235: RNA INTERFERENCE IN SKIN INDICATIONS
GACTCATCTGCTA
>HV696239.1 JP 2012502991-A/234: RNA INTERFERENCE IN SKIN INDICATIONS
TCAGAACAAGAAA
>HV696238.1 JP 2012502991-A/233: RNA INTERFERENCE IN SKIN INDICATIONS
ATCTGGAGAAACA
>HV696237.1 JP 2012502991-A/232: RNA INTERFERENCE IN SKIN INDICATIONS
ATTTCGAGCAGAA
>HV696236.1 JP 2012502991-A/231: RNA INTERFERENCE IN SKIN INDICATIONS
AGACTTGGGCAAT
>HV696235.1 JP 2012502991-A/230: RNA INTERFERENCE IN SKIN INDICATIONS
ATGTGACTGCTGA
>HV696234.1 JP 2012502991-A/229: RNA INTERFERENCE IN SKIN INDICATIONS
GAAAGTACAAAGA
>HV696233.1 JP 2012502991-A/228: RNA INTERFERENCE IN SKIN INDICATIONS
AGAAAGTACAAAG
>HV696232.1 JP 2012502991-A/227: RNA INTERFERENCE IN SKIN INDICATIONS
AGGTGGAAATGAA
>HV696231.1 JP 2012502991-A/226: RNA INTERFERENCE IN SKIN INDICATIONS
AATGAAGAAAGTA
>HV696230.1 JP 2012502991-A/225: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696229.1 JP 2012502991-A/224: RNA INTERFERENCE IN SKIN INDICATIONS
ACAAATACGATTT
>HV696228.1 JP 2012502991-A/223: RNA INTERFERENCE IN SKIN INDICATIONS
ACAAATACGATTT
>HV696227.1 JP 2012502991-A/222: RNA INTERFERENCE IN SKIN INDICATIONS
ATTTGGCTACAAA
>HV696224.1 JP 2012502991-A/219: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696223.1 JP 2012502991-A/218: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696222.1 JP 2012502991-A/217: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696221.1 JP 2012502991-A/216: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696220.1 JP 2012502991-A/215: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696219.1 JP 2012502991-A/214: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696218.1 JP 2012502991-A/213: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696217.1 JP 2012502991-A/212: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696216.1 JP 2012502991-A/211: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696215.1 JP 2012502991-A/210: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696214.1 JP 2012502991-A/209: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696213.1 JP 2012502991-A/208: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696212.1 JP 2012502991-A/207: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696211.1 JP 2012502991-A/206: RNA INTERFERENCE IN SKIN INDICATIONS
ACTGAATACCAAT
>HV696210.1 JP 2012502991-A/205: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696209.1 JP 2012502991-A/204: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696208.1 JP 2012502991-A/203: RNA INTERFERENCE IN SKIN INDICATIONS
TGTAGGATGTCTA
>HV696205.1 JP 2012502991-A/200: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696200.1 JP 2012502991-A/195: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696199.1 JP 2012502991-A/194: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696198.1 JP 2012502991-A/193: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696197.1 JP 2012502991-A/192: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696196.1 JP 2012502991-A/191: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696195.1 JP 2012502991-A/190: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696192.1 JP 2012502991-A/187: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696191.1 JP 2012502991-A/186: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696190.1 JP 2012502991-A/185: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696189.1 JP 2012502991-A/184: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696188.1 JP 2012502991-A/183: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696187.1 JP 2012502991-A/182: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696186.1 JP 2012502991-A/181: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696185.1 JP 2012502991-A/180: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696184.1 JP 2012502991-A/179: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV696183.1 JP 2012502991-A/178: RNA INTERFERENCE IN SKIN INDICATIONS
CTGTGGAAGTCTA
>HV688671.1 JP 2011501666-A/8: BIFIDOBACTERIAL SPECIES
TCGTCGCCTCGGC
>HV593710.1 JP 2010537640-A/84: Composition of Asymmetric RNA Duplex as MicroRNA Mimetic or Inhibitor
CTGATATTGATGG
>HV600411.1 JP 2010284171-A/7: LLG POLYPEPTIDES OF THE TRIACYLGLYCEROL LIPASE FAMILY, AND COMPOSITIONS AND METHODS FOR THEIR USE IN ENZYMATIC HYDROLYSYS, AND PROTEIN AND GENE THERAPIES
TTTTTTTTTTTGA
>HV579567.1 JP 2010213722-A/61: MARKERS FOR PRENATAL DIAGNOSIS AND MONITORING
AGCGAGAGATGCC
>HV588788.1 JP 2010273681-A/111: Methods for Selecting Medications
CAACGTGCTGGTG
>HV588756.1 JP 2010273681-A/79: Methods for Selecting Medications
TGGAGATCATGAT
>HV599680.1 JP 2011004744-A/790: HBM Variants that Modulate Bone Mass and Lipid Levels
CACCGTCAGTGCT
>HV599674.1 JP 2011004744-A/784: HBM Variants that Modulate Bone Mass and Lipid Levels
CATTTGGCCCCTA
>HV588721.1 JP 2010273681-A/44: Methods for Selecting Medications
AGCTTATTACAGC
>HV588670.1 JP 2011015679-A/7: METHODS AND REAGENTS FOR THE EARLY DETECTION OF MELANOMA
ATCCGGCGGCCAC
>HV578963.1 JP 2010525814-A/3: PEPTIDE NUCLEIC ACID PROBES FOR ANALYSIS OF CERTAIN STAPHYLOCOCCUS SPECIES
GCTAATACGCCGC
>HV578961.1 JP 2010525814-A/1: PEPTIDE NUCLEIC ACID PROBES FOR ANALYSIS OF CERTAIN STAPHYLOCOCCUS SPECIES
AGACGTGCATAGT
>HV599672.1 JP 2011004744-A/782: HBM Variants that Modulate Bone Mass and Lipid Levels
TCCGAGGAGACGC
>HV599666.1 JP 2011004744-A/776: HBM Variants that Modulate Bone Mass and Lipid Levels
CGGGGCAGCCGGG
>HV599664.1 JP 2011004744-A/774: HBM Variants that Modulate Bone Mass and Lipid Levels
GGTCTCGCCCTTC
>HV599663.1 JP 2011004744-A/773: HBM Variants that Modulate Bone Mass and Lipid Levels
ATGTGTGTGGCAG
>HV599659.1 JP 2011004744-A/769: HBM Variants that Modulate Bone Mass and Lipid Levels
GCAGAGACCAGAC
>HV599652.1 JP 2011004744-A/762: HBM Variants that Modulate Bone Mass and Lipid Levels
CAGCCCGGCCCAC
>HV599649.1 JP 2011004744-A/759: HBM Variants that Modulate Bone Mass and Lipid Levels
AGACAACACACTG
>HV599646.1 JP 2011004744-A/756: HBM Variants that Modulate Bone Mass and Lipid Levels
CAGAATCGAAGTG
>HV599639.1 JP 2011004744-A/749: HBM Variants that Modulate Bone Mass and Lipid Levels
CGAGGAGGCCATC
>HV578322.1 JP 2010521193-A/33: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION
GCATTGGTATTCA
>HV578321.1 JP 2010521193-A/32: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION
GCATTGGTATTCA
>HV578320.1 JP 2010521193-A/31: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION
GCATTGGTATTCA
>HV578319.1 JP 2010521193-A/30: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION
GCATTGGTATTCA
>HV578318.1 JP 2010521193-A/29: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION
GCATTGGTATTCA
>HV578317.1 JP 2010521193-A/28: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION
GCATTGGTATTCA
>HV578316.1 JP 2010521193-A/27: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION
GCATTGGTATTCA
>HV578315.1 JP 2010521193-A/26: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION
GCATTGGTATTCA
>HV578299.1 JP 2010521193-A/10: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION
CATTGGTATTCAG
>HV578298.1 JP 2010521193-A/9: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION
GCATTGGTATTCA
>HV578297.1 JP 2010521193-A/8: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION
AGCATTGGTATTC
>HV578296.1 JP 2010521193-A/7: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION
CAGCATTGGTATT
>HV578264.1 JP 2010213718-A/13: AN EXPRESSION CASSETTE AND VECTOR FOR TRANSIENT OR STABLE EXPRESSION OF EXOGENOUS MOLECULES
GATCCGCGGCCGC
>HV578256.1 JP 2010213718-A/5: AN EXPRESSION CASSETTE AND VECTOR FOR TRANSIENT OR STABLE EXPRESSION OF EXOGENOUS MOLECULES
CTACTTAAGCCGC
>HV598916.1 JP 2011004744-A/26: HBM Variants that Modulate Bone Mass and Lipid Levels
AATTCGGCACGAG
>HV598724.1 JP 2010539993-A/6: Engineered Dendritic Cells And Uses For The Treatment Of Cancer
AGGTCANAGGTCA
>HV575399.1 JP 2010150280-A/85: IMMUNOSTIMULATORY NUCLEIC ACID MOLECULES
TGTCGTTGTCGTT
>HV574895.1 JP 2010142247-A/40: IL-6 receptor/fusion protein of IL-6
CGGGGCAGTAAGT
>HV574875.1 JP 2010142247-A/20: IL-6 receptor/fusion protein of IL-6
CGGGGCGCCACCT
>HV586117.1 JP 2010284172-A/17: Peptide Acceptor Ligation Methods
AAAAAAAAAAAAA
>HV574454.1 JP 2010148524-A/32: 5' CPG Nucleic Acids and Methods of Use
TCGTTTTTTTTTT
>HV600992.1 JP 2011037863-A/14: Immunostimulatory G,U-Containing Oligoribonucleotides
TTTTTGTGTGTGT
>HV600990.1 JP 2011037863-A/12: Immunostimulatory G,U-Containing Oligoribonucleotides
GGGGGGTGTGTGT
>GZ341535.1 Sequence 5 from patent US 8188259
TTGCTACCAGTCT
>GZ340583.1 Sequence 9 from patent US 8188254
CGGCGTCGTGCCG
>GZ340580.1 Sequence 6 from patent US 8188254
CGGCGNNNTGCCG
>GZ340577.1 Sequence 3 from patent US 8188254
CGGCGCCGTGCCG
>GZ339593.1 Sequence 1559 from patent US 8188059
TAGCCACCAACTG
>GZ339470.1 Sequence 1432 from patent US 8188059
TAGCCTCTGGATT
>GZ339202.1 Sequence 1163 from patent US 8188059
GCTAGCCTCTGGA
>GZ338410.1 Sequence 292 from patent US 8188059
GCACACAGCTGCC
>GZ338400.1 Sequence 280 from patent US 8188059
GGCATGAGCTTCA
>GZ338371.1 Sequence 245 from patent US 8188059
TGTTCCAGCCCAG
>GZ337030.1 Sequence 20 from patent US 8187815
TGCCGTCAAAAGC
>GZ336932.1 Sequence 13 from patent US 8187813
TTGCTCGCAGCCG
>GZ335703.1 Sequence 8 from patent US 8106180
GAGGAGAGGACAG
>GZ335702.1 Sequence 7 from patent US 8106180
GAGGAGAGGGAGG
>GZ332687.1 Sequence 788 from patent US 8106025
TGCTGCATCTCTG
>GZ329053.1 Sequence 3709 from patent US 8105826
GTCACCCTGTTGG
>GZ328310.1 Sequence 2966 from patent US 8105826
TGAACGCATCTCC
>GZ327480.1 Sequence 2136 from patent US 8105826
GGCCATAGNTTGC
>GZ325406.1 Sequence 18 from patent US 8105825
AGGTCANAGGTCA
>GZ321999.1 Sequence 5 from patent US 8183361
TTGCTACCAGTCT
>GZ321994.1 Sequence 319 from patent US 8183360
GAAGGASAMGCTG
>GZ321993.1 Sequence 318 from patent US 8183360
TGCGACVTGGGGC
>GZ321697.1 Sequence 13 from patent US 8183360
TTTACCCGGTTCA
>GZ321693.1 Sequence 9 from patent US 8183360
GTTTACCCGGTTC
>GZ321032.1 Sequence 12 from patent US 8183044
CTAGCCGAGTAGC
>GZ319860.1 Sequence 95 from patent US 8182991
CCGGTCGTCCTGG
>GZ319752.1 Sequence 191 from patent US 8182990
GTGGCCCAGAGCA
>GZ315351.1 Sequence 2345 from patent US 8182996
GTCGTCGGAGGGA
>GZ315350.1 Sequence 2344 from patent US 8182996
GTCGTCGGAGGGA
>GZ315349.1 Sequence 2343 from patent US 8182996
GCGGGTGGTGTTC
>GZ311136.1 Sequence 2912 from patent US 8193331
CACGTTTCTTGGA
>GZ307235.1 Sequence 5 from patent US 8192990
CTCTTCCTTTTTC
>GZ306858.1 Sequence 68 from patent US 8192953
CTGAATGGGGCCG
>GZ306721.1 Sequence 463 from patent US 8192938
CACCCACCACTGG
>GZ305850.1 Sequence 8 from patent US 8192934
AATTGCCCGGGCG
>GZ305849.1 Sequence 7 from patent US 8192934
CTAGGCCCGGGCG
>GZ305848.1 Sequence 6 from patent US 8192934
GATCGCCCGGGCG
>GZ305832.1 Sequence 37 from patent US 8192932
CGTGTCGCCCTTA
>GZ305828.1 Sequence 31 from patent US 8192932
NAAGGGCGAGTCG
>GZ305305.1 Sequence 63 from patent US 8178659
CCGCCCGTCACAC
>GZ305300.1 Sequence 26 from patent US 8178659
CCAGCAGCCGCGG
>GZ303740.1 Sequence 788 from patent US 8178506
TGCTGCATCTCTG
>GZ302944.1 Sequence 45 from patent US 8178504
GGCCNNNNNGGCC
>GZ302930.1 Sequence 28 from patent US 8178504
NACNNNNGTAYCN
>GZ301953.1 Sequence 21 from patent US 8178294
CCAGCCTGACTTC
>GZ275546.1 Sequence 67 from patent US 8168389
CGGAGATGGCCCA
>GZ275368.1 Sequence 58 from patent US 8168381
TCCCGTATCGACC
>GZ275365.1 Sequence 55 from patent US 8168381
AAGGTGGTATACC
>GZ275362.1 Sequence 52 from patent US 8168381
TCCCGAGTCGACC
>GZ253370.1 Sequence 109 from patent US 8163708
GCCGAACGAACAA
>GZ253368.1 Sequence 107 from patent US 8163708
GCCGAACGAACAA
>GZ253359.1 Sequence 98 from patent US 8163708
ATTGTCACACTCC
>GZ253358.1 Sequence 97 from patent US 8163708
ATTGTCACACTCC
>GZ253357.1 Sequence 96 from patent US 8163708
ATTGTCACACTCC
>GZ253355.1 Sequence 94 from patent US 8163708
ATTGTCACACTCC
>GZ253348.1 Sequence 87 from patent US 8163708
CATGGATTTGCAC
>GZ253347.1 Sequence 86 from patent US 8163708
CATGGATTTGCAC
>GZ253345.1 Sequence 84 from patent US 8163708
CATGGATTTGCAC
>GZ253335.1 Sequence 62 from patent US 8163708
ATTGTCACACTCC
>GZ253325.1 Sequence 52 from patent US 8163708
GCCGTTCGTTCTT
>GZ253316.1 Sequence 43 from patent US 8163708
AGTCTGATAAGCT
>GZ253307.1 Sequence 34 from patent US 8163708
ACGATTAGCATTA
>GZ253298.1 Sequence 25 from patent US 8163708
CATGGATTTGCAC
>GZ253289.1 Sequence 16 from patent US 8163708
ATTGTCACACTCC
>GZ252625.1 Sequence 17 from patent US 8163501
TGCTCCGGCGCCA
>GZ252259.1 Sequence 46 from patent US 8163483
CCCAACYCTCTGG
>GZ252258.1 Sequence 45 from patent US 8163483
AGAGGGRGATGGG
>GZ252257.1 Sequence 44 from patent US 8163483
AGGAGARGGGGAT
>GZ252256.1 Sequence 43 from patent US 8163483
GCCCCCMCTACTG
>GZ252255.1 Sequence 42 from patent US 8163483
CTACGTRGAGGGG
>GZ252254.1 Sequence 41 from patent US 8163483
TCCTGCRCATCTT
>GZ252253.1 Sequence 40 from patent US 8163483
TCGTCCRCATCCT
>GZ252252.1 Sequence 39 from patent US 8163483
TCATGCRCATCAC
>GZ252251.1 Sequence 38 from patent US 8163483
CACCAAYGAGTTC
>GZ252249.1 Sequence 36 from patent US 8163483
AGTCTGYGTCTCG
>GZ252248.1 Sequence 35 from patent US 8163483
CGTCTTKAAATAG
>GZ252247.1 Sequence 34 from patent US 8163483
TCCCCTYCTCCCT
>GZ252246.1 Sequence 33 from patent US 8163483
GGTCTCYCTCTAT
>GZ252227.1 Sequence 32 from patent US 8163482
GCAGAGAACAAAG
>GZ252184.1 Sequence 26 from patent US 8163480
CTCTGAGCGGGCG
>GZ252103.1 Sequence 3 from patent US 8163476
AAGCTTGCACCAT
>GZ250862.1 Sequence 102 from patent US 8158768
TCGAACGTTCGAG
>GZ249140.1 Sequence 183 from patent US 8158419
CACATCGATACTG
>GZ248567.1 Sequence 27 from patent US 8158400
DTAAACATGTAGG
>GZ246703.1 Sequence 59 from patent US 8158355
GGTGANNNNNNNN
>GZ246693.1 Sequence 49 from patent US 8158355
GAAGANNNNNNNN
>GZ246690.1 Sequence 46 from patent US 8158355
GGTGANNNNNNNN
>GZ244741.1 Sequence 15 from patent US 8153772
TACGTGNACCCAG
>GZ244407.1 Sequence 154 from patent US 8153608
CTATCTGACGTTC
>GZ244402.1 Sequence 149 from patent US 8153608
CTATCTGACGTTC
>GZ244397.1 Sequence 144 from patent US 8153608
TGACGTTCTCTGT
>GZ244393.1 Sequence 140 from patent US 8153608
CTATCTGACGTTC
>GZ244391.1 Sequence 138 from patent US 8153608
CTATCTGACGTTC
>GZ244389.1 Sequence 136 from patent US 8153608
TGACGTTCTCTGT
>GZ244388.1 Sequence 135 from patent US 8153608
TGACGTTCTCTGT
>GZ244386.1 Sequence 133 from patent US 8153608
TGACGTTCTCTGT
>GZ244385.1 Sequence 132 from patent US 8153608
TGACGTTCTCTGT
>GZ244384.1 Sequence 131 from patent US 8153608
TGACGTTCTCTGT
>GZ244382.1 Sequence 129 from patent US 8153608
TGACGTTCTCTGT
>GZ244381.1 Sequence 128 from patent US 8153608
TGACGTTCTCTGT
>GZ244380.1 Sequence 127 from patent US 8153608
TGACGTTCTCTGT
>GZ244378.1 Sequence 125 from patent US 8153608
TGACGTTCTCTGT
>GZ244377.1 Sequence 124 from patent US 8153608
TGACGTTCTCTGT
>GZ244376.1 Sequence 123 from patent US 8153608
TGACGTTCTCTGT
>GZ244375.1 Sequence 122 from patent US 8153608
TGACGTTCTCTGT
>GZ244374.1 Sequence 121 from patent US 8153608
TGACGTTCTCTGT
>GZ244373.1 Sequence 120 from patent US 8153608
TGACGTTCTCTGT
>GZ244368.1 Sequence 115 from patent US 8153608
TGACGTTCTCTGT
>GZ244367.1 Sequence 114 from patent US 8153608
CCTACTAGCGTTC
>GZ244365.1 Sequence 112 from patent US 8153608
CCTACTAGCGTTC
>GZ244363.1 Sequence 110 from patent US 8153608
CCTACTAGCGTTC
>GZ244362.1 Sequence 109 from patent US 8153608
CCTACTAGCGTTC
>GZ244359.1 Sequence 106 from patent US 8153608
TAGCGTTCTCATC
>GZ244358.1 Sequence 105 from patent US 8153608
TAGCGTTCTCATC
>GZ244300.1 Sequence 33 from patent US 8153608
NNTCTGACNTTCT
>GZ244296.1 Sequence 29 from patent US 8153608
NNTCTGTCNTTCT
>GZ244273.1 Sequence 6 from patent US 8153608
TGACGTTCTCTGT
>GZ244272.1 Sequence 5 from patent US 8153608
TGACGTTCTCTGT
>GZ244168.1 Sequence 81 from patent US 8153606
AAACTGAGCTCCA
>GZ244090.1 Sequence 3 from patent US 8153606
TGGAGCTCAGTTT
>GZ243919.1 Sequence 24 from patent US 8153604
TTGTCTAACCCTA
>GZ243918.1 Sequence 23 from patent US 8153604
TAGGTGTAAGCAA
>GZ243914.1 Sequence 17 from patent US 8153604
GTTAGGGTTAGAC
>GZ243910.1 Sequence 13 from patent US 8153604
CAGTTAGGGTTAG
>GZ243909.1 Sequence 12 from patent US 8153604
TAGGGTTAGACAA
>GZ243906.1 Sequence 9 from patent US 8153604
ACGGTGGAAGGCG
>GZ243905.1 Sequence 8 from patent US 8153604
CGGTGGAAGGCGG
>GZ243903.1 Sequence 6 from patent US 8153604
GTGGAAGGCGGCA
>GZ243902.1 Sequence 5 from patent US 8153604
GGAAGGCGGCAGG
>GZ231471.1 Sequence 4 from patent US 8153366
CTCAGGTGATCCA
>GZ231400.1 Sequence 79 from patent US 8153365
CAAACAAACCACA
>GZ231399.1 Sequence 78 from patent US 8153365
CAAACAAACCACA
>GZ231398.1 Sequence 77 from patent US 8153365
GGTGGTTTGTTTG
>GZ231397.1 Sequence 76 from patent US 8153365
CAAACAAACCACA
>GZ231396.1 Sequence 75 from patent US 8153365
CAAACAAACCACA
>GZ231395.1 Sequence 74 from patent US 8153365
GGTGGTTTGTTTG
>GZ231394.1 Sequence 73 from patent US 8153365
CAAACAAACCACA
>GZ231393.1 Sequence 72 from patent US 8153365
CAAACAAACCACA
>GZ231392.1 Sequence 71 from patent US 8153365
GGTGGTTTGTTTG
>GZ231385.1 Sequence 64 from patent US 8153365
ATAAAGTGTAAAG
>GZ231381.1 Sequence 60 from patent US 8153365
ATAAAGTGTAAAG
>GZ231379.1 Sequence 58 from patent US 8153365
ATAAAGTGTAAAG
>GZ231369.1 Sequence 48 from patent US 8153365
GGTGGTTTGTTTG
>GZ231368.1 Sequence 47 from patent US 8153365
GGTGGTTTGTTTG
>GZ231367.1 Sequence 46 from patent US 8153365
GGTGGTTTGTTTG
>GZ231365.1 Sequence 44 from patent US 8153365
GGTGGTTTGTTTG
>GZ231364.1 Sequence 43 from patent US 8153365
GGTGGTTTGTTTG
>GZ231363.1 Sequence 42 from patent US 8153365
AGAGCCGATAACA
>GZ231362.1 Sequence 41 from patent US 8153365
AGAGCCGATAACA
>GZ231361.1 Sequence 40 from patent US 8153365
AGAGCCGATAACA
>GZ231360.1 Sequence 39 from patent US 8153365
TTCCACAGCACAA
>GZ231359.1 Sequence 38 from patent US 8153365
TTCCACAGCACAA
>GZ231358.1 Sequence 37 from patent US 8153365
TTCCACAGCACAA
>GZ231353.1 Sequence 32 from patent US 8153365
GGTGGTTTGTTTG
>GZ231352.1 Sequence 31 from patent US 8153365
GGTGGTTTGTTTG
>GZ231351.1 Sequence 30 from patent US 8153365
GGTGGTTTGTTTG
>GZ231350.1 Sequence 29 from patent US 8153365
GGTGGTTTGTTTG
>GZ231349.1 Sequence 28 from patent US 8153365
GGTGGTTTGTTTG
>GZ231330.1 Sequence 9 from patent US 8153365
GGTGGTTTGTTTG
>GZ231329.1 Sequence 8 from patent US 8153365
GGTGGTTTGTTTG
>GZ231328.1 Sequence 7 from patent US 8153365
GGTGGTTTGTTTG
>GZ231327.1 Sequence 6 from patent US 8153365
GGTGGTTTGTTTG
>GZ231326.1 Sequence 5 from patent US 8153365
GGTGGTTTGTTTG
>GZ231325.1 Sequence 4 from patent US 8153365
GGTGGTTTGTTTG
>GZ231324.1 Sequence 3 from patent US 8153365
GGTGGTTTGTTTG
>GZ231323.1 Sequence 2 from patent US 8153365
ATAAAGTGTAAAG
>GZ229570.1 Sequence 14 from patent US 8153141
NNNNNGTGTGTGT
>GZ229568.1 Sequence 12 from patent US 8153141
GGGGGGTGTGTGT
>GZ280499.1 Sequence 18 from patent US 8168426
AGGTCANAGGTCA
>HV570124.1 WO 2012020839-A/104: A pharmaceutical composition for treating cancers
GTACTCCAGATGG
>HV570123.1 WO 2012020839-A/103: A pharmaceutical composition for treating cancers
CACAGACTGACAC
>HV570122.1 WO 2012020839-A/102: A pharmaceutical composition for treating cancers
GTCCATCTCTATT
>HV570121.1 WO 2012020839-A/101: A pharmaceutical composition for treating cancers
CATGAGTGACTGG
>HV570120.1 WO 2012020839-A/100: A pharmaceutical composition for treating cancers
CTCCATTAGAGAC
>HV570119.1 WO 2012020839-A/99: A pharmaceutical composition for treating cancers
AACATCCTGACAG
>HV570118.1 WO 2012020839-A/98: A pharmaceutical composition for treating cancers
ACTAGATGTGAGG
>HV570117.1 WO 2012020839-A/97: A pharmaceutical composition for treating cancers
GTCTCACAATCAC
>HV570116.1 WO 2012020839-A/96: A pharmaceutical composition for treating cancers
GGTGTCTGGTTCA
>HV570115.1 WO 2012020839-A/95: A pharmaceutical composition for treating cancers
GTACAGTGCTGAT
>HV570114.1 WO 2012020839-A/94: A pharmaceutical composition for treating cancers
CATTAGTAGAGGT
>HV570113.1 WO 2012020839-A/93: A pharmaceutical composition for treating cancers
CTCAAGTACCTCA
>HV570112.1 WO 2012020839-A/92: A pharmaceutical composition for treating cancers
ACCTAACACTCCT
>HV570111.1 WO 2012020839-A/91: A pharmaceutical composition for treating cancers
ATCTCCAACCAAC
>HV570110.1 WO 2012020839-A/90: A pharmaceutical composition for treating cancers
TATAGGTATCTGG
>HV570109.1 WO 2012020839-A/89: A pharmaceutical composition for treating cancers
ACCACATTATCTG
>HV570108.1 WO 2012020839-A/88: A pharmaceutical composition for treating cancers
TTGACTCTCTCTT
>HV570107.1 WO 2012020839-A/87: A pharmaceutical composition for treating cancers
CAATACCAATAGC
>HV570106.1 WO 2012020839-A/86: A pharmaceutical composition for treating cancers
CAGAATCACCACA
>HV570105.1 WO 2012020839-A/85: A pharmaceutical composition for treating cancers
TATCTGCACTTGG
>HV570104.1 WO 2012020839-A/84: A pharmaceutical composition for treating cancers
TACTACCATTGAC
>HV570103.1 WO 2012020839-A/83: A pharmaceutical composition for treating cancers
CTAGAGCAAGCTC
>HV570102.1 WO 2012020839-A/82: A pharmaceutical composition for treating cancers
GATGAGATTATGG
>HV570101.1 WO 2012020839-A/81: A pharmaceutical composition for treating cancers
CCACTACAGATTC
>HV570100.1 WO 2012020839-A/80: A pharmaceutical composition for treating cancers
TCAACAGTGGAAG
>HV570099.1 WO 2012020839-A/79: A pharmaceutical composition for treating cancers
CTGTCACTCTTTC
>HV570098.1 WO 2012020839-A/78: A pharmaceutical composition for treating cancers
CTGCAAGAGACTG
>HV570097.1 WO 2012020839-A/77: A pharmaceutical composition for treating cancers
TCTAGACTGTATC
>HV570096.1 WO 2012020839-A/76: A pharmaceutical composition for treating cancers
TATCAAGAAGGTG
>HV570095.1 WO 2012020839-A/75: A pharmaceutical composition for treating cancers
GAATGATCTCCAG
>HV570094.1 WO 2012020839-A/74: A pharmaceutical composition for treating cancers
TTTTGGTGGCCTC
>HV570093.1 WO 2012020839-A/73: A pharmaceutical composition for treating cancers
GTGGCCTCATTGG
>HV570092.1 WO 2012020839-A/72: A pharmaceutical composition for treating cancers
CCTCATTGGCTCC
>HV570091.1 WO 2012020839-A/71: A pharmaceutical composition for treating cancers
TCATTGGCTCCTT
>HV570090.1 WO 2012020839-A/70: A pharmaceutical composition for treating cancers
AGCTGCTTATAGT
>HV570089.1 WO 2012020839-A/69: A pharmaceutical composition for treating cancers
AGTTACATGACTG
>HV570088.1 WO 2012020839-A/68: A pharmaceutical composition for treating cancers
GTTACATGACTGC
>HV570087.1 WO 2012020839-A/67: A pharmaceutical composition for treating cancers
TACATGACTGCTG
>HV570086.1 WO 2012020839-A/66: A pharmaceutical composition for treating cancers
GGTCCAGTAGCTT
>HV570085.1 WO 2012020839-A/65: A pharmaceutical composition for treating cancers
GTAGCTTCTTGGT
>HV570084.1 WO 2012020839-A/64: A pharmaceutical composition for treating cancers
TTCACATCAGCCT
>HV570083.1 WO 2012020839-A/63: A pharmaceutical composition for treating cancers
ATCAGCCTCAGTC
>HV570082.1 WO 2012020839-A/62: A pharmaceutical composition for treating cancers
AGCCTCAGTCATG
>HV570081.1 WO 2012020839-A/61: A pharmaceutical composition for treating cancers
CTCAGTCATGGCT
>HV570080.1 WO 2012020839-A/60: A pharmaceutical composition for treating cancers
CTCAGCACTCCTA
>HV570079.1 WO 2012020839-A/59: A pharmaceutical composition for treating cancers
CTGAGGTGTGTTA
>HV570078.1 WO 2012020839-A/58: A pharmaceutical composition for treating cancers
GTGCAGATACAGC
>HV570077.1 WO 2012020839-A/57: A pharmaceutical composition for treating cancers
TGGTCTCAGATAA
>HV570076.1 WO 2012020839-A/56: A pharmaceutical composition for treating cancers
CATGTTGTATACA
>HV570075.1 WO 2012020839-A/55: A pharmaceutical composition for treating cancers
TTAGGTTCAGATT
>HV570074.1 WO 2012020839-A/54: A pharmaceutical composition for treating cancers
TAATGAGCTGGAA
>HV570073.1 WO 2012020839-A/53: A pharmaceutical composition for treating cancers
GTCATACAGTAAG
>HV570072.1 WO 2012020839-A/52: A pharmaceutical composition for treating cancers
AGAGCTGCACATG
>HV570071.1 WO 2012020839-A/51: A pharmaceutical composition for treating cancers
ACAAGCTTGCTCT
>HV570070.1 WO 2012020839-A/50: A pharmaceutical composition for treating cancers
AAGAGAGACTGCT
>HV570069.1 WO 2012020839-A/49: A pharmaceutical composition for treating cancers
TAGCTTGACCAAG
>HV570068.1 WO 2012020839-A/48: A pharmaceutical composition for treating cancers
GACCAAGTCATGT
>HV570067.1 WO 2012020839-A/47: A pharmaceutical composition for treating cancers
AGCATGAGTACAG
>HV570066.1 WO 2012020839-A/46: A pharmaceutical composition for treating cancers
GTCATAGCAATAA
>HV570065.1 WO 2012020839-A/45: A pharmaceutical composition for treating cancers
ATTTAGATCTGTC
>HV570064.1 WO 2012020839-A/44: A pharmaceutical composition for treating cancers
GTTGAGGAGCATT
>HV570063.1 WO 2012020839-A/43: A pharmaceutical composition for treating cancers
CAGGTATATGAGG
>HV570062.1 WO 2012020839-A/42: A pharmaceutical composition for treating cancers
CCATACCTGCTGA
>HV570061.1 WO 2012020839-A/41: A pharmaceutical composition for treating cancers
GGAATGAGTAACA
>HV570060.1 WO 2012020839-A/40: A pharmaceutical composition for treating cancers
ACAATTAGAGTCC
>HV570059.1 WO 2012020839-A/39: A pharmaceutical composition for treating cancers
GTCCTCTGTTCTG
>HV570058.1 WO 2012020839-A/38: A pharmaceutical composition for treating cancers
TGGATATGATCTG
>HV570057.1 WO 2012020839-A/37: A pharmaceutical composition for treating cancers
AACCATAGTCAGC
>HV570056.1 WO 2012020839-A/36: A pharmaceutical composition for treating cancers
TCTGTGTATGAGT
>HV570055.1 WO 2012020839-A/35: A pharmaceutical composition for treating cancers
ATTCATCAGGTTC
>HV570054.1 WO 2012020839-A/34: A pharmaceutical composition for treating cancers
ACATCCTCTGCTC
>HV570053.1 WO 2012020839-A/33: A pharmaceutical composition for treating cancers
TTGTTGATACTGG
>HV570052.1 WO 2012020839-A/32: A pharmaceutical composition for treating cancers
CCTTAGCAGGTAG
>HV570051.1 WO 2012020839-A/31: A pharmaceutical composition for treating cancers
GTCATGAAGAGTC
>HV570050.1 WO 2012020839-A/30: A pharmaceutical composition for treating cancers
GAATAGTACTCAG
>HV570049.1 WO 2012020839-A/29: A pharmaceutical composition for treating cancers
ATACCAGCAATTC
>HV570048.1 WO 2012020839-A/28: A pharmaceutical composition for treating cancers
TATCTACTTCTGC
>HV570047.1 WO 2012020839-A/27: A pharmaceutical composition for treating cancers
CCTCTAGATCAAT
>HV570046.1 WO 2012020839-A/26: A pharmaceutical composition for treating cancers
TCTCTTGATATGC
>HV570045.1 WO 2012020839-A/25: A pharmaceutical composition for treating cancers
AGCAATGATCAAG
>HV570044.1 WO 2012020839-A/24: A pharmaceutical composition for treating cancers
GTAAGACTGTCTG
>HV570043.1 WO 2012020839-A/23: A pharmaceutical composition for treating cancers
CTCATTCACCATA
>HV570042.1 WO 2012020839-A/22: A pharmaceutical composition for treating cancers
TCATCCAGAGATA
>HV570041.1 WO 2012020839-A/21: A pharmaceutical composition for treating cancers
CTAATAGCAAACC
>HV570040.1 WO 2012020839-A/20: A pharmaceutical composition for treating cancers
AGCAAACCTTGAT
>HV569776.1 WO 2012014988-A/29: Method of manufacturing an RNA-containing probe for detection of target base
AAAGTGGACGGCA
>HV569758.1 WO 2012014988-A/11: Method of manufacturing an RNA-containing probe for detection of target base
ATTCACAAACGAA
>HV567724.1 JP 2012024090-A/157: QIAGEN GAITHERSBURG, INC
AAGGCACAGCTTG
>HV567691.1 JP 2012024090-A/124: QIAGEN GAITHERSBURG, INC
GGTGGACCGGTCG
>HV567685.1 JP 2012024090-A/118: QIAGEN GAITHERSBURG, INC
CCACCTCCTGCGT
>HV567637.1 JP 2012024090-A/70: QIAGEN GAITHERSBURG, INC
CACACACCTCCCA
>HV567636.1 JP 2012024090-A/69: QIAGEN GAITHERSBURG, INC
ACACAGAACCTCA
>HV567634.1 JP 2012024090-A/67: QIAGEN GAITHERSBURG, INC
CTCCAGGATGACG
>HV567633.1 JP 2012024090-A/66: QIAGEN GAITHERSBURG, INC
ACACCTCCCAACG
>HV567615.1 JP 2012024090-A/48: QIAGEN GAITHERSBURG, INC
GTTCCTGGCGCAG
>HV567613.1 JP 2012024090-A/46: QIAGEN GAITHERSBURG, INC
TTCCAGAACCACG
>HV567609.1 JP 2012024090-A/42: QIAGEN GAITHERSBURG, INC
TATCGCCATCCAG
>HV567608.1 JP 2012024090-A/41: QIAGEN GAITHERSBURG, INC
CTGTTTGCCGACA
>HV567600.1 JP 2012024090-A/33: QIAGEN GAITHERSBURG, INC
AAAAATAACCCCA
>HV566258.1 JP 2012024026-A/187: STREPTCOCCUS MUTANS (SM) SPECIFIC APTAMER, SM GROWTH INHIBITORY AGENT AND METHOD FOR DETECTING SM
TAATTGGGGCGGT
>HV566145.1 JP 2012024026-A/74: STREPTCOCCUS MUTANS (SM) SPECIFIC APTAMER, SM GROWTH INHIBITORY AGENT AND METHOD FOR DETECTING SM
GGGGGGCGGCGGG
>HV565584.1 JP 2012019728-A/11: Method for screening an agent for modifying the transcription of human ABCA1
AGGCCAGAGTCCC
>HV573699.1 JP 2012502074-A/120: Composition comprising a complexed (m)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof
GCCGCCACCATGG
>HV573688.1 JP 2012502074-A/109: Composition comprising a complexed (m)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof
GCCGCCACCATGG
>HV573650.1 JP 2012502074-A/71: Composition comprising a complexed (m)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof
GGGTTTTTTTGGG
>HV573639.1 JP 2012502074-A/60: Composition comprising a complexed (m)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof
GGTTTTTTTTTGG
>HV572377.1 JP 2012501643-A/1: METHODS AND KITS FOR NUCLEIC ACID SEQUENCING
AGTCATCGTAGCT
>HV571380.1 JP 2012500004-A/36: METHOD OF IDENTIFYING DISEASE RISK FACTORS
CAGAATCCTGCGT
>HV560382.1 JP 2011529686-A/6: SELECTIVE INHIBITION OF POLYGLUTAMINE PROTEIN EXPRESSION
GCTGCTGCTGCTG
>HV560310.1 JP 2011528912-A/66: PROTEIN SCREENING METHODS
TTTTTTTTTTTTT
>HV560149.1 JP 2011529691-A/384: CIRCULATING MUTANT DNA TO ASSESS TUMOR DYNAMICS
ACACAGGAAGCAG
>HV565174.1 JP 2011530289-A/1137: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GAGAAATAAAGTT
>HV565173.1 JP 2011530289-A/1136: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CGAGAAATAAAGT
>HV565171.1 JP 2011530289-A/1134: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AACTTTAAGCAAC
>HV565169.1 JP 2011530289-A/1132: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CAAGCTTAGAACT
>HV565159.1 JP 2011530289-A/1122: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTGTTGATTGAAA
>HV565144.1 JP 2011530289-A/1107: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTGTCTTTTTAAG
>HV565139.1 JP 2011530289-A/1102: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GTTTGACTGCATC
>HV565135.1 JP 2011530289-A/1098: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TATATGAATGGAG
>HV565131.1 JP 2011530289-A/1094: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TAATAGTTTCTCC
>HV565130.1 JP 2011530289-A/1093: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AAGCACATATATA
>HV565128.1 JP 2011530289-A/1091: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGTGTGTGAATTT
>HV565119.1 JP 2011530289-A/1082: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AAGTTTGGTTTTG
>HV565111.1 JP 2011530289-A/1074: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CAAAACCACAAAT
>HV565104.1 JP 2011530289-A/1067: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AAACAAAAGAGAG
>HV565102.1 JP 2011530289-A/1065: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CTTTAAAGTAAAG
>HV565100.1 JP 2011530289-A/1063: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ATTTTGTTCTACA
>HV565099.1 JP 2011530289-A/1062: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ATATGATTACTTT
>HV565097.1 JP 2011530289-A/1060: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TAATGCTAAGAAA
>HV565095.1 JP 2011530289-A/1058: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ACGTAATATTTCA
>HV565088.1 JP 2011530289-A/1051: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GCTTTTTATTAAT
>HV565079.1 JP 2011530289-A/1042: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TCATTCTTACAAT
>HV565076.1 JP 2011530289-A/1039: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GTCTAAGTGTTTG
>HV565071.1 JP 2011530289-A/1034: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGATGAGTACAAA
>HV565065.1 JP 2011530289-A/1028: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CTCTACTAAAAAT
>HV565060.1 JP 2011530289-A/1023: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GAGAAAATTTCAA
>HV565033.1 JP 2011530289-A/996: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTATTCAGATCGC
>HV565029.1 JP 2011530289-A/992: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TATATTAAAAGTT
>HV565028.1 JP 2011530289-A/991: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CTTTGTTAAATAT
>HV565006.1 JP 2011530289-A/969: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTGGATTCATCAG
>HV564983.1 JP 2011530289-A/946: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ATTTGTTATTGTG
>HV564975.1 JP 2011530289-A/938: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GGAGATGAGAGAC
>HV564974.1 JP 2011530289-A/937: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTTGACTGCTGTG
>HV564973.1 JP 2011530289-A/936: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TAAAAATAAATAT
>HV564972.1 JP 2011530289-A/935: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TATAAAAATAAAT
>HV564971.1 JP 2011530289-A/934: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CGATCGATACAGA
>HV564968.1 JP 2011530289-A/931: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GCAAGACAAGAAA
>HV564964.1 JP 2011530289-A/927: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TCCATGTCTTTGG
>HV564963.1 JP 2011530289-A/926: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TCAAGACTGCTTG
>HV564962.1 JP 2011530289-A/925: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CAGGGTCCAGAAG
>HV564959.1 JP 2011530289-A/922: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GTTTCCATCCTCC
>HV564958.1 JP 2011530289-A/921: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GAAGAAATGAAAC
>HV564951.1 JP 2011530289-A/914: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AACCTTCCCAAAC
>HV564950.1 JP 2011530289-A/913: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CGACTATCTCGAC
>HV564949.1 JP 2011530289-A/912: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GACCAAGGTCAAC
>HV564948.1 JP 2011530289-A/911: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGCAACTACAGAC
>HV564947.1 JP 2011530289-A/910: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AATTCTACTTTGA
>HV564946.1 JP 2011530289-A/909: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TGAATGCTTCATG
>HV564945.1 JP 2011530289-A/908: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTGAATGCTTCAT
>HV564944.1 JP 2011530289-A/907: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AATCTTCCTTCTA
>HV564941.1 JP 2011530289-A/904: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TCTTTGTTGATTG
>HV564939.1 JP 2011530289-A/902: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TCCTACTGTGTAA
>HV564938.1 JP 2011530289-A/901: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ATATCCTACTGTG
>HV564933.1 JP 2011530289-A/896: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ATATATTTCTCCA
>HV564932.1 JP 2011530289-A/895: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGAGACATGAAAT
>HV564930.1 JP 2011530289-A/893: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ACCTGGCAATTGT
>HV564928.1 JP 2011530289-A/891: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CCTAAAGGTTGTC
>HV564925.1 JP 2011530289-A/888: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GGCACCTCTGTCC
>HV564923.1 JP 2011530289-A/886: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTTGACTGCATCG
>HV564920.1 JP 2011530289-A/883: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CATTTACAGGGAC
>HV564919.1 JP 2011530289-A/882: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TCATTTACAGGGA
>HV564918.1 JP 2011530289-A/881: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ACGAGAAGAAGAT
>HV564916.1 JP 2011530289-A/879: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TACACCATATATG
>HV564915.1 JP 2011530289-A/878: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TACTTCCTAGAAA
>HV564914.1 JP 2011530289-A/877: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGTTTCTCCAAAT
>HV564911.1 JP 2011530289-A/874: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GAGCAATGTATGT
>HV564908.1 JP 2011530289-A/871: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AATGTTTACTACC
>HV564905.1 JP 2011530289-A/868: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CAACTTTTTCATA
>HV564903.1 JP 2011530289-A/866: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TGATACCATATGA
>HV564900.1 JP 2011530289-A/863: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTAACTTTCCAGT
>HV564898.1 JP 2011530289-A/861: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GCCAGTTTTCGGA
>HV564891.1 JP 2011530289-A/854: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AAGCAAGTATTGT
>HV564888.1 JP 2011530289-A/851: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TAAAAGAAGTCCA
>HV564887.1 JP 2011530289-A/850: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ATCAGTTATGCCG
>HV564885.1 JP 2011530289-A/848: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TCTGGAAGCCTGG
>HV564878.1 JP 2011530289-A/841: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TATTCTCTTCACT
>HV564876.1 JP 2011530289-A/839: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CAGTAGCTTTGAG
>HV564874.1 JP 2011530289-A/837: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GAACTAATCATGA
>HV564871.1 JP 2011530289-A/834: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CTCTTCTTACATT
>HV564868.1 JP 2011530289-A/831: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TGCCTAAAATTGT
>HV564866.1 JP 2011530289-A/829: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTTATTTTCAGTA
>HV564861.1 JP 2011530289-A/824: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CCAGGCTGAATTA
>HV564858.1 JP 2011530289-A/821: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TATCCTTTGTTTC
>HV564856.1 JP 2011530289-A/819: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTTTTAATTTATT
>HV564855.1 JP 2011530289-A/818: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GTTGTTAATGGGC
>HV564850.1 JP 2011530289-A/813: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CTTCGGTCCAGTT
>HV564847.1 JP 2011530289-A/810: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GACTAGCTATTAA
>HV564846.1 JP 2011530289-A/809: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AATCTTCATCATA
>HV564842.1 JP 2011530289-A/805: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CTCTGTGAAGTGT
>HV564835.1 JP 2011530289-A/798: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTGATAGGAATAG
>HV564833.1 JP 2011530289-A/796: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ATAAAATCCTTCT
>HV564832.1 JP 2011530289-A/795: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGATTAAACCTAC
>HV564829.1 JP 2011530289-A/792: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GGATCTATTTATG
>HV564826.1 JP 2011530289-A/789: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CTCACCAAACAGA
>HV564823.1 JP 2011530289-A/786: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTACAGTATTCCA
>HV564822.1 JP 2011530289-A/785: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTAGACTTGGAGA
>HV564820.1 JP 2011530289-A/783: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GTTTTTATGTGGA
>HV564819.1 JP 2011530289-A/782: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ATGGAAGCACTAG
>HV564817.1 JP 2011530289-A/780: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGGGTTCTGGGAT
>HV564814.1 JP 2011530289-A/777: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GCAAACTCAGCAC
>HV564813.1 JP 2011530289-A/776: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GTTTTGACTTAAC
>HV564810.1 JP 2011530289-A/773: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AAACTGAAACCAT
>HV564807.1 JP 2011530289-A/770: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGCATAAAACAGT
>HV564803.1 JP 2011530289-A/766: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GGTCTTACCGGCT
>HV564802.1 JP 2011530289-A/765: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GCAAGCGGTCTTA
>HV564800.1 JP 2011530289-A/763: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TCGACAAACCAAT
>HV564799.1 JP 2011530289-A/762: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CAACAGTCAATGG
>HV564795.1 JP 2011530289-A/758: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ATGTTCAGTCACA
>HV564794.1 JP 2011530289-A/757: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGTCAATATCCAC
>HV564790.1 JP 2011530289-A/753: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TGGAATACCTAAG
>HV564788.1 JP 2011530289-A/751: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTCTTGGTGCGTG
>HV564786.1 JP 2011530289-A/749: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GTGAAGCCGCTCG
>HV564781.1 JP 2011530289-A/744: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGAGTTCAAAAGC
>HV564780.1 JP 2011530289-A/743: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CAGAGTTCAAAAG
>HV564779.1 JP 2011530289-A/742: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGTCAACAGTCTG
>HV564767.1 JP 2011530289-A/730: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTCAAATGCATTT
>HV564765.1 JP 2011530289-A/728: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CAGTGGGACAGAG
>HV564764.1 JP 2011530289-A/727: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GTTAAGGACTTCT
>HV564761.1 JP 2011530289-A/724: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CACCATCACACCA
>HV564753.1 JP 2011530289-A/716: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TGAGTTAAACGAA
>HV564752.1 JP 2011530289-A/715: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GAAAGCATTTGTT
>HV564750.1 JP 2011530289-A/713: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CAAAGAAAGATAG
>HV564749.1 JP 2011530289-A/712: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ATTTTCCTCCCTT
>HV564740.1 JP 2011530289-A/703: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AAACACAGATAAC
>HV564722.1 JP 2011530289-A/685: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ATTTTGAGTTTTC
>HV564719.1 JP 2011530289-A/682: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CTTCCGAGCCATC
>HV564713.1 JP 2011530289-A/676: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GCAATTGTGACCC
>HV564711.1 JP 2011530289-A/674: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGTAAAGATCCTA
>HV564706.1 JP 2011530289-A/669: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CTACTTTGAGGGC
>HV564688.1 JP 2011530289-A/651: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CCTTGCATGACAT
>HV564684.1 JP 2011530289-A/647: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGTAAAGATGCTA
>HV564678.1 JP 2011530289-A/641: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ATTTAAGCCCATA
>HV564676.1 JP 2011530289-A/639: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TCGCTGTAGTATT
>HV564674.1 JP 2011530289-A/637: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CATCAAAGCAAGT
>HV564665.1 JP 2011530289-A/628: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CGATTCCCTCTCA
>HV564662.1 JP 2011530289-A/625: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AATGCTAAGAAAT
>HV564657.1 JP 2011530289-A/620: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CACACTCATTCCT
>HV564651.1 JP 2011530289-A/614: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TACTAACATCTGG
>HV564648.1 JP 2011530289-A/611: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTTGATTAATGTT
>HV564646.1 JP 2011530289-A/609: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTGCTTTTCATGT
>HV564645.1 JP 2011530289-A/608: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TGAAAATGAGCAT
>HV564641.1 JP 2011530289-A/604: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGATGTGCATTTC
>HV564638.1 JP 2011530289-A/601: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTTAATTTATTAA
>HV564634.1 JP 2011530289-A/597: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGAACAGATTTGA
>HV564633.1 JP 2011530289-A/596: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AATCTGGATTCAA
>HV564630.1 JP 2011530289-A/593: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ACGAAAGAGAAGC
>HV564626.1 JP 2011530289-A/589: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AAGGATACAAAAA
>HV564621.1 JP 2011530289-A/584: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AATTTGAATGACC
>HV564615.1 JP 2011530289-A/578: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CATACTATTAGCC
>HV564611.1 JP 2011530289-A/574: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AAAAGGTGAAAAA
>HV564609.1 JP 2011530289-A/572: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CCCTCTGATTTAG
>HV564608.1 JP 2011530289-A/571: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GAAAGCGAAAAAT
>HV564606.1 JP 2011530289-A/569: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GAAACTACTAGTG
>HV564602.1 JP 2011530289-A/565: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ATGAATTCAAGTT
>HV564590.1 JP 2011530289-A/553: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ACTTTGGATGTTC
>HV564589.1 JP 2011530289-A/552: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CCAATAATGAAGA
>HV564587.1 JP 2011530289-A/550: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CAGGGAATTATAC
>HV564582.1 JP 2011530289-A/545: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TGTCCTCAATTGT
>HV564578.1 JP 2011530289-A/541: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CACATACAAAATG
>HV564577.1 JP 2011530289-A/540: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GTTATGTTCAGTC
>HV564574.1 JP 2011530289-A/537: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TGGAAGATTCAGC
>HV564572.1 JP 2011530289-A/535: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AACGTATCTCCTA
>HV564568.1 JP 2011530289-A/531: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CAAGCAACTACAT
>HV564565.1 JP 2011530289-A/528: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TAAGCAGAGTTCA
>HV564564.1 JP 2011530289-A/527: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTAAGCAGAGTTC
>HV564563.1 JP 2011530289-A/526: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ATTTAAGCAGAGT
>HV564562.1 JP 2011530289-A/525: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GATTTAAGCAGAG
>HV564557.1 JP 2011530289-A/520: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GCATAACTAAAGG
>HV564556.1 JP 2011530289-A/519: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
AGGAAGAAGCCCT
>HV564553.1 JP 2011530289-A/516: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CCATCAATAAGGA
>HV564552.1 JP 2011530289-A/515: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GACCATCAATAAG
>HV564550.1 JP 2011530289-A/513: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GCTGCTTATGTCT
>HV564091.1 JP 2011530289-A/54: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTTCTTCGGAGTT
>HV564084.1 JP 2011530289-A/47: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTTCTTCGGAGTT
>HV564082.1 JP 2011530289-A/45: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GGATCTTATTTCT
>HV564075.1 JP 2011530289-A/38: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
GGATCTTATTTCT
>HV564073.1 JP 2011530289-A/36: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CTACACAAATCAG
>HV564062.1 JP 2011530289-A/25: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
ATCAGCGATTTTT
>HV564054.1 JP 2011530289-A/17: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
TTCGGAGACAATG
>HV564042.1 JP 2011530289-A/5: NUCLEIC ACID COMPOUNDS FOR INHIBITING PLK1 GENE EXPRESSION AND USES THEREOF
CTACACAAATCAG
>HV563271.1 JP 2011530288-A/1137: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GAGAAATAAAGTT
>HV563270.1 JP 2011530288-A/1136: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CGAGAAATAAAGT
>HV563268.1 JP 2011530288-A/1134: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AACTTTAAGCAAC
>HV563266.1 JP 2011530288-A/1132: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CAAGCTTAGAACT
>HV563256.1 JP 2011530288-A/1122: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTGTTGATTGAAA
>HV563241.1 JP 2011530288-A/1107: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTGTCTTTTTAAG
>HV563236.1 JP 2011530288-A/1102: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GTTTGACTGCATC
>HV563232.1 JP 2011530288-A/1098: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TATATGAATGGAG
>HV563228.1 JP 2011530288-A/1094: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TAATAGTTTCTCC
>HV563227.1 JP 2011530288-A/1093: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AAGCACATATATA
>HV563225.1 JP 2011530288-A/1091: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGTGTGTGAATTT
>HV563216.1 JP 2011530288-A/1082: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AAGTTTGGTTTTG
>HV563208.1 JP 2011530288-A/1074: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CAAAACCACAAAT
>HV563201.1 JP 2011530288-A/1067: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AAACAAAAGAGAG
>HV563199.1 JP 2011530288-A/1065: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CTTTAAAGTAAAG
>HV563197.1 JP 2011530288-A/1063: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ATTTTGTTCTACA
>HV563196.1 JP 2011530288-A/1062: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ATATGATTACTTT
>HV563194.1 JP 2011530288-A/1060: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TAATGCTAAGAAA
>HV563192.1 JP 2011530288-A/1058: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ACGTAATATTTCA
>HV563185.1 JP 2011530288-A/1051: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GCTTTTTATTAAT
>HV563176.1 JP 2011530288-A/1042: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TCATTCTTACAAT
>HV563173.1 JP 2011530288-A/1039: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GTCTAAGTGTTTG
>HV563168.1 JP 2011530288-A/1034: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGATGAGTACAAA
>HV563162.1 JP 2011530288-A/1028: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CTCTACTAAAAAT
>HV563157.1 JP 2011530288-A/1023: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GAGAAAATTTCAA
>HV563130.1 JP 2011530288-A/996: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTATTCAGATCGC
>HV563126.1 JP 2011530288-A/992: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TATATTAAAAGTT
>HV563125.1 JP 2011530288-A/991: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CTTTGTTAAATAT
>HV563103.1 JP 2011530288-A/969: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTGGATTCATCAG
>HV563080.1 JP 2011530288-A/946: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ATTTGTTATTGTG
>HV563072.1 JP 2011530288-A/938: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GGAGATGAGAGAC
>HV563071.1 JP 2011530288-A/937: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTTGACTGCTGTG
>HV563070.1 JP 2011530288-A/936: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TAAAAATAAATAT
>HV563069.1 JP 2011530288-A/935: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TATAAAAATAAAT
>HV563068.1 JP 2011530288-A/934: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CGATCGATACAGA
>HV563065.1 JP 2011530288-A/931: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GCAAGACAAGAAA
>HV563061.1 JP 2011530288-A/927: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TCCATGTCTTTGG
>HV563060.1 JP 2011530288-A/926: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TCAAGACTGCTTG
>HV563059.1 JP 2011530288-A/925: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CAGGGTCCAGAAG
>HV563056.1 JP 2011530288-A/922: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GTTTCCATCCTCC
>HV563055.1 JP 2011530288-A/921: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GAAGAAATGAAAC
>HV563048.1 JP 2011530288-A/914: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AACCTTCCCAAAC
>HV563047.1 JP 2011530288-A/913: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CGACTATCTCGAC
>HV563046.1 JP 2011530288-A/912: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GACCAAGGTCAAC
>HV563045.1 JP 2011530288-A/911: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGCAACTACAGAC
>HV563044.1 JP 2011530288-A/910: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AATTCTACTTTGA
>HV563043.1 JP 2011530288-A/909: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TGAATGCTTCATG
>HV563042.1 JP 2011530288-A/908: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTGAATGCTTCAT
>HV563041.1 JP 2011530288-A/907: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AATCTTCCTTCTA
>HV563038.1 JP 2011530288-A/904: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TCTTTGTTGATTG
>HV563036.1 JP 2011530288-A/902: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TCCTACTGTGTAA
>HV563035.1 JP 2011530288-A/901: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ATATCCTACTGTG
>HV563030.1 JP 2011530288-A/896: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ATATATTTCTCCA
>HV563029.1 JP 2011530288-A/895: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGAGACATGAAAT
>HV563027.1 JP 2011530288-A/893: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ACCTGGCAATTGT
>HV563025.1 JP 2011530288-A/891: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CCTAAAGGTTGTC
>HV563022.1 JP 2011530288-A/888: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GGCACCTCTGTCC
>HV563020.1 JP 2011530288-A/886: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTTGACTGCATCG
>HV563017.1 JP 2011530288-A/883: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CATTTACAGGGAC
>HV563016.1 JP 2011530288-A/882: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TCATTTACAGGGA
>HV563015.1 JP 2011530288-A/881: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ACGAGAAGAAGAT
>HV563013.1 JP 2011530288-A/879: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TACACCATATATG
>HV563012.1 JP 2011530288-A/878: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TACTTCCTAGAAA
>HV563011.1 JP 2011530288-A/877: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGTTTCTCCAAAT
>HV563008.1 JP 2011530288-A/874: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GAGCAATGTATGT
>HV563005.1 JP 2011530288-A/871: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AATGTTTACTACC
>HV563002.1 JP 2011530288-A/868: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CAACTTTTTCATA
>HV563000.1 JP 2011530288-A/866: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TGATACCATATGA
>HV562997.1 JP 2011530288-A/863: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTAACTTTCCAGT
>HV562995.1 JP 2011530288-A/861: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GCCAGTTTTCGGA
>HV562988.1 JP 2011530288-A/854: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AAGCAAGTATTGT
>HV562985.1 JP 2011530288-A/851: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TAAAAGAAGTCCA
>HV562984.1 JP 2011530288-A/850: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ATCAGTTATGCCG
>HV562982.1 JP 2011530288-A/848: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TCTGGAAGCCTGG
>HV562975.1 JP 2011530288-A/841: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TATTCTCTTCACT
>HV562973.1 JP 2011530288-A/839: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CAGTAGCTTTGAG
>HV562971.1 JP 2011530288-A/837: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GAACTAATCATGA
>HV562968.1 JP 2011530288-A/834: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CTCTTCTTACATT
>HV562965.1 JP 2011530288-A/831: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TGCCTAAAATTGT
>HV562963.1 JP 2011530288-A/829: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTTATTTTCAGTA
>HV562958.1 JP 2011530288-A/824: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CCAGGCTGAATTA
>HV562955.1 JP 2011530288-A/821: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TATCCTTTGTTTC
>HV562953.1 JP 2011530288-A/819: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTTTTAATTTATT
>HV562952.1 JP 2011530288-A/818: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GTTGTTAATGGGC
>HV562947.1 JP 2011530288-A/813: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CTTCGGTCCAGTT
>HV562944.1 JP 2011530288-A/810: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GACTAGCTATTAA
>HV562943.1 JP 2011530288-A/809: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AATCTTCATCATA
>HV562939.1 JP 2011530288-A/805: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CTCTGTGAAGTGT
>HV562932.1 JP 2011530288-A/798: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTGATAGGAATAG
>HV562930.1 JP 2011530288-A/796: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ATAAAATCCTTCT
>HV562929.1 JP 2011530288-A/795: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGATTAAACCTAC
>HV562926.1 JP 2011530288-A/792: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GGATCTATTTATG
>HV562923.1 JP 2011530288-A/789: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CTCACCAAACAGA
>HV562920.1 JP 2011530288-A/786: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTACAGTATTCCA
>HV562919.1 JP 2011530288-A/785: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTAGACTTGGAGA
>HV562917.1 JP 2011530288-A/783: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GTTTTTATGTGGA
>HV562916.1 JP 2011530288-A/782: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ATGGAAGCACTAG
>HV562914.1 JP 2011530288-A/780: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGGGTTCTGGGAT
>HV562911.1 JP 2011530288-A/777: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GCAAACTCAGCAC
>HV562910.1 JP 2011530288-A/776: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GTTTTGACTTAAC
>HV562907.1 JP 2011530288-A/773: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AAACTGAAACCAT
>HV562904.1 JP 2011530288-A/770: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGCATAAAACAGT
>HV562900.1 JP 2011530288-A/766: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GGTCTTACCGGCT
>HV562899.1 JP 2011530288-A/765: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GCAAGCGGTCTTA
>HV562897.1 JP 2011530288-A/763: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TCGACAAACCAAT
>HV562896.1 JP 2011530288-A/762: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CAACAGTCAATGG
>HV562892.1 JP 2011530288-A/758: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ATGTTCAGTCACA
>HV562891.1 JP 2011530288-A/757: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGTCAATATCCAC
>HV562887.1 JP 2011530288-A/753: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TGGAATACCTAAG
>HV562885.1 JP 2011530288-A/751: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTCTTGGTGCGTG
>HV562883.1 JP 2011530288-A/749: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GTGAAGCCGCTCG
>HV562878.1 JP 2011530288-A/744: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGAGTTCAAAAGC
>HV562877.1 JP 2011530288-A/743: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CAGAGTTCAAAAG
>HV562876.1 JP 2011530288-A/742: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGTCAACAGTCTG
>HV562864.1 JP 2011530288-A/730: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTCAAATGCATTT
>HV562862.1 JP 2011530288-A/728: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CAGTGGGACAGAG
>HV562861.1 JP 2011530288-A/727: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GTTAAGGACTTCT
>HV562858.1 JP 2011530288-A/724: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CACCATCACACCA
>HV562850.1 JP 2011530288-A/716: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TGAGTTAAACGAA
>HV562849.1 JP 2011530288-A/715: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GAAAGCATTTGTT
>HV562847.1 JP 2011530288-A/713: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CAAAGAAAGATAG
>HV562846.1 JP 2011530288-A/712: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ATTTTCCTCCCTT
>HV562837.1 JP 2011530288-A/703: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AAACACAGATAAC
>HV562819.1 JP 2011530288-A/685: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ATTTTGAGTTTTC
>HV562816.1 JP 2011530288-A/682: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CTTCCGAGCCATC
>HV562810.1 JP 2011530288-A/676: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GCAATTGTGACCC
>HV562808.1 JP 2011530288-A/674: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGTAAAGATCCTA
>HV562803.1 JP 2011530288-A/669: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CTACTTTGAGGGC
>HV562785.1 JP 2011530288-A/651: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CCTTGCATGACAT
>HV562781.1 JP 2011530288-A/647: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGTAAAGATGCTA
>HV562775.1 JP 2011530288-A/641: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ATTTAAGCCCATA
>HV562773.1 JP 2011530288-A/639: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TCGCTGTAGTATT
>HV562771.1 JP 2011530288-A/637: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CATCAAAGCAAGT
>HV562762.1 JP 2011530288-A/628: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CGATTCCCTCTCA
>HV562759.1 JP 2011530288-A/625: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AATGCTAAGAAAT
>HV562754.1 JP 2011530288-A/620: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CACACTCATTCCT
>HV562748.1 JP 2011530288-A/614: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TACTAACATCTGG
>HV562745.1 JP 2011530288-A/611: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTTGATTAATGTT
>HV562743.1 JP 2011530288-A/609: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTGCTTTTCATGT
>HV562742.1 JP 2011530288-A/608: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TGAAAATGAGCAT
>HV562738.1 JP 2011530288-A/604: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGATGTGCATTTC
>HV562735.1 JP 2011530288-A/601: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTTAATTTATTAA
>HV562731.1 JP 2011530288-A/597: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGAACAGATTTGA
>HV562730.1 JP 2011530288-A/596: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AATCTGGATTCAA
>HV562727.1 JP 2011530288-A/593: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ACGAAAGAGAAGC
>HV562723.1 JP 2011530288-A/589: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AAGGATACAAAAA
>HV562718.1 JP 2011530288-A/584: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AATTTGAATGACC
>HV562712.1 JP 2011530288-A/578: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CATACTATTAGCC
>HV562708.1 JP 2011530288-A/574: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AAAAGGTGAAAAA
>HV562706.1 JP 2011530288-A/572: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CCCTCTGATTTAG
>HV562705.1 JP 2011530288-A/571: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GAAAGCGAAAAAT
>HV562703.1 JP 2011530288-A/569: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GAAACTACTAGTG
>HV562699.1 JP 2011530288-A/565: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ATGAATTCAAGTT
>HV562687.1 JP 2011530288-A/553: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ACTTTGGATGTTC
>HV562686.1 JP 2011530288-A/552: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CCAATAATGAAGA
>HV562684.1 JP 2011530288-A/550: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CAGGGAATTATAC
>HV562679.1 JP 2011530288-A/545: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TGTCCTCAATTGT
>HV562675.1 JP 2011530288-A/541: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CACATACAAAATG
>HV562674.1 JP 2011530288-A/540: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GTTATGTTCAGTC
>HV562671.1 JP 2011530288-A/537: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TGGAAGATTCAGC
>HV562669.1 JP 2011530288-A/535: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AACGTATCTCCTA
>HV562665.1 JP 2011530288-A/531: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CAAGCAACTACAT
>HV562662.1 JP 2011530288-A/528: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TAAGCAGAGTTCA
>HV562661.1 JP 2011530288-A/527: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTAAGCAGAGTTC
>HV562660.1 JP 2011530288-A/526: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ATTTAAGCAGAGT
>HV562659.1 JP 2011530288-A/525: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GATTTAAGCAGAG
>HV562654.1 JP 2011530288-A/520: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GCATAACTAAAGG
>HV562653.1 JP 2011530288-A/519: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
AGGAAGAAGCCCT
>HV562650.1 JP 2011530288-A/516: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CCATCAATAAGGA
>HV562649.1 JP 2011530288-A/515: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GACCATCAATAAG
>HV562647.1 JP 2011530288-A/513: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GCTGCTTATGTCT
>HV562188.1 JP 2011530288-A/54: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTTCTTCGGAGTT
>HV562181.1 JP 2011530288-A/47: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTTCTTCGGAGTT
>HV562179.1 JP 2011530288-A/45: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GGATCTTATTTCT
>HV562172.1 JP 2011530288-A/38: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
GGATCTTATTTCT
>HV562170.1 JP 2011530288-A/36: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CTACACAAATCAG
>HV562159.1 JP 2011530288-A/25: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
ATCAGCGATTTTT
>HV562151.1 JP 2011530288-A/17: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
TTCGGAGACAATG
>HV562139.1 JP 2011530288-A/5: NUCLEIC ACID COMPOUNDS FOR INHIBITING BIRC5 GENE EXPRESSION AND USES THEREOF
CTACACAAATCAG
>GZ224940.1 Sequence 14 from patent US 8148341
ACAGTTCGTCCAT
>GZ224093.1 Sequence 2 from patent US 8148085
GGCCNNNNNGGCC
>GZ218432.1 Sequence 1559 from patent US 8143230
TAGCCACCAACTG
>GZ218309.1 Sequence 1432 from patent US 8143230
TAGCCTCTGGATT
>GZ218041.1 Sequence 1163 from patent US 8143230
GCTAGCCTCTGGA
>GZ217249.1 Sequence 292 from patent US 8143230
GCACACAGCTGCC
>GZ217239.1 Sequence 280 from patent US 8143230
GGCATGAGCTTCA
>GZ217210.1 Sequence 245 from patent US 8143230
TGTTCCAGCCCAG
>GZ211242.1 Sequence 6 from patent US 8143006
ATCGAGCCCTGNC
>GZ211202.1 Sequence 403 from patent US 8143005
TGGTGTAAGGTAG
>GZ211199.1 Sequence 400 from patent US 8143005
TGGTATAAGGTAG
>GZ210738.1 Sequence 16 from patent US 8143002
TTTTGTTTTCCTT
>GZ210730.1 Sequence 8 from patent US 8143002
ATTTTATCTGTTA
>GZ208273.1 Sequence 76 from patent US 8137951
GGGCCGGATCCGC
>GZ207317.1 Sequence 17 from patent US 8137676
CGGATGGGAGTGC
>GZ207312.1 Sequence 12 from patent US 8137676
AGGCCATGGTGTC
>GZ207308.1 Sequence 8 from patent US 8137676
TACGCTGCAGTCC
>HV553693.1 JP 2011527891-A/20: Brassica plant comprising a mutant INDEHISCENT allele
CGGTGGTGGCTCG
>HV553692.1 JP 2011527891-A/19: Brassica plant comprising a mutant INDEHISCENT allele
TGGTGGTGGCTCG
>HV553690.1 JP 2011527891-A/17: Brassica plant comprising a mutant INDEHISCENT allele
GCCGACGAGCCAC
>HV553689.1 JP 2011527891-A/16: Brassica plant comprising a mutant INDEHISCENT allele
ACCGACGAGCCAC
>HV553681.1 JP 2011527891-A/8: Brassica plant comprising a mutant INDEHISCENT allele
GTGGTGGCTCGTC
>HV553462.1 JP 2011527568-A/268: COMPLEMENT ANTAGONISTS AND USES THEREOF
CCTTTCAACCATG
>HV552515.1 WO 2011152043-A/3: TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS
TATACAAAGTTGT
>HV550443.1 JP 2011246467-A/5: A NEW METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF MALIGNANT DISEASES
TGGTGGTGGTGGT
>GZ198772.1 Sequence 788 from patent US 8133876
TGCTGCATCTCTG
>GZ197430.1 Sequence 51 from patent US 8133709
ATGCCCTTNNATG
>GZ196828.1 Sequence 81 from patent US 8133486
GTGTTATCAAAGG
>GZ192192.1 Sequence 177 from patent US 8129348
GATCCGAAGACTA
>GZ192191.1 Sequence 176 from patent US 8129348
CAACTAGTCTTCG
>GZ192188.1 Sequence 173 from patent US 8129348
GATCCGAAGACTA
>GZ192187.1 Sequence 172 from patent US 8129348
CAACTAGTCTTCG
>GZ192184.1 Sequence 169 from patent US 8129348
GATCCGAAGACTA
>GZ192183.1 Sequence 168 from patent US 8129348
CAACTAGTCTTCG
>GZ192180.1 Sequence 164 from patent US 8129348
GATCCGAAGACTA
>GZ192179.1 Sequence 163 from patent US 8129348
CAACTAGTCTTCG
>GZ191986.1 Sequence 7 from patent US 8129315
TTTTTTNNTTTTT
>GZ191982.1 Sequence 3 from patent US 8129315
GCGACCGATTCGC
>GZ190707.1 Sequence 21 from patent US 8129119
GGGAATCTTGGGG
>GZ187381.1 Sequence 12 from patent US 8129112
TGGCCCAGAGATG
>GZ187380.1 Sequence 11 from patent US 8129112
TGGGCCAGAGATG
>GZ187139.1 Sequence 3 from patent US 8129106
TCATGCGCTGACA
>GZ187138.1 Sequence 2 from patent US 8129106
TCATGCGCTGACA
>GZ187137.1 Sequence 1 from patent US 8129106
TGTCAGCGCATGA
>GZ182521.1 Sequence 8 from patent US 8124722
CTAGAAATTCCTA
>GZ182520.1 Sequence 7 from patent US 8124722
AGCTTAGGAATTT
>GZ182329.1 Sequence 75 from patent US 8124406
GGCCGCWGCGGCC
>S78223.1 angiotensinogen|AGT {internal fragment} [human, preeclampsia patient R.M., Genomic Mutant, 13 nt]
TTCCACTTCGTCA
>HV549320.1 JP 2011526795-A/13: NOVEL REGULATORY ELEMENTS
GCCGCCACCATGG
>HV548851.1 JP 2011526494-A/115: RNA ANTAGONISTS TARGETING HSP27
CAAAAGAACACAC
>HV548850.1 JP 2011526494-A/114: RNA ANTAGONISTS TARGETING HSP27
TCAAAAGAACACA
>HV548849.1 JP 2011526494-A/113: RNA ANTAGONISTS TARGETING HSP27
ATCAAAAGAACAC
>HV548848.1 JP 2011526494-A/112: RNA ANTAGONISTS TARGETING HSP27
TATCAAAAGAACA
>HV548836.1 JP 2011526494-A/100: RNA ANTAGONISTS TARGETING HSP27
ACAGCCAGTGGCG
>HV548835.1 JP 2011526494-A/99: RNA ANTAGONISTS TARGETING HSP27
CACAGCCAGTGGC
>HV548834.1 JP 2011526494-A/98: RNA ANTAGONISTS TARGETING HSP27
GCACAGCCAGTGG
>HV548833.1 JP 2011526494-A/97: RNA ANTAGONISTS TARGETING HSP27
GGCACAGCCAGTG
>HV548821.1 JP 2011526494-A/85: RNA ANTAGONISTS TARGETING HSP27
TTGCAGCTTCTGG
>HV548820.1 JP 2011526494-A/84: RNA ANTAGONISTS TARGETING HSP27
TTTGCAGCTTCTG
>HV548819.1 JP 2011526494-A/83: RNA ANTAGONISTS TARGETING HSP27
TTTTGCAGCTTCT
>HV548818.1 JP 2011526494-A/82: RNA ANTAGONISTS TARGETING HSP27
ATTTTGCAGCTTC
>HV548806.1 JP 2011526494-A/70: RNA ANTAGONISTS TARGETING HSP27
GTGATCTCGTTGG
>HV548805.1 JP 2011526494-A/69: RNA ANTAGONISTS TARGETING HSP27
GGTGATCTCGTTG
>HV548804.1 JP 2011526494-A/68: RNA ANTAGONISTS TARGETING HSP27
TGGTGATCTCGTT
>HV548803.1 JP 2011526494-A/67: RNA ANTAGONISTS TARGETING HSP27
ATGGTGATCTCGT
>HV548791.1 JP 2011526494-A/55: RNA ANTAGONISTS TARGETING HSP27
GTGGCTAGCTTGG
>HV548790.1 JP 2011526494-A/54: RNA ANTAGONISTS TARGETING HSP27
CGTGGCTAGCTTG
>HV548789.1 JP 2011526494-A/53: RNA ANTAGONISTS TARGETING HSP27
GCGTGGCTAGCTT
>HV548788.1 JP 2011526494-A/52: RNA ANTAGONISTS TARGETING HSP27
TGCGTGGCTAGCT
>HV548776.1 JP 2011526494-A/40: RNA ANTAGONISTS TARGETING HSP27
GTATTTCCGCGTG
>HV548775.1 JP 2011526494-A/39: RNA ANTAGONISTS TARGETING HSP27
TGTATTTCCGCGT
>HV548774.1 JP 2011526494-A/38: RNA ANTAGONISTS TARGETING HSP27
GTGTATTTCCGCG
>HV548773.1 JP 2011526494-A/37: RNA ANTAGONISTS TARGETING HSP27
CGTGTATTTCCGC
>HV548761.1 JP 2011526494-A/25: RNA ANTAGONISTS TARGETING HSP27
ACGGTCAGTGTGC
>HV548760.1 JP 2011526494-A/24: RNA ANTAGONISTS TARGETING HSP27
CGGTCAGTGTGCC
>HV548759.1 JP 2011526494-A/23: RNA ANTAGONISTS TARGETING HSP27
GGTCAGTGTGCCC
>HV548758.1 JP 2011526494-A/22: RNA ANTAGONISTS TARGETING HSP27
GTCAGTGTGCCCT
>HV548746.1 JP 2011526494-A/10: RNA ANTAGONISTS TARGETING HSP27
ATGTAGCCATGCT
>HV548745.1 JP 2011526494-A/9: RNA ANTAGONISTS TARGETING HSP27
GATGTAGCCATGC
>HV548744.1 JP 2011526494-A/8: RNA ANTAGONISTS TARGETING HSP27
AGATGTAGCCATG
>HV548743.1 JP 2011526494-A/7: RNA ANTAGONISTS TARGETING HSP27
GAGATGTAGCCAT
>HV548697.1 JP 2011526482-A/278: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
GGGACAGTTGTGC
>HV548686.1 JP 2011526482-A/267: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
CAATTGCCTCTTG
>HV548679.1 JP 2011526482-A/260: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
CTACAGCACCACA
>HV548675.1 JP 2011526482-A/256: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
AAACTCAGAATAT
>HV548655.1 JP 2011526482-A/236: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
AAGCTTCTTGTCC
>HV548635.1 JP 2011526482-A/216: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
GAGAGAAGGTAGC
>HV548631.1 JP 2011526482-A/212: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
GAGAAGGTAGCAC
>HV548626.1 JP 2011526482-A/207: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
AGAAGGTAGCACA
>HV548614.1 JP 2011526482-A/195: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
TGCAAGCTATGAT
>HV548608.1 JP 2011526482-A/189: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
CAAGCTATGATGG
>HV548596.1 JP 2011526482-A/177: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
GGGACAGTTGTGC
>HV548591.1 JP 2011526482-A/172: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
TGGGTGATTGTGA
>HV548586.1 JP 2011526482-A/167: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
GGGTGATTGTGAC
>HV548582.1 JP 2011526482-A/163: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
GGTGATTGTGACA
>HV548573.1 JP 2011526482-A/154: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
ATCACAAAGAAGT
>HV548552.1 JP 2011526482-A/133: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
CTGTAGAGGAGCA
>HV548543.1 JP 2011526482-A/124: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
GTAGTGACCTTCG
>HV548538.1 JP 2011526482-A/119: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
TAGTGACCTTCGA
>HV548534.1 JP 2011526482-A/115: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
AGTGACCTTCGAT
>HV548532.1 JP 2011526482-A/113: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
GTTTCATCGAGCC
>HV548530.1 JP 2011526482-A/111: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
TTTCATCGAGCCT
>HV548525.1 JP 2011526482-A/106: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
GATGTTGAGATTA
>HV548521.1 JP 2011526482-A/102: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
ATGTTGAGATTAT
>HV548514.1 JP 2011526482-A/95: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
GTTGAGATTATTG
>HV548507.1 JP 2011526482-A/88: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
TGAGATTATTGCC
>HV548505.1 JP 2011526482-A/86: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
TTCGTCTCAGTTG
>HV548502.1 JP 2011526482-A/83: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
TCGTCTCAGTTGC
>HV548499.1 JP 2011526482-A/80: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
CGTCTCAGTTGCA
>HV548494.1 JP 2011526482-A/75: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
AGAAGCTGTTGAA
>HV548493.1 JP 2011526482-A/74: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
CAATTGCCTCTTG
>HV548492.1 JP 2011526482-A/73: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
CAAACATGCCCTT
>HV548488.1 JP 2011526482-A/69: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
AACATGCCCTTAT
>HV548484.1 JP 2011526482-A/65: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
ACATGCCCTTATG
>HV548474.1 JP 2011526482-A/55: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
TGATATAAATAAC
>HV548458.1 JP 2011526482-A/39: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
AAATAACATTCCG
>HV548453.1 JP 2011526482-A/34: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
AATAACATTCCGC
>HV548448.1 JP 2011526482-A/29: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
ATAACATTCCGCA
>HV548443.1 JP 2011526482-A/24: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
TAACATTCCGCAA
>HV548438.1 JP 2011526482-A/19: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
AACATTCCGCAAA
>HV548434.1 JP 2011526482-A/15: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
ACATTCCGCAAAC
>HV548427.1 JP 2011526482-A/8: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
ATTCCGCAAACCC
>HV548422.1 JP 2011526482-A/3: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
TTCCGCAAACCCA
>HV548420.1 JP 2011526482-A/1: RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)
GCAGATAAGAAAC
>JA774784.1 Sequence 19 from Patent WO2012020040
TCGCCATGCTGCT
>JA778895.1 Sequence 29 from Patent EP2419537
AGTCTGATAAGCT
>JA778894.1 Sequence 28 from Patent EP2419537
CACTATAAGCACT
>JA777251.1 Sequence 30 from Patent EP2420574
TACACGGACCACA
>JA777250.1 Sequence 29 from Patent EP2420574
TACACGGACCGCA
>GZ164094.1 Sequence 24 from patent US 8114982
CTACGATACTAGA
>GZ159940.1 Sequence 666 from patent US 8114974
TTCTTKTYYTTTT
>GZ159913.1 Sequence 639 from patent US 8114974
GRTGYAYGGRTGY
>GZ159847.1 Sequence 573 from patent US 8114974
AAWNRTAAAYARG
>GZ159812.1 Sequence 538 from patent US 8114974
RMACCCANNCAYY
>GZ159808.1 Sequence 534 from patent US 8114974
GAANNTTCNNGAA
>GZ159140.1 Sequence 6 from patent US 8114962
CCGGGTTTTCCCC
>GZ159137.1 Sequence 3 from patent US 8114962
AGGGGACTTTCCG
>GZ159136.1 Sequence 2 from patent US 8114962
AAGGGACTTTCCC
>GZ159135.1 Sequence 1 from patent US 8114962
TGGGGATTCCCCA
>GZ158448.1 Sequence 9 from patent US 8114850
TGGTGGTGGTGGT
>GZ158379.1 Sequence 1 from patent US 8114847
TCGCAGCCGTCCA
>GZ156645.1 Sequence 2345 from patent US 8114601
GTCGTCGGAGGGA
>GZ156644.1 Sequence 2344 from patent US 8114601
GTCGTCGGAGGGA
>GZ156643.1 Sequence 2343 from patent US 8114601
GCGGGTGGTGTTC
>GZ151965.1 Sequence 150 from patent US 8114418
AAAAAAAACGCCG
>GZ151941.1 Sequence 126 from patent US 8114418
TCGGAAANGTTCG
>GZ151923.1 Sequence 108 from patent US 8114418
TCGGAACCGTTCG
>GZ151922.1 Sequence 107 from patent US 8114418
TCGGTACCGTTCG
>GZ151921.1 Sequence 106 from patent US 8114418
TCGGTATCGGTCG
>GZ151916.1 Sequence 101 from patent US 8114418
TCGTTAACGTTCG
>GZ151914.1 Sequence 99 from patent US 8114418
TNGTGAACGTTCG
>GZ151912.1 Sequence 97 from patent US 8114418
TCGTGAACGTTCG
>GZ151636.1 Sequence 81 from patent US 8114404
GTGTTATCAAAGG
>GZ139626.1 Sequence 49 from patent US 8110653
TTCCGCGGATCCG
>GZ138139.1 Sequence 788 from patent US 8110558
TGCTGCATCTCTG
>GZ107147.1 Sequence 110 from patent US 8119369
GGTCTCNACCTCC
>GZ107146.1 Sequence 109 from patent US 8119369
GGAGGTNGAGACC
>GZ106902.1 Sequence 72 from patent US 8119344
GGGGCACCTGGGG
>GZ106899.1 Sequence 69 from patent US 8119344
GGGGCACTTGGGG
>GZ106896.1 Sequence 66 from patent US 8119344
GGGGTCCCGACTC
>GZ106892.1 Sequence 62 from patent US 8119344
CCGGGCCGCCAAG
>GZ106888.1 Sequence 58 from patent US 8119344
GGGGTCCCGACTC
>GZ106886.1 Sequence 56 from patent US 8119344
CCGGGCCGCCAAG
>GZ106874.1 Sequence 44 from patent US 8119344
GGGGTCCCGACTC
>GZ106864.1 Sequence 34 from patent US 8119344
GGGGTCCCGACTC
>GZ106737.1 Sequence 282 from patent US 8119340
GTGGACGTTCGGC
>GZ106730.1 Sequence 268 from patent US 8119340
TTGGGTGTTCGGC
>GZ106718.1 Sequence 243 from patent US 8119340
GTGGACGTTCGGC
>JA772952.1 Sequence 81 from Patent EP2352830
AAACTGAGCTCCA
>JA772874.1 Sequence 3 from Patent EP2352830
TGGAGCTCAGTTT
>JA765351.1 Sequence 19 from Patent EP2418279
TCGCCATGCTGCT
>GZ050435.1 Sequence 80 from patent US 8101734
GGTGAGGCAGCAC
>JA763977.1 Sequence 22 from Patent EP2413963
CTGTGGCAATGGC
>JA761617.1 Sequence 19 from Patent WO2012013823
GGCCGACTCGGCC
>JA761616.1 Sequence 18 from Patent WO2012013823
GGCCCCTGAGGCC
>JA761615.1 Sequence 17 from Patent WO2012013823
GGCCACGCTGGCC
>JA761614.1 Sequence 16 from Patent WO2012013823
GGCCGCTATGGCC
>JA761613.1 Sequence 15 from Patent WO2012013823
GGCCTGACGGGCC
>JA761612.1 Sequence 14 from Patent WO2012013823
GGCCCGTACGGCC
>JA761611.1 Sequence 13 from Patent WO2012013823
GGCCATGCAGGCC
>JA760665.1 Sequence 12 from Patent WO2012012716
CTGTGCCTGCTGT
>JA758037.1 Sequence 3 from Patent WO2012010711
GTCTGTGGAAGCG
>HV538519.1 JP 2011211938-A/55: Plasmid vector
GGGGTGCCGGTGG
>HV538517.1 JP 2011211938-A/53: Plasmid vector
TGTTGCTGGGGTG
>HV538205.1 JP 2011193844-A/13: Method to identify the variety and strain of Lactococcus lactis subsp
CTGACAAGTCTGT
>HV541212.1 WO 2011125467-A/55: Plasmid vector
GGGGTGCCGGTGG
>HV541210.1 WO 2011125467-A/53: Plasmid vector
TGTTGCTGGGGTG
>HV540566.1 JP 2011204261-A/431: RESEQUENCING PATHOGEN MICROARRAY
AGCAAAAAGCAGG
>JA734761.1 Sequence 15 from Patent EP2407558
GATCACACCACGC
>JA719663.1 Sequence 22 from Patent WO2006076017
TGCGCAGTGTCGC
>JA723883.1 Sequence 6 from Patent WO2012003950
TAATTCCTTGATA
>JA695718.1 Sequence 1593 from Patent WO2011154542
GCTATATGCAGGG
>JA695710.1 Sequence 1585 from Patent WO2011154542
CCGAAAAATTGGG
>JA695700.1 Sequence 1575 from Patent WO2011154542
CTGCTGTTGGCAG
>JA695687.1 Sequence 1562 from Patent WO2011154542
CCCTCCTAAGCGG
>JA695686.1 Sequence 1561 from Patent WO2011154542
CTCCCTCCTAAGC
>JA695685.1 Sequence 1560 from Patent WO2011154542
GCAGGCGTCACCC
>JA695681.1 Sequence 1556 from Patent WO2011154542
CGGTTCACTCGGC
>JA695680.1 Sequence 1555 from Patent WO2011154542
CCGGTGAGGAGGG
>JA695679.1 Sequence 1554 from Patent WO2011154542
GCCGGTGAGGAGG
>JA695674.1 Sequence 1549 from Patent WO2011154542
CGCACTTGTAGCG
>JA699161.1 Sequence 262 from Patent WO2011159153
GAANNKTCBDGWM
>JA698864.1 Sequence 8 from Patent WO2011157453
CGTGTACGCAGTC
>JA694594.1 Sequence 469 from Patent WO2011154542
TTTTAGTGCACAT
>JA689566.1 Sequence 96 from Patent EP2399611
GGATTTCTTTGGC
>JA689544.1 Sequence 74 from Patent EP2399611
CGGCAGTGCCCCG
>JA689541.1 Sequence 71 from Patent EP2399611
CCCGAGGAGCGGG
>JA694514.1 Sequence 389 from Patent WO2011154542
AAAACATCTTGTT
>JA694506.1 Sequence 381 from Patent WO2011154542
CATTGTTCAATAT
>JA694504.1 Sequence 379 from Patent WO2011154542
ATTGTTCAATATC
>JA694500.1 Sequence 375 from Patent WO2011154542
TCTGAAAATGTTT
>JA694412.1 Sequence 287 from Patent WO2011154542
ACTTTTAACTTGA
>JA694407.1 Sequence 282 from Patent WO2011154542
TTGTCATAGATTT
>JA694115.1 Sequence 72 from Patent WO2011154427
CAGGAACTCCAGG
>JA694070.1 Sequence 27 from Patent WO2011154427
AAGAGGTAGGGCG
>JA696230.1 Sequence 2105 from Patent WO2011154542
GGATTTCTTTGGC
>JA696208.1 Sequence 2083 from Patent WO2011154542
CGGCAGTGCCCCG
>JA696205.1 Sequence 2080 from Patent WO2011154542
CCCGACGAGCCGG
>JA696124.1 Sequence 1999 from Patent WO2011154542
GAGCCACTGCGCC
>JA695836.1 Sequence 1711 from Patent WO2011154542
CGTTGTACTCTCG
>JA695814.1 Sequence 1689 from Patent WO2011154542
GCGGCCATCTGCG
>JA695813.1 Sequence 1688 from Patent WO2011154542
GGCCATCTGCGCC
>JA695808.1 Sequence 1683 from Patent WO2011154542
CGGCTTCCTCCCC
>JA695800.1 Sequence 1675 from Patent WO2011154542
AGGCACCGGGCAG
>JA695799.1 Sequence 1674 from Patent WO2011154542
GCACCGGGCAGTC
>GY855611.1 Sequence 137814 from patent US 8084598
CTGTGGGTTGCTA
>GY854214.1 Sequence 136417 from patent US 8084598
ACCATAAACCTTA
>GY852935.1 Sequence 135138 from patent US 8084598
ACCAAATGCCTGC
>GY851810.1 Sequence 134013 from patent US 8084598
GCAGTTACATGCA
>GY850269.1 Sequence 132472 from patent US 8084598
TAGAAAAATGCAC
>GY847863.1 Sequence 130066 from patent US 8084598
TGCCTAACAGCAA
>GY846900.1 Sequence 129103 from patent US 8084598
GGCCCCCACCTCG
>GY843792.1 Sequence 125995 from patent US 8084598
GCCACATGCCTTA
>GY828914.1 Sequence 111117 from patent US 8084598
AACCCATCCAGCT
>GY827941.1 Sequence 110144 from patent US 8084598
GACTGATTTGCTG
>GY805962.1 Sequence 88165 from patent US 8084598
ACCAAATGCCTGG
>GY805398.1 Sequence 87601 from patent US 8084598
TCAGCACTGTGAA
>GY801711.1 Sequence 83914 from patent US 8084598
ACATGAAGCACAA
>GY799365.1 Sequence 81568 from patent US 8084598
GGCCCCCACCTCC
>GY796098.1 Sequence 78301 from patent US 8084598
ACCAAATGCCTAA
>GY793362.1 Sequence 75565 from patent US 8084598
ACCGTATGCCTTA
>GY793275.1 Sequence 75478 from patent US 8084598
TGGAAAGAACAGA
>GY790962.1 Sequence 73165 from patent US 8084598
TGGGTGGGGTGGG
>GY790022.1 Sequence 72225 from patent US 8084598
CAGCAATATTGCC
>GY789996.1 Sequence 72199 from patent US 8084598
TAGCCTTACTTGA
>GY716261.1 Sequence 11 from patent US 8084589
GTGTCAAAGGTCA
>GY714846.1 Sequence 17 from patent US 8084248
TGAGGTTGATTAG
>GY714740.1 Sequence 20 from patent US 8084232
CATCCAACAGAAT
>GY714430.1 Sequence 3 from patent US 8084213
AGCACTCTACTAT
>GY714429.1 Sequence 2 from patent US 8084213
ATGATAGAAGCAC
>GY714407.1 Sequence 4 from patent US 8084211
CTTATTTCCCTCA
>GY713145.1 Sequence 79 from patent US 8080644
CAAACAAACCACA
>GY713144.1 Sequence 78 from patent US 8080644
CAAACAAACCACA
>GY713143.1 Sequence 77 from patent US 8080644
GGTGGTTTGTTTG
>GY713142.1 Sequence 76 from patent US 8080644
CAAACAAACCACA
>GY713141.1 Sequence 75 from patent US 8080644
CAAACAAACCACA
>GY713140.1 Sequence 74 from patent US 8080644
GGTGGTTTGTTTG
>GY713139.1 Sequence 73 from patent US 8080644
CAAACAAACCACA
>GY713138.1 Sequence 72 from patent US 8080644
CAAACAAACCACA
>GY713137.1 Sequence 71 from patent US 8080644
GGTGGTTTGTTTG
>GY713130.1 Sequence 64 from patent US 8080644
ATAAAGTGTAAAG
>GY713126.1 Sequence 60 from patent US 8080644
ATAAAGTGTAAAG
>GY713124.1 Sequence 58 from patent US 8080644
ATAAAGTGTAAAG
>GY713114.1 Sequence 48 from patent US 8080644
GGTGGTTTGTTTG
>GY713113.1 Sequence 47 from patent US 8080644
GGTGGTTTGTTTG
>GY713112.1 Sequence 46 from patent US 8080644
GGTGGTTTGTTTG
>GY713110.1 Sequence 44 from patent US 8080644
GGTGGTTTGTTTG
>GY713109.1 Sequence 43 from patent US 8080644
GGTGGTTTGTTTG
>GY713108.1 Sequence 42 from patent US 8080644
AGAGCCGATAACA
>GY713107.1 Sequence 41 from patent US 8080644
AGAGCCGATAACA
>GY713106.1 Sequence 40 from patent US 8080644
AGAGCCGATAACA
>GY713105.1 Sequence 39 from patent US 8080644
TTCCACAGCACAA
>GY713104.1 Sequence 38 from patent US 8080644
TTCCACAGCACAA
>GY713103.1 Sequence 37 from patent US 8080644
TTCCACAGCACAA
>GY713098.1 Sequence 32 from patent US 8080644
GGTGGTTTGTTTG
>GY713097.1 Sequence 31 from patent US 8080644
GGTGGTTTGTTTG
>GY713096.1 Sequence 30 from patent US 8080644
GGTGGTTTGTTTG
>GY713095.1 Sequence 29 from patent US 8080644
GGTGGTTTGTTTG
>GY713094.1 Sequence 28 from patent US 8080644
GGTGGTTTGTTTG
>GY713075.1 Sequence 9 from patent US 8080644
GGTGGTTTGTTTG
>GY713074.1 Sequence 8 from patent US 8080644
GGTGGTTTGTTTG
>GY713073.1 Sequence 7 from patent US 8080644
GGTGGTTTGTTTG
>GY713072.1 Sequence 6 from patent US 8080644
GGTGGTTTGTTTG
>GY713071.1 Sequence 5 from patent US 8080644
GGTGGTTTGTTTG
>GY713070.1 Sequence 4 from patent US 8080644
GGTGGTTTGTTTG
>GY713069.1 Sequence 3 from patent US 8080644
GGTGGTTTGTTTG
>GY713068.1 Sequence 2 from patent US 8080644
ATAAAGTGTAAAG
>GY771706.1 Sequence 53909 from patent US 8084598
TCTGCAGCTGGCC
>GY769155.1 Sequence 51358 from patent US 8084598
CACTACCCTTCCA
>GY766565.1 Sequence 48768 from patent US 8084598
ACCAAATGCCTTT
>GY765993.1 Sequence 48196 from patent US 8084598
ACCAAATGCCTTC
>GY758312.1 Sequence 40515 from patent US 8084598
GGTGCAATGTGAT
>GY757155.1 Sequence 39358 from patent US 8084598
TGCCCCCACCTCA
>GY755844.1 Sequence 38047 from patent US 8084598
TCCAGTTACCTCA
>GY755448.1 Sequence 37651 from patent US 8084598
TCAACAAAACTCC
>GY750521.1 Sequence 32724 from patent US 8084598
ACCATAAATCTTA
>GY727998.1 Sequence 10201 from patent US 8084598
GAAACTTGCTCAA
>GY724008.1 Sequence 6211 from patent US 8084598
ACCAAATGCCTTT
>HV536245.1 JP 2011522526-A/35: 5' Triphosphate Oligonucleotide with Blunt End and Uses Thereof
GTGTGTGTGTGTC
>HV536233.1 JP 2011522526-A/23: 5' Triphosphate Oligonucleotide with Blunt End and Uses Thereof
GTGTGTGTGTGTT
>HV532377.1 JP 2011182797-A/12: Recombinant influenza viruses for vaccines and gene therapy
AAAACGAGGGGGG
>HV532376.1 JP 2011182797-A/11: Recombinant influenza viruses for vaccines and gene therapy
TTTTGCTCCCCCC
>JA688091.1 Sequence 15 from Patent EP2396408
CGGCAGCCCTCGC
>GY710565.1 Sequence 17 from patent US 8076517
AGGTCANAGGTCA
>GY707712.1 Sequence 2 from patent US 8076078
CTTTTGGGACCGC
>GY707711.1 Sequence 1 from patent US 8076078
GCGGTCCCAAAAG
>GY707034.1 Sequence 40 from patent US 8075903
CCACGGGCGCCGT
>GY658383.1 Sequence 18 from patent US 8071388
TTGGTGCTCGAGT
>GY657220.1 Sequence 5 from patent US 8071309
CGTGGTACCCCTT
>GY657218.1 Sequence 3 from patent US 8071309
CGTGGTGACCCTT
>GY656835.1 Sequence 703 from patent US 8071306
AGGCAGTGCGACC
>GY656152.1 Sequence 20 from patent US 8071306
TGGAGTGTGACAA
>GY653653.1 Sequence 8 from patent US 8071297
TCCCGTGGGCACG
>JA684668.1 Sequence 10 from Patent EP2393930
TGAGTACTATGAG
>GY670214.1 Sequence 11 from patent US 8073627
CACCCTCTAAATC
>GY670206.1 Sequence 3 from patent US 8073627
CGTGGTACCCCTT
>GY670204.1 Sequence 1 from patent US 8073627
CGTGGTGACCCTT
>JA677374.1 Sequence 111 from Patent EP2393028
CAACGTGCTGGTG
>JA677342.1 Sequence 79 from Patent EP2393028
TGGAGATCATGAT
>JA677307.1 Sequence 44 from Patent EP2393028
AGCTTATTACAGC
>JA677167.1 Sequence 154 from Patent EP2392675
TTCTGCCGCAGCG
>JA677004.1 Sequence 154 from Patent EP2392673
TTCTGCCGCAGCG
>JA676841.1 Sequence 154 from Patent EP2392672
TTCTGCCGCAGCG
>JA676678.1 Sequence 154 from Patent EP2392671
TTCTGCCGCAGCG
>GY530647.1 Sequence 21 from patent US 8067549
GACCATACTTCAC
>GY530599.1 Sequence 80 from patent US 8067544
CTATGATAGTAGT
>GY528880.1 Sequence 27 from patent US 8067218
DTAAACATGTAGG
>GY524541.1 Sequence 8 from patent US 8067162
CGCAATNNAACGC
>GY524538.1 Sequence 5 from patent US 8067162
AAAAAAAAAAAAA
>GY524537.1 Sequence 4 from patent US 8067162
TTTTTTNTTTTTT
>GY524536.1 Sequence 3 from patent US 8067162
TTTTTTNNTTTTT
>GY524535.1 Sequence 2 from patent US 8067162
GCGTTAAATTGCG
>GY524534.1 Sequence 1 from patent US 8067162
CGCAATNTAACGC
>GY522409.1 Sequence 3932 from patent US 8063184
CCTACCCCGCACT
>GY522383.1 Sequence 3906 from patent US 8063184
GGCACCGGACAGG
>GY522311.1 Sequence 3834 from patent US 8063184
CACTGCTTCGTGG
>GY522051.1 Sequence 3574 from patent US 8063184
CACTGCTTCGTGG
>GY522020.1 Sequence 3543 from patent US 8063184
GCGTGGTGTGCGG
>GY522017.1 Sequence 3540 from patent US 8063184
GGCGTGGTGTGCG
>GY522014.1 Sequence 3537 from patent US 8063184
GGGCGTGGTGTGC
>GY522010.1 Sequence 3533 from patent US 8063184
GGGCCAGATGCGT
>GY521974.1 Sequence 3497 from patent US 8063184
GCCCCTGATAGCC
>GY521954.1 Sequence 3477 from patent US 8063184
CACTGCTTCGTGG
>GY521922.1 Sequence 3445 from patent US 8063184
TGTGTCTGAGCCC
>GY521912.1 Sequence 3435 from patent US 8063184
CACTGCTTCGTGG
>GY521887.1 Sequence 3410 from patent US 8063184
GCCATCACTGCCC
>GY521837.1 Sequence 3360 from patent US 8063184
TCTCGCCCTCGTA
>GY521786.1 Sequence 3309 from patent US 8063184
GGGATCCTGGTGG
>GY521694.1 Sequence 3217 from patent US 8063184
CACTGCTTCGTGG
>GY521652.1 Sequence 3175 from patent US 8063184
CACTGCTTCGTGG
>GY521640.1 Sequence 3163 from patent US 8063184
TCCACTCCGAGCT
>GY521639.1 Sequence 3162 from patent US 8063184
TCCACTCCGAGCT
>GY521635.1 Sequence 3158 from patent US 8063184
CACTGCTTCGTGG
>GY521553.1 Sequence 3076 from patent US 8063184
CCCGCCATCTAGG
>GY521527.1 Sequence 3050 from patent US 8063184
GTGGGCGGTGTCT
>GY521507.1 Sequence 3030 from patent US 8063184
TTGCGGACCGCTG
>GY521468.1 Sequence 2991 from patent US 8063184
CGGGGGACACCCG
>GY521454.1 Sequence 2977 from patent US 8063184
GTGAGGGTCTGGG
>GY521359.1 Sequence 2882 from patent US 8063184
TGAAGGCCTCCTC
>GY521351.1 Sequence 2874 from patent US 8063184
CTTGCAGGCAGGT
>GY521345.1 Sequence 2868 from patent US 8063184
CACTGCTTCGTGG
>GY520977.1 Sequence 2392 from patent US 8063184
ATTCTCTCAGACT
>GY520960.1 Sequence 2375 from patent US 8063184
GCCAAGGAGCACG
>GY520956.1 Sequence 2371 from patent US 8063184
GGCCAAGGAGCAC
>GY520952.1 Sequence 2367 from patent US 8063184
TGGCCAAGGAGCA
>GY520949.1 Sequence 2364 from patent US 8063184
GTCTGCTTCTGGA
>GY520783.1 Sequence 2198 from patent US 8063184
CACTGCTTCGTGG
>GY520782.1 Sequence 2197 from patent US 8063184
CACTGCTTCGTGG
>GY520766.1 Sequence 2181 from patent US 8063184
CACTGCTTCGTGG
>GY520760.1 Sequence 2175 from patent US 8063184
CACTGCTTCGTGG
>GY520381.1 Sequence 1796 from patent US 8063184
ATTCTCTCAGACT
>GY520316.1 Sequence 1731 from patent US 8063184
CAACGCTTCCTCC
>GY519772.1 Sequence 1187 from patent US 8063184
CAACGCTTCGTGG
>GY519764.1 Sequence 1179 from patent US 8063184
CACTGCTTCGTGG
>GY519758.1 Sequence 1173 from patent US 8063184
CACTGCTTCGTGG
>GY519671.1 Sequence 1086 from patent US 8063184
CACTGCTTCGTGG
>GY519665.1 Sequence 1080 from patent US 8063184
CACTGCTTCGTGG
>GY519659.1 Sequence 1074 from patent US 8063184
CACTGCTTCGTGG
>GY519647.1 Sequence 1062 from patent US 8063184
CAACGCTTCGTGG
>GY519539.1 Sequence 954 from patent US 8063184
CACTGCTTCGTGG
>GY519531.1 Sequence 946 from patent US 8063184
CACTGCTTCGTGG
>GY519525.1 Sequence 940 from patent US 8063184
CACTGCTTCGTGG
>GY519519.1 Sequence 934 from patent US 8063184
CACTGCTTCGTGG
>GY519513.1 Sequence 928 from patent US 8063184
CACTGCTTCGTGG
>GY519507.1 Sequence 922 from patent US 8063184
CACTGCTTCGTGG
>GY519501.1 Sequence 916 from patent US 8063184
CACTGCTTCGTGG
>GY519449.1 Sequence 864 from patent US 8063184
CACTGCTTCGTGG
>GY519415.1 Sequence 830 from patent US 8063184
CACTGCTTCGTGG
>GY519338.1 Sequence 753 from patent US 8063184
CACTGCTTCGTGG
>GY519299.1 Sequence 714 from patent US 8063184
GGGCCAGAGGGCT
>GY518907.1 Sequence 235 from patent US 8063184
ACGAGCGTCTTTG
>GY517142.1 Sequence 84 from patent US 8062850
TAAAGGAAACTTA
>GY516030.1 Sequence 11 from patent US 8058508
AATACTTCCACCC
>GY511674.1 Sequence 38 from patent US 8057997
AGTATTGAGGATN
>GY511670.1 Sequence 34 from patent US 8057997
NAGTATTGACCTA
>GY511599.1 Sequence 198 from patent US 8057993
NNNNCNNGAAAAN
>GY511419.1 Sequence 18 from patent US 8057806
TTTTGCTCCCCCC
>GY511336.1 Sequence 31 from patent US 8057793
GATCGCGGCCGCA
>GY511335.1 Sequence 30 from patent US 8057793
AGCTTGCGGCCGC
>GY510675.1 Sequence 24 from patent US 8053630
YNMTATAAATANA
>GY509088.1 Sequence 158 from patent US 8052974
GGCCCAGCCGGCC
>HV510730.1 JP 2011519562-A/56: TRANSCRIPTIONAL AND POST-TRANSCRIPTION REGULATION OF TRANSCRIPTION FACTOR FOR DROUGHT RESISTANCE
TNNTTNGNNCANT
>HV512306.1 JP 2011521930-A/1: CHEMICAL RNA SYNTHESIS METHOD
TTTTTTTTTTTTN
>JA666468.1 Sequence 240 from Patent WO2011139710
GTTAAGGACTTCT
>JA666465.1 Sequence 237 from Patent WO2011139710
CACCATCACACCA
>JA659919.1 Sequence 10 from Patent WO2011133142
TGGTGGTGGTGGT
>JA637558.1 Sequence 5 from Patent EP2382193
AGGACAAAGGTCA
>JA635720.1 Sequence 728 from Patent EP2381965
CACATACCTGAAT
>GY507751.1 Sequence 7 from patent US 8048918
AGGTCANAGGTCA
>GY507749.1 Sequence 5 from patent US 8048918
AGGTCNAAGGTCA
>GY505200.1 Sequence 13 from patent US 8043850
TCCGGACTCAGAT
>JA625359.1 Sequence 38 from Patent EP2380972
ATAACTTCGTATA
>JA630473.1 Sequence 265 from Patent EP2366031
AGCACTGCAGGTA
>JA619544.1 Sequence 265 from Patent EP2376661
AGCACTGCAGGTA
>HV455709.1 JP 2011135823-A/10: Oligonucleotide Probe and the Use Thereof
GATTGCNGATACC
>HV455708.1 JP 2011135823-A/9: Oligonucleotide Probe and the Use Thereof
GGTATCNGCAATC
>HV455701.1 JP 2011135823-A/2: Oligonucleotide Probe and the Use Thereof
GATTCCNGATACC
>HV455700.1 JP 2011135823-A/1: Oligonucleotide Probe and the Use Thereof
GGTATCNGCAATC
>HV455657.1 JP 2011135824-A/2: Method of Detection of Oligomucletide
GATTCCNGATACC
>HV455656.1 JP 2011135824-A/1: Method of Detection of Oligomucletide
GGTATCNGCAATC
>HV501173.1 JP 2011518121-A/28: Steroidal Ligands and Their Use in Gene Switch Modulation
AGGTCANAGGTCA
>HV491321.1 JP 2011132249-A/7: Method for Purifying Plasmid DNA
GAAAAAGGAAGAG
>GY487868.1 Sequence 127 from patent US 8039446
ATGAAATAGATCC
>GY487867.1 Sequence 126 from patent US 8039446
CATGAAATAGATC
>GY487866.1 Sequence 125 from patent US 8039446
ACATGAAATAGAT
>GY487865.1 Sequence 124 from patent US 8039446
AACATGAAATAGA
>GY487853.1 Sequence 112 from patent US 8039446
TTCTACACCATTA
>GY487852.1 Sequence 111 from patent US 8039446
GTTCTACACCATT
>GY487851.1 Sequence 110 from patent US 8039446
TGTTCTACACCAT
>GY487850.1 Sequence 109 from patent US 8039446
GTGTTCTACACCA
>GY487838.1 Sequence 97 from patent US 8039446
ATTGCTGTAGCAG
>GY487837.1 Sequence 96 from patent US 8039446
AATTGCTGTAGCA
>GY487836.1 Sequence 95 from patent US 8039446
AAATTGCTGTAGC
>GY487835.1 Sequence 94 from patent US 8039446
GAAATTGCTGTAG
>GY487823.1 Sequence 82 from patent US 8039446
CAAGCAAAGTCAG
>GY487822.1 Sequence 81 from patent US 8039446
GCAAGCAAAGTCA
>GY487821.1 Sequence 80 from patent US 8039446
AGCAAGCAAAGTC
>GY487820.1 Sequence 79 from patent US 8039446
AAGCAAGCAAAGT
>GY487818.1 Sequence 77 from patent US 8039446
AGCAAGCAAAGTC
>GY487808.1 Sequence 67 from patent US 8039446
TCTTGTGATCCAT
>GY487807.1 Sequence 66 from patent US 8039446
ATCTTGTGATCCA
>GY487806.1 Sequence 65 from patent US 8039446
CATCTTGTGATCC
>GY487805.1 Sequence 64 from patent US 8039446
CCATCTTGTGATC
>GY487784.1 Sequence 43 from patent US 8039446
CTGCTTGTGGTCC
>GY487783.1 Sequence 42 from patent US 8039446
TCTGCTTGTGGTC
>GY487782.1 Sequence 41 from patent US 8039446
CTCTGCTTGTGGT
>GY487781.1 Sequence 40 from patent US 8039446
ACTCTGCTTGTGG
>GY487768.1 Sequence 27 from patent US 8039446
CTGCCATTTTAGC
>GY487767.1 Sequence 26 from patent US 8039446
ACTGCCATTTTAG
>GY487766.1 Sequence 25 from patent US 8039446
CACTGCCATTTTA
>GY487765.1 Sequence 24 from patent US 8039446
GCACTGCCATTTT
>GY487751.1 Sequence 10 from patent US 8039446
AGCTGATGGACCA
>GY487750.1 Sequence 9 from patent US 8039446
AAGCTGATGGACC
>GY487749.1 Sequence 8 from patent US 8039446
AAAGCTGATGGAC
>GY487748.1 Sequence 7 from patent US 8039446
GAAAGCTGATGGA
>GY487686.1 Sequence 16 from patent US 8039443
GTGAACGTTCGAG
>GY487572.1 Sequence 5 from patent US 8039259
CTCTTCCTTTTTC
>GY482560.1 Sequence 143 from patent US 8030285
CGTTCTCGGGGGG
>GY482520.1 Sequence 103 from patent US 8030285
TTCCTTCGAGCTC
>GY482495.1 Sequence 78 from patent US 8030285
GGGGTCGACAGGG
>GY482491.1 Sequence 74 from patent US 8030285
GGCGTCGACGGGG
>GY482434.1 Sequence 17 from patent US 8030285
CTCGAGCGTTCTC
>GY473111.1 Sequence 5 from patent US 8029784
TGGTGGTGGTGGT
>JA610843.1 Sequence 2 from Patent WO2011119057
DATCGACCTCAAT
>JA610842.1 Sequence 1 from Patent WO2011119057
DCGGATTTATGCA
>JA610756.1 Sequence 19 from Patent WO2011119956
CGGCCACGCTGGA
>JA609500.1 Sequence 463 from Patent EP2374814
ATGGGGGGGGGAG
>HV454088.1 WO 2004042054-A/33: Genetic polymorphism associated with periodontal diseases
CTGGGCCGACTTG
>HV454087.1 WO 2004042054-A/32: Genetic polymorphism associated with periodontal diseases
AGCTGCGTGAAGC
>HV454085.1 WO 2004042054-A/30: Genetic polymorphism associated with periodontal diseases
CCGACGTGCGGCC
>HV454108.1 WO 2004042054-A/53: Genetic polymorphism associated with periodontal diseases
ACGCACCAAGTCA
>HV454103.1 WO 2004042054-A/48: Genetic polymorphism associated with periodontal diseases
ACTCCCCTGCCTC
>HV454102.1 WO 2004042054-A/47: Genetic polymorphism associated with periodontal diseases
CTGGGCCAACTTG
>HV454099.1 WO 2004042054-A/44: Genetic polymorphism associated with periodontal diseases
TCCGACATGCGGC
>HV454094.1 WO 2004042054-A/39: Genetic polymorphism associated with periodontal diseases
ACGCACGAAGTCA
>HV454093.1 WO 2004042054-A/38: Genetic polymorphism associated with periodontal diseases
AGGCAGGAAGATC
>HV446321.1 WO 1998013524-A/24: Probe and method for detecting polynucleotide
NGACCATGATTAC
>HV446310.1 WO 1998013524-A/13: Probe and method for detecting polynucleotide
NGACCATGATTAC
>HV449991.1 WO 1999059636-A/23: VEGF activity inhibitor
GGCCGCTACGTAA
>HV449990.1 WO 1999059636-A/22: VEGF activity inhibitor
GATCTTACGTAGC
>HV449269.1 WO 1999040118-A/15: Antibody against human VEGF receptor KDR
GGCCGCTACGTAA
>HV449268.1 WO 1999040118-A/14: Antibody against human VEGF receptor KDR
GATCTTACGTAGC
>HV447705.1 WO 1998058065-A/17: Mold-resistant plant and method for constructing the same
TTCATGATATCGC
>HV446963.1 WO 1998037187-A/61: Cancer-associated gene
TTTTTTTTTTTGG
>HV446962.1 WO 1998037187-A/60: Cancer-associated gene
TTTTTTTTTTTGC
>HV446961.1 WO 1998037187-A/59: Cancer-associated gene
TTTTTTTTTTTGA
>HV446960.1 WO 1998037187-A/58: Cancer-associated gene
TTTTTTTTTTTCG
>HV446959.1 WO 1998037187-A/57: Cancer-associated gene
TTTTTTTTTTTCC
>HV446958.1 WO 1998037187-A/56: Cancer-associated gene
TTTTTTTTTTTCA
>HV446957.1 WO 1998037187-A/55: Cancer-associated gene
TTTTTTTTTTTAG
>HV446956.1 WO 1998037187-A/54: Cancer-associated gene
TTTTTTTTTTTAC
>HV446955.1 WO 1998037187-A/53: Cancer-associated gene
TTTTTTTTTTTAA
>HV450476.1 WO 2000010383-A/75: Method for modifying chromosomes or fragments thereof
GGCCGCWGCGGCC
>GY472674.1 Sequence 44 from patent US 8034998
TCTCTGCGGCCGC
>GY472614.1 Sequence 152 from patent US 8034994
CGCGGTGACGCCA
>GY472613.1 Sequence 151 from patent US 8034994
GCGCGTGACGCTC
>GY472610.1 Sequence 142 from patent US 8034994
CGTGACGTAAGTA
>GY472609.1 Sequence 141 from patent US 8034994
ACTTACGTCACGT
>GY472608.1 Sequence 140 from patent US 8034994
AGACGTGACGTAA
>GY472607.1 Sequence 139 from patent US 8034994
CAAGACGTGACGT
>GY472380.1 Sequence 31 from patent US 8034922
CATAGGATATACT
>GY472271.1 Sequence 11 from patent US 8034911
GTGTCACCTAAAT
>GY472264.1 Sequence 3 from patent US 8034911
TCCCGCTCCTAGA
>GY472194.1 Sequence 79 from patent US 8034909
CAAACAAACCACA
>GY472193.1 Sequence 78 from patent US 8034909
CAAACAAACCACA
>GY472192.1 Sequence 77 from patent US 8034909
GGTGGTTTGTTTG
>GY472191.1 Sequence 76 from patent US 8034909
CAAACAAACCACA
>GY472190.1 Sequence 75 from patent US 8034909
CAAACAAACCACA
>GY472189.1 Sequence 74 from patent US 8034909
GGTGGTTTGTTTG
>GY472188.1 Sequence 73 from patent US 8034909
CAAACAAACCACA
>GY472187.1 Sequence 72 from patent US 8034909
CAAACAAACCACA
>GY472186.1 Sequence 71 from patent US 8034909
GGTGGTTTGTTTG
>GY472179.1 Sequence 64 from patent US 8034909
ATAAAGTGTAAAG
>GY472175.1 Sequence 60 from patent US 8034909
ATAAAGTGTAAAG
>GY472173.1 Sequence 58 from patent US 8034909
ATAAAGTGTAAAG
>GY472163.1 Sequence 48 from patent US 8034909
GGTGGTTTGTTTG
>GY472162.1 Sequence 47 from patent US 8034909
GGTGGTTTGTTTG
>GY472161.1 Sequence 46 from patent US 8034909
GGTGGTTTGTTTG
>GY472159.1 Sequence 44 from patent US 8034909
GGTGGTTTGTTTG
>GY472158.1 Sequence 43 from patent US 8034909
GGTGGTTTGTTTG
>GY472157.1 Sequence 42 from patent US 8034909
AGAGCCGATAACA
>GY472156.1 Sequence 41 from patent US 8034909
AGAGCCGATAACA
>GY472155.1 Sequence 40 from patent US 8034909
AGAGCCGATAACA
>GY472154.1 Sequence 39 from patent US 8034909
TTCCACAGCACAA
>GY472153.1 Sequence 38 from patent US 8034909
TTCCACAGCACAA
>GY472152.1 Sequence 37 from patent US 8034909
TTCCACAGCACAA
>GY472147.1 Sequence 32 from patent US 8034909
GGTGGTTTGTTTG
>GY472146.1 Sequence 31 from patent US 8034909
GGTGGTTTGTTTG
>GY472145.1 Sequence 30 from patent US 8034909
GGTGGTTTGTTTG
>GY472144.1 Sequence 29 from patent US 8034909
GGTGGTTTGTTTG
>GY472143.1 Sequence 28 from patent US 8034909
GGTGGTTTGTTTG
>GY472124.1 Sequence 9 from patent US 8034909
GGTGGTTTGTTTG
>GY472123.1 Sequence 8 from patent US 8034909
GGTGGTTTGTTTG
>GY472122.1 Sequence 7 from patent US 8034909
GGTGGTTTGTTTG
>GY472121.1 Sequence 6 from patent US 8034909
GGTGGTTTGTTTG
>GY472120.1 Sequence 5 from patent US 8034909
GGTGGTTTGTTTG
>GY472119.1 Sequence 4 from patent US 8034909
GGTGGTTTGTTTG
>GY472118.1 Sequence 3 from patent US 8034909
GGTGGTTTGTTTG
>GY472117.1 Sequence 2 from patent US 8034909
ATAAAGTGTAAAG
>GY471177.1 Sequence 86 from patent US 8034587
GGTACGTGGTTTC
>GY471169.1 Sequence 19 from patent US 8034587
CTTTGGTCGATGG
>JA532843.1 Sequence 16 from Patent EP2371970
TTTCCTCTCCCTC
>JA532840.1 Sequence 13 from Patent EP2371970
GGCAACGGAGGAA
>JA532839.1 Sequence 12 from Patent EP2371970
CCTTTTCCTCCTT
>JA532835.1 Sequence 8 from Patent EP2371970
GAAGAGGAAGAAG
>JA530474.1 Sequence 20 from Patent EP2356216
CATCCAACAGAAT
>GY444652.1 Sequence 1241 from patent US 8013142
TGCAGCTGATTGT
>GY444613.1 Sequence 1202 from patent US 8013142
TGCAGCTGATTGT
>GY444027.1 Sequence 616 from patent US 8013142
TGGTGCTAGCATT
>GY444023.1 Sequence 612 from patent US 8013142
TGGTGCTAGCATT
>GY364807.1 Sequence 21 from patent US 8026082
AAAATCTGGGGAA
>GY364806.1 Sequence 20 from patent US 8026082
ATTATGTGGGGTA
>GY364805.1 Sequence 19 from patent US 8026082
ATTATGTGGGGTA
>GY364804.1 Sequence 18 from patent US 8026082
GCATACCGGGGCC
>GY364803.1 Sequence 17 from patent US 8026082
GGTTTGTGGGGCC
>GY364802.1 Sequence 16 from patent US 8026082
TATTTCTGGGGTA
>GY364749.1 Sequence 56 from patent US 8026066
GTAGAAACCTCGC
>GY360733.1 Sequence 8 from patent US 8026052
AATTGCCCGGGCG
>GY360732.1 Sequence 7 from patent US 8026052
CTAGGCCCGGGCG
>GY360731.1 Sequence 6 from patent US 8026052
GATCGCCCGGGCG
>GY360283.1 Sequence 85 from patent US 8025878
GCCGCCRCCANGG
>GY360245.1 Sequence 21 from patent US 8025877
GACCATACTTCAC
>GY360159.1 Sequence 4 from patent US 8024129
TCAGTTGCAATTC
>GY360157.1 Sequence 1 from patent US 8024129
AGTCAACGTTAAG
>GY358731.1 Sequence 154 from patent US 8022045
GCAGACCCCGCTG
>GY358706.1 Sequence 123 from patent US 8022045
ACAGGCCCCTGAG
>GY358575.1 Sequence 32 from patent US 8021883
CTGATCCGGCCTT
>GY357802.1 Sequence 127 from patent US 8021845
CTCGGAGTCCAGG
>GY357796.1 Sequence 121 from patent US 8021845
CTCGGAGTCCGGG
>GY357338.1 Sequence 10 from patent US 8021653
GTAAGTGCGCCCT
>GY356148.1 Sequence 3 from patent US 8017829
CCCCAACCTCGTC
>GY351827.1 Sequence 4 from patent US 8017744
GAAAAAGGAAGAG
>GY351823.1 Sequence 7 from patent US 8017743
CGTGGTACCCCTT
>GY351821.1 Sequence 5 from patent US 8017743
CGTGGTGACCCTT
>GY351581.1 Sequence 303 from patent US 8017559
GGCCGCAGGTGCG
>GY351580.1 Sequence 301 from patent US 8017559
TATGCGGCCCAGC
>GY350592.1 Sequence 7 from patent US 8017358
CGTGGTACCCCTT
>GY350590.1 Sequence 5 from patent US 8017358
CGTGGTGACCCTT
>GY350356.1 Sequence 10 from patent US 8017341
GTAAAACGGCCAG
>GY349985.1 Sequence 7 from patent US 8017322
CGTGGTACCCCTT
>GY349983.1 Sequence 5 from patent US 8017322
CGTGGTGACCCTT
>GY345830.1 Sequence 22 from patent US 8008459
TTTCCGCAACAGT
>GY345819.1 Sequence 11 from patent US 8008459
GGCCNNNNNGGCC
>GY345818.1 Sequence 10 from patent US 8008459
GGCCNNNNNGGCC
>GY345105.1 Sequence 85 from patent US 8008266
TGTCGTTGTCGTT
>GY343348.1 Sequence 8 from patent US 8007814
GAGCCTCCTGTAC
>GY343347.1 Sequence 7 from patent US 8007814
GAACCTCCTTTAC
>HV445133.1 JP 2011516423-A/2: NEUTRALIZING MOLECULES TO VIRAL ANTIGENS
GGCCNNNNNGGCC
>HV436838.1 JP 2011115168-A/85175: GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF
TGCTGGCCGTCCA
>HV444702.1 JP 2011514163-A/41: Compositions and Methods for Analysis of Nucleic Acid Molecules During Amplification Reactions
CGGACGACGAGCT
>HV436394.1 JP 2011115168-A/84731: GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF
TGCGGCTCCACCA
>HV349516.1 JP 2011103875-A/2: Modified promoters
CGAAAGCGGTTTA
>HV349515.1 JP 2011103875-A/1: Modified promoters
TGTAAGCGGTTAA
>HV349453.1 JP 2011115122-A/6: Method for pretreating sample and method for detecting genes
ATACAACTTGTCA
>HV348678.1 JP 2011109963-A/14: Method for determining wheat variety suitable for noodle
ATGGTGGAAGGGC
>HV348677.1 JP 2011109963-A/13: Method for determining wheat variety suitable for noodle
ATGGTGGAAGAGC
>JA476280.1 Sequence 36 from Patent EP2324126
CAGAATCCTGCGT
>JA483283.1 Sequence 6 from Patent EP2294212
CACGCACAGCGGC
>JA474321.1 Sequence 6 from Patent EP2342341
GGGTCGCAGCTGG
>JA482702.1 Sequence 79 from Patent EP2341057
CAAACAAACCACA
>JA482701.1 Sequence 78 from Patent EP2341057
CAAACAAACCACA
>JA482700.1 Sequence 77 from Patent EP2341057
GGTGGTTTGTTTG
>JA482699.1 Sequence 76 from Patent EP2341057
CAAACAAACCACA
>JA482698.1 Sequence 75 from Patent EP2341057
CAAACAAACCACA
>JA482697.1 Sequence 74 from Patent EP2341057
GGTGGTTTGTTTG
>JA482696.1 Sequence 73 from Patent EP2341057
CAAACAAACCACA
>JA482695.1 Sequence 72 from Patent EP2341057
CAAACAAACCACA
>JA482694.1 Sequence 71 from Patent EP2341057
GGTGGTTTGTTTG
>JA482687.1 Sequence 64 from Patent EP2341057
ATAAAGTGTAAAG
>JA482683.1 Sequence 60 from Patent EP2341057
ATAAAGTGTAAAG
>JA482681.1 Sequence 58 from Patent EP2341057
ATAAAGTGTAAAG
>JA482671.1 Sequence 48 from Patent EP2341057
GGTGGTTTGTTTG
>JA482670.1 Sequence 47 from Patent EP2341057
GGTGGTTTGTTTG
>JA482669.1 Sequence 46 from Patent EP2341057
GGTGGTTTGTTTG
>JA482667.1 Sequence 44 from Patent EP2341057
GGTGGTTTGTTTG
>JA482666.1 Sequence 43 from Patent EP2341057
GGTGGTTTGTTTG
>JA482665.1 Sequence 42 from Patent EP2341057
AGAGCCGATAACA
>JA482664.1 Sequence 41 from Patent EP2341057
AGAGCCGATAACA
>JA482663.1 Sequence 40 from Patent EP2341057
AGAGCCGATAACA
>JA482662.1 Sequence 39 from Patent EP2341057
TTCCACAGCACAA
>JA482661.1 Sequence 38 from Patent EP2341057
TTCCACAGCACAA
>JA482660.1 Sequence 37 from Patent EP2341057
TTCCACAGCACAA
>JA482655.1 Sequence 32 from Patent EP2341057
GGTGGTTTGTTTG
>JA482654.1 Sequence 31 from Patent EP2341057
GGTGGTTTGTTTG
>JA482653.1 Sequence 30 from Patent EP2341057
GGTGGTTTGTTTG
>JA482652.1 Sequence 29 from Patent EP2341057
GGTGGTTTGTTTG
>JA482651.1 Sequence 28 from Patent EP2341057
GGTGGTTTGTTTG
>JA482632.1 Sequence 9 from Patent EP2341057
GGTGGTTTGTTTG
>JA482631.1 Sequence 8 from Patent EP2341057
GGTGGTTTGTTTG
>JA482630.1 Sequence 7 from Patent EP2341057
GGTGGTTTGTTTG
>JA482629.1 Sequence 6 from Patent EP2341057
GGTGGTTTGTTTG
>JA482628.1 Sequence 5 from Patent EP2341057
GGTGGTTTGTTTG
>JA482627.1 Sequence 4 from Patent EP2341057
GGTGGTTTGTTTG
>JA482626.1 Sequence 3 from Patent EP2341057
GGTGGTTTGTTTG
>JA482625.1 Sequence 2 from Patent EP2341057
ATAAAGTGTAAAG
>JA492383.1 Sequence 5 from Patent WO2011087707
TACCTTCTTTGYY
>JA492382.1 Sequence 4 from Patent WO2011087707
TACCTTCTTCGGG
>JA492381.1 Sequence 3 from Patent WO2011087707
ATAACGTCTTTCA
>JA492380.1 Sequence 2 from Patent WO2011087707
TCCGTATGGTGGG
>JA482389.1 Sequence 79 from Patent EP2341058
CAAACAAACCACA
>JA482388.1 Sequence 78 from Patent EP2341058
CAAACAAACCACA
>JA482387.1 Sequence 77 from Patent EP2341058
GGTGGTTTGTTTG
>JA482386.1 Sequence 76 from Patent EP2341058
CAAACAAACCACA
>JA482385.1 Sequence 75 from Patent EP2341058
CAAACAAACCACA
>JA482384.1 Sequence 74 from Patent EP2341058
GGTGGTTTGTTTG
>JA482383.1 Sequence 73 from Patent EP2341058
CAAACAAACCACA
>JA482382.1 Sequence 72 from Patent EP2341058
CAAACAAACCACA
>JA482381.1 Sequence 71 from Patent EP2341058
GGTGGTTTGTTTG
>JA482374.1 Sequence 64 from Patent EP2341058
ATAAAGTGTAAAG
>JA482370.1 Sequence 60 from Patent EP2341058
ATAAAGTGTAAAG
>JA482368.1 Sequence 58 from Patent EP2341058
ATAAAGTGTAAAG
>JA482358.1 Sequence 48 from Patent EP2341058
GGTGGTTTGTTTG
>JA482357.1 Sequence 47 from Patent EP2341058
GGTGGTTTGTTTG
>JA482356.1 Sequence 46 from Patent EP2341058
GGTGGTTTGTTTG
>JA482354.1 Sequence 44 from Patent EP2341058
GGTGGTTTGTTTG
>JA482353.1 Sequence 43 from Patent EP2341058
GGTGGTTTGTTTG
>JA482352.1 Sequence 42 from Patent EP2341058
AGAGCCGATAACA
>JA482351.1 Sequence 41 from Patent EP2341058
AGAGCCGATAACA
>JA482350.1 Sequence 40 from Patent EP2341058
AGAGCCGATAACA
>JA482349.1 Sequence 39 from Patent EP2341058
TTCCACAGCACAA
>JA482348.1 Sequence 38 from Patent EP2341058
TTCCACAGCACAA
>JA482347.1 Sequence 37 from Patent EP2341058
TTCCACAGCACAA
>JA482342.1 Sequence 32 from Patent EP2341058
GGTGGTTTGTTTG
>JA482341.1 Sequence 31 from Patent EP2341058
GGTGGTTTGTTTG
>JA482340.1 Sequence 30 from Patent EP2341058
GGTGGTTTGTTTG
>JA482339.1 Sequence 29 from Patent EP2341058
GGTGGTTTGTTTG
>JA482338.1 Sequence 28 from Patent EP2341058
GGTGGTTTGTTTG
>JA482319.1 Sequence 9 from Patent EP2341058
GGTGGTTTGTTTG
>JA482318.1 Sequence 8 from Patent EP2341058
GGTGGTTTGTTTG
>JA482317.1 Sequence 7 from Patent EP2341058
GGTGGTTTGTTTG
>JA482316.1 Sequence 6 from Patent EP2341058
GGTGGTTTGTTTG
>JA482315.1 Sequence 5 from Patent EP2341058
GGTGGTTTGTTTG
>JA482314.1 Sequence 4 from Patent EP2341058
GGTGGTTTGTTTG
>JA482313.1 Sequence 3 from Patent EP2341058
GGTGGTTTGTTTG
>JA482312.1 Sequence 2 from Patent EP2341058
ATAAAGTGTAAAG
>JA505003.1 Sequence 11 from Patent WO2011098775
TAAGGGCCCAAGG
>JA469931.1 Sequence 336 from Patent EP2356259
TTATTTCCCAGGT
>JA469861.1 Sequence 266 from Patent EP2356259
AATAGCGAGAGNG
>JA469860.1 Sequence 265 from Patent EP2356259
AATAGCGAGAANG
>JA469859.1 Sequence 264 from Patent EP2356259
GATAAGAAGAANC
>JA469858.1 Sequence 263 from Patent EP2356259
AATAAGAAGAANC
>JA469857.1 Sequence 262 from Patent EP2356259
CAAAAGAAAAANT
>JA469856.1 Sequence 261 from Patent EP2356259
CAAAAGAACAANT
>JA469855.1 Sequence 260 from Patent EP2356259
CAACAGAACAANT
>JA469854.1 Sequence 259 from Patent EP2356259
CAACAGCACAANT
>JA469853.1 Sequence 258 from Patent EP2356259
CCACAGCATACNC
>JA469852.1 Sequence 257 from Patent EP2356259
CCACAGCCTACNC
>JA469851.1 Sequence 256 from Patent EP2356259
CCACCGCCTACNC
>JA469850.1 Sequence 255 from Patent EP2356259
CCACCGCCTCCNC
>JA508531.1 Sequence 1 from Patent EP2350283
GGGTCGCAGCTGG
>JA508529.1 Sequence 2 from Patent EP2342360
TAGGGTTAGACAA
>JA464971.1 Sequence 11 from Patent EP2339004
AATACTTCCACCC
>JA469063.1 Sequence 26 from Patent EP2356219
AGGTCANAGGTCA
>JA459889.1 Sequence 12 from Patent EP2345716
AAAACGAGGGGGG
>JA459888.1 Sequence 11 from Patent EP2345716
TTTTGCTCCCCCC
>JA457408.1 Sequence 6 from Patent EP2365076
GCCAATTGTTGCC
>JA457407.1 Sequence 5 from Patent EP2365076
AACAATTGGCGGC
>JA461047.1 Sequence 45 from Patent EP2340256
CCACGCTGCTGAG
>JA461046.1 Sequence 44 from Patent EP2340256
GAAGGTGTGCACG
>JA455957.1 Sequence 69 from Patent EP2316030
TTTTTTTTTTTTT
>JA453533.1 Sequence 12 from Patent WO2011057119
GCCAATCCTACGC
>JA451256.1 Sequence 101 from Patent EP2324045
TCATGCGGATCCA
>JA451255.1 Sequence 100 from Patent EP2324045
AGGCTGATTCGGT
>JA451254.1 Sequence 99 from Patent EP2324045
ACCGAATCAGCCT
>JA451253.1 Sequence 98 from Patent EP2324045
CTTACGGCGAATG
>JA451252.1 Sequence 97 from Patent EP2324045
CATTCGCCGTAAG
>JA451251.1 Sequence 96 from Patent EP2324045
TGGATCCGCATGA
>JA451226.1 Sequence 71 from Patent EP2324045
TCCGACTAAGCCA
>JA451225.1 Sequence 70 from Patent EP2324045
GAATGCCGCTTAC
>JA451224.1 Sequence 69 from Patent EP2324045
ACCTAGGCGTACT
>JA451223.1 Sequence 68 from Patent EP2324045
CTGAGTACCTGAT
>JA451222.1 Sequence 67 from Patent EP2324045
GTAAGCGGCATTC
>JA451221.1 Sequence 66 from Patent EP2324045
AGTACGCCTAGGT
>JA451220.1 Sequence 65 from Patent EP2324045
ATCAGGTACTCAG
>JA451219.1 Sequence 64 from Patent EP2324045
TGGCTTAGTCGGA
>JA449463.1 Sequence 3 from Patent WO2011054936
GACGCATACCGGC
>JA449462.1 Sequence 2 from Patent WO2011054936
ACGCACACGGACA
>JA449461.1 Sequence 1 from Patent WO2011054936
AAGCCCTAGCAGA
>JA418038.1 Sequence 2 from Patent EP2330214
GCCGACCGCTCTT
>JA418037.1 Sequence 1 from Patent EP2330214
TGCGGTCGACGTT
>JA428774.1 Sequence 88 from Patent WO2011094199
TTCCGTGAAGATC
>JA428695.1 Sequence 9 from Patent WO2011094199
CGCGAGTCTCCTC
>JA428694.1 Sequence 8 from Patent WO2011094199
CGCGACTCTCCTC
>JA428691.1 Sequence 5 from Patent WO2011094199
TCATCTCTGATAA
>JA428690.1 Sequence 4 from Patent WO2011094199
TCATGTGTGATAA
>JA428689.1 Sequence 3 from Patent WO2011094199
TCATCTGTGATAA
>JA428653.1 Sequence 88 from Patent WO2011094205
TTCCGTGAAGATC
>JA428574.1 Sequence 9 from Patent WO2011094205
CGCGAGTCTCCTC
>JA428573.1 Sequence 8 from Patent WO2011094205
CGCGACTCTCCTC
>JA428570.1 Sequence 5 from Patent WO2011094205
TCATCTCTGATAA
>JA428569.1 Sequence 4 from Patent WO2011094205
TCATGTGTGATAA
>JA428568.1 Sequence 3 from Patent WO2011094205
TCATCTGTGATAA
>JA428397.1 Sequence 104 from Patent EP2360252
TGTCGTTGTCGTT
>JA424609.1 Sequence 21 from Patent EP2348119
GCCGCCACCATGG
>JA431234.1 Sequence 44 from Patent WO2011097388
ATGCATGCATGCA
>JA397879.1 Sequence 30 from Patent WO2011061625
GCCGCCRCCATGG
>GY342767.1 Sequence 8 from patent US 8003781
GTTAAGGCCAAAG
>GY342766.1 Sequence 7 from patent US 8003781
CAGAATTGGCGCT
>GY342765.1 Sequence 6 from patent US 8003781
AGCTAAAGAGCTC
>GY342764.1 Sequence 5 from patent US 8003781
TATATCCCTCCTA
>GY339261.1 Sequence 48 from patent US 8003619
AACCTGTCCTTCA
>GY339174.1 Sequence 5 from patent US 8003389
CTCTTCCTTTTTC
>GY337261.1 Sequence 126 from patent US 8003115
TCGGAAANGTTCG
>GY337251.1 Sequence 116 from patent US 8003115
TNGTGAACGTTCG
>GY337249.1 Sequence 114 from patent US 8003115
TCGTTAACGTTCG
>GY337243.1 Sequence 108 from patent US 8003115
TCGGAACCGTTCG
>GY337242.1 Sequence 107 from patent US 8003115
TCGGTACCGTTCG
>GY337241.1 Sequence 106 from patent US 8003115
TCGGTATCGGTCG
>GY337240.1 Sequence 105 from patent US 8003115
TCGTGAACGTTCG
>GY337236.1 Sequence 101 from patent US 8003115
TCGTTAACGTTCG
>GY337234.1 Sequence 99 from patent US 8003115
TNGTGAACGTTCG
>GY337232.1 Sequence 97 from patent US 8003115
TCGTGAACGTTCG
>GY333717.1 Sequence 196 from patent US 7998939
GGTAGGGTGGTGG
>GY333519.1 Sequence 24 from patent US 7998938
TTGTCTAACCCTA
>GY333518.1 Sequence 23 from patent US 7998938
TAGGTGTAAGCAA
>GY333514.1 Sequence 17 from patent US 7998938
GTTAGGGTTAGAC
>GY333510.1 Sequence 13 from patent US 7998938
CAGTTAGGGTTAG
>GY333509.1 Sequence 12 from patent US 7998938
TAGGGTTAGACAA
>GY333506.1 Sequence 9 from patent US 7998938
ACGGTGGAAGGCG
>GY333505.1 Sequence 8 from patent US 7998938
CGGTGGAAGGCGG
>GY333503.1 Sequence 6 from patent US 7998938
GTGGAAGGCGGCA
>GY333502.1 Sequence 5 from patent US 7998938
GGAAGGCGGCAGG
>GY329387.1 Sequence 28 from patent US 7998492
CGGCGCCGTGCCG
>GY327761.1 Sequence 121 from patent US 7994395
CAATAGCAATCCC
>GY327756.1 Sequence 116 from patent US 7994395
ACTGCCCTTCTGC
>GY327752.1 Sequence 112 from patent US 7994395
AAGGTCGAAAATT
>GY327740.1 Sequence 100 from patent US 7994395
TCTGGGAGGCAGC
>HV341216.1 WO 2011052755-A/12: Probe for detecting of polymorphism of MPL gene and use thereof
GGAAACTGCTTCC
>HV340829.1 WO 2011061937-A/41: METHODS FOR PRODUCING ANTIBODY-PRODUCING CELLS THAT PRODUCE DESIRED POLYPEPTIDES
GGTGAGTACTAGT
>HV345222.1 JP 2011510640-A/109: Nucleic acids of formula (I) (NuGlXmGnNv)a and derivatives thereof as an immune-stimulating agent/adjuvant
GCCGCCACCATGG
>HV345184.1 JP 2011510640-A/71: Nucleic acids of formula (I) (NuGlXmGnNv)a and derivatives thereof as an immune-stimulating agent/adjuvant
GGGTTTTTTTGGG
>HV345173.1 JP 2011510640-A/60: Nucleic acids of formula (I) (NuGlXmGnNv)a and derivatives thereof as an immune-stimulating agent/adjuvant
GGTTTTTTTTTGG
>HV340549.1 JP 2011101647-A/153: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
CTATCTGACGTTC
>HV340544.1 JP 2011101647-A/148: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
CTATCTGACGTTC
>HV340539.1 JP 2011101647-A/143: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340535.1 JP 2011101647-A/139: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
CTATCTGACGTTC
>HV340533.1 JP 2011101647-A/137: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
CTATCTGACGTTC
>HV340531.1 JP 2011101647-A/135: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340530.1 JP 2011101647-A/134: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340528.1 JP 2011101647-A/132: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340527.1 JP 2011101647-A/131: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340526.1 JP 2011101647-A/130: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340524.1 JP 2011101647-A/128: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340523.1 JP 2011101647-A/127: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340522.1 JP 2011101647-A/126: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340520.1 JP 2011101647-A/124: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340519.1 JP 2011101647-A/123: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340518.1 JP 2011101647-A/122: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340517.1 JP 2011101647-A/121: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340516.1 JP 2011101647-A/120: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340515.1 JP 2011101647-A/119: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340510.1 JP 2011101647-A/114: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340509.1 JP 2011101647-A/113: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
CCTACTAGCGTTC
>HV340507.1 JP 2011101647-A/111: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
CCTACTAGCGTTC
>HV340505.1 JP 2011101647-A/109: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
CCTACTAGCGTTC
>HV340504.1 JP 2011101647-A/108: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
CCTACTAGCGTTC
>HV340501.1 JP 2011101647-A/105: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TAGCGTTCTCATC
>HV340500.1 JP 2011101647-A/104: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TAGCGTTCTCATC
>HV340429.1 JP 2011101647-A/33: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
NNTCTGACNTTCT
>HV340425.1 JP 2011101647-A/29: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
NNTCTGTCNTTCT
>HV340402.1 JP 2011101647-A/6: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV340401.1 JP 2011101647-A/5: MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES
TGACGTTCTCTGT
>HV347127.1 JP 2011511051-A/10: BIOLOGICAL MATERIALS AND USES THEREOF
TGGTGGTGGTGGT
>HV348092.1 JP 2011512821-A/23: Cold Shock Protein Compositions and Methods and Kits for the Use Thereof
GACATCGTCCTCG
>GY320943.1 Sequence 10 from patent US 7985739
GTTTACAGACAGA
>GY319831.1 Sequence 80 from patent US 7985543
AAGTGTGCAGGTG
>GY319792.1 Sequence 41 from patent US 7985543
CACCTGCACACTT
>GY317088.1 Sequence 21 from patent US 7981671
AACAAGGGGGGAA
>GY317056.1 Sequence 3 from patent US 7981670
AGTCAAGACCAAG
>GY315890.1 Sequence 26 from patent US 7981616
ATCCCCTTGGCAA
>GY315871.1 Sequence 7 from patent US 7981616
GCCACCATTACCT
>GY315870.1 Sequence 6 from patent US 7981616
TGTAGCTGTTGCA
>GY315868.1 Sequence 4 from patent US 7981616
TGAAGTACACTGG
>GY315867.1 Sequence 3 from patent US 7981616
GCAGTGACTTCGT
>GY314968.1 Sequence 4 from patent US 7981604
GCTGGCGGATGAC
>GY312025.1 Sequence 337 from patent US 7989612
TTCCGCGTACGTT
>GY312021.1 Sequence 331 from patent US 7989612
TTCCGCGTACGNN
>GY311988.1 Sequence 296 from patent US 7989612
TTCCGCGTACGTT
>GY311987.1 Sequence 294 from patent US 7989612
TTCCGCGTACGTT
>GY311779.1 Sequence 84 from patent US 7989612
TTCCGCGTACGTT
>GY311457.1 Sequence 23 from patent US 7989603
TAGGTGTAAGCAA
>GY311456.1 Sequence 22 from patent US 7989603
TAGGGTTAGACAA
>GY311453.1 Sequence 19 from patent US 7989603
TAGGTGTAAGCAA
>GY311452.1 Sequence 18 from patent US 7989603
TAGGGTTAGACAA
>GY311278.1 Sequence 24 from patent US 7989428
TTGTCTAACCCTA
>GY311277.1 Sequence 23 from patent US 7989428
TAGGTGTAAGCAA
>GY311273.1 Sequence 17 from patent US 7989428
GTTAGGGTTAGAC
>GY311269.1 Sequence 13 from patent US 7989428
CAGTTAGGGTTAG
>GY311268.1 Sequence 12 from patent US 7989428
TAGGGTTAGACAA
>GY311265.1 Sequence 9 from patent US 7989428
ACGGTGGAAGGCG
>GY311264.1 Sequence 8 from patent US 7989428
CGGTGGAAGGCGG
>GY311262.1 Sequence 6 from patent US 7989428
GTGGAAGGCGGCA
>GY311261.1 Sequence 5 from patent US 7989428
GGAAGGCGGCAGG
>GY310757.1 Sequence 6 from patent US 7989187
AGAAAGGAGGTGA
>GY310728.1 Sequence 77 from patent US 7989185
TTCTAGTATGCCA
>GY310726.1 Sequence 75 from patent US 7989185
CTCTAGCATGCCA
>GY310725.1 Sequence 73 from patent US 7989185
CTCTAGTATGCCA
>GY310666.1 Sequence 7 from patent US 7989185
GAAAAGAGAGGAT
>GY310665.1 Sequence 6 from patent US 7989185
TTCTAGTATGCCA
>GY310417.1 Sequence 2 from patent US 7989169
GCCGACCGCTCTT
>GY310416.1 Sequence 1 from patent US 7989169
TGCGGTCGACGTT
>GY310323.1 Sequence 6 from patent US 7989167
CTAGAAAACCTTC
>GY310322.1 Sequence 5 from patent US 7989167
CTAGAAGACCTTC
>GY310321.1 Sequence 4 from patent US 7989167
AGAGTTGGTATCC
>GY310320.1 Sequence 3 from patent US 7989167
AGAGTTCGTATCC
>GY310319.1 Sequence 2 from patent US 7989167
CTGAAGGTTTTGC
>GY310318.1 Sequence 1 from patent US 7989167
CTGAAGTTTTTGC
>HV333584.1 JP 2011509080-A/12: DIAGNOSTIC AND THERAPEUTIC METHODS FOR EFMR (EPILEPSY AND MENTAL RETARDATION LIMITED TO FEMALES)
ACCAAGYAGAAGA
>HV333583.1 JP 2011509080-A/11: DIAGNOSTIC AND THERAPEUTIC METHODS FOR EFMR (EPILEPSY AND MENTAL RETARDATION LIMITED TO FEMALES)
ACCAAGCAGAAGA
>HV333582.1 JP 2011509080-A/10: DIAGNOSTIC AND THERAPEUTIC METHODS FOR EFMR (EPILEPSY AND MENTAL RETARDATION LIMITED TO FEMALES)
ACCAAGYAGAAGA
>HV333024.1 JP 2011507534-A/307: Silencing of Polo-Like Kinase Expression Using Interfering RNA
CCTACCTCCGGAT
>HV333023.1 JP 2011507534-A/306: Silencing of Polo-Like Kinase Expression Using Interfering RNA
CTACCTCCGGATC
>HV333022.1 JP 2011507534-A/305: Silencing of Polo-Like Kinase Expression Using Interfering RNA
TACCTCCGGATCA
>HV333009.1 JP 2011507534-A/292: Silencing of Polo-Like Kinase Expression Using Interfering RNA
TCACCCTCCTTAA
>HV333008.1 JP 2011507534-A/291: Silencing of Polo-Like Kinase Expression Using Interfering RNA
CACCCTCCTTAAA
>HV333007.1 JP 2011507534-A/290: Silencing of Polo-Like Kinase Expression Using Interfering RNA
ACCCTCCTTAAAT
>HV332481.1 JP 2011505868-A/12: Novel siRNA Structure for Minimizing Off-target Effects and Relaxing Saturation of RNAi Machinery and the Use Thereof
CAGGCGTTCTCTA
>HV332480.1 JP 2011505868-A/11: Novel siRNA Structure for Minimizing Off-target Effects and Relaxing Saturation of RNAi Machinery and the Use Thereof
TAGAGAACGCCTG
>HV332009.1 JP 2011505798-A/56: RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF MCL-1
ATAGCACCATGGT
>HV324325.1 JP 2011507493-A/8: Methods for selective labeling and detection of target nucleic acids using immobilized peptide nucleic acid probes
CCGCAAGTGCAGA
>HV324323.1 JP 2011507493-A/6: Methods for selective labeling and detection of target nucleic acids using immobilized peptide nucleic acid probes
GCCATGATAGTGG
>HV324319.1 JP 2011507493-A/2: Methods for selective labeling and detection of target nucleic acids using immobilized peptide nucleic acid probes
CCCCTGAATCCAG
>HV043092.1 JP 2009132737-A/44: NUCLEIC ACID COMPOSITIONS FOR STIMULATING IMMUNE RESPONSES
TCGTCGTTTTTCG
>HV043088.1 JP 2009132737-A/40: NUCLEIC ACID COMPOSITIONS FOR STIMULATING IMMUNE RESPONSES
TTTCGGTCGTTTT
>HV120183.1 JP 2009045070-A/4: DNA PURIFICATION BY FORMING A TRIPLE HELIX WITH AN IMMOBILIZED OLIGONUCLEOTIDE
GAAAAAGGAAGAG
>HV187297.1 JP 2005528713-A/35: METHOD FOR SOLVING FREQUENCY, FREQUENCY DISTRIBUTION AND SEQUENCE-MATCHING PROBLEMS
TATAACGTATTAG
>HV187288.1 JP 2005528713-A/26: METHOD FOR SOLVING FREQUENCY, FREQUENCY DISTRIBUTION AND SEQUENCE-MATCHING PROBLEMS
GTATTAGACACGG
>HV187279.1 JP 2005528713-A/17: METHOD FOR SOLVING FREQUENCY, FREQUENCY DISTRIBUTION AND SEQUENCE-MATCHING PROBLEMS
GGATACGTCGTAT
>HV187270.1 JP 2005528713-A/8: METHOD FOR SOLVING FREQUENCY, FREQUENCY DISTRIBUTION AND SEQUENCE-MATCHING PROBLEMS
GTCGTATAACGTA
>HV192911.1 JP 2000510342-A/8: Construction of apomict seed
TTTTTTTTTTTCA
>HV192906.1 JP 2000510342-A/3: Construction of apomict seed
TTTTTTTTTTTGC
>HV189825.1 JP 2006320326-A/6: METHOD OF DETECTION OF NUCLEIC ACIDS WITH A SPECIFIC SEQUENCE COMPOSITION
CCGGGTTTTCCCC
>HV189822.1 JP 2006320326-A/3: METHOD OF DETECTION OF NUCLEIC ACIDS WITH A SPECIFIC SEQUENCE COMPOSITION
AGGGGACTTTCCG
>HV189821.1 JP 2006320326-A/2: METHOD OF DETECTION OF NUCLEIC ACIDS WITH A SPECIFIC SEQUENCE COMPOSITION
AAGGGACTTTCCC
>HV189820.1 JP 2006320326-A/1: METHOD OF DETECTION OF NUCLEIC ACIDS WITH A SPECIFIC SEQUENCE COMPOSITION
TGGGGATTCCCCA
>HV198914.1 JP 2000517183-A/3: CD95 regulatory gene sequences and transcription factors
KMMTGAKGTMAKM
>HV195397.1 JP 2000512630-A/14: 2'-Substituted nucleoside and oligonucleotide derivative
AGGTGTCCGCATC
>HV195274.1 JP 1999225761-A/23: Oligonucleotide probe and method for determing the presence of prokaryote using the same
ACGTGCTACAATG
>HV195255.1 JP 1999225761-A/4: Oligonucleotide probe and method for determing the presence of prokaryote using the same
ATCCGGATTTATT
>HV195214.1 JP 1999228600-A/6: Improvement in antibody or concerning antibody
TGCAGCATCAGCC
>HV222588.1 JP 2003510282-A/796: Immunostimulatory Nucleic Acids
GGGGTTGGGGGTT
>HV222476.1 JP 2003510282-A/704: Immunostimulatory Nucleic Acids
GCTAGACGTTAGC
>HV222429.1 JP 2003510282-A/657: Immunostimulatory Nucleic Acids
TCGCGAATTCGCG
>HV198387.1 JP 2000516808-A/12: MHC binding peptide oligomers and methods of use
GAATGCNCATTGC
>HV198386.1 JP 2000516808-A/11: MHC binding peptide oligomers and methods of use
GCAATGNGCATTC
>HV222028.1 JP 2003510282-A/256: Immunostimulatory Nucleic Acids
TGTCGTTGTCGTT
